This is a repository copy of *Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis:A multicentre, randomised controlled trial of the ProLife programme in South Africa*.

White Rose Research Online URL for this paper:
https://eprints.whiterose.ac.uk/id/eprint/182113/

Version: Accepted Version

BMJ Open

Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in South Africa

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

BMJ

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Effect of a brief motivational interview and text message intervention targeting tobacco smoking,**

2 **alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult**

3 **patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in**

4 **South Africa**

5 Goedele Maria Louwagie[1, 2], Mona Kanaan[3], Neo Keitumetse Morojele[4, 5], André van Zyl[1], Andrew

6 Stephen Moriarty[3], Jinshuo Li[3], Kamran Siddiqi[3], Astrid Turner[2], Noreen Dadirai Mdege[3], Olufemi

7 Babatunde Omole[6], John Tumbo[1], Max Oscar Bachmann[7], Steve Parrott[3], Olalekan Ayo-Yusuf[1, 2]

8 Correspondence to Goedele Maria Louwagie; goedele.louwagie@up.ac.za

9

10 [1]Goedele Maria Louwagie, Sefako Makgatho Health Sciences University and [2]School of Health

11 Systems and Public Health, University of Pretoria , RSA; goedele.louwagie@up.ac.za

12

13 [3]Mona Kanaan, Department of Health Sciences, University of York, UK; mona.kanaan@york.ac.uk

14

15 [4]Neo Keitumetse Morojele, Department of Psychology, University of Johannesburg and [5]Alcohol,

16 Tobacco and Other Drug Research Unit, South African Medical Research Council, RSA;

17 nmorojele@uj.ac.za

18

19 [1]André van Zyl, Sefako Makgatho Health Sciences University, RSA; drevanzyl@gmail.com

20

21 [3]Andrew Stephen Moriarty, Department of Health Sciences and the Hull York Medical School,

22 University of York, UK; andrew.moriarty@york.ac.uk

23

24 [3]Jinshuo Li, Department of Health Sciences, University of York, UK; jinshuo.li@york.ac.uk

25

26 [3]Kamran Siddiqi, Department of Health Sciences and the Hull York Medical School, University of York,

27 UK; kamran.siddiqi@york.ac.uk

28

29 [2]Astrid Turner, School of Health Systems and Public Health, University of Pretoria, RSA;

30 astrid.turner@up.ac.za

31

32 [3]Noreen Dadirai Mdege, Department of Health Sciences, University of York, UK;

33 noreen.mdege@york.ac.uk

34

35 [6]Olufemi Babatunde Omole, Department of Family Medicine, University of Witwatersrand, RSA;

36 Olufemi.Omole@wits.ac.za

37

38 [1]John Tumbo, Department of Family Medicine, Sefako Makgatho Health Sciences University, RSA;

39 tumbo@lantic.net

40

41 [7]Max Oscar Bachmann, Norwich Medical School, University of East Anglia, UK;

42 m.bachmann@uea.ac.uk

43

1

44 [3]Steve Parrott, Department of Health Sciences, University of York, UK; steve.parrott@york.ac.uk

45

46 [1]Olalekan Ayo-Yusuf, Africa Centre for Tobacco Industry Monitoring & Policy Research, Sefako

47 Makgatho Health Sciences University, and [2]School of Health Systems and Public Health, University of

48 Pretoria, RSA; lekan.ayo-yusuf@smu.ac.za

49

50 **ABSTRACT**

51 **Objectives:** To investigate the effectiveness of a complex behavioural intervention, ProLife, on

52 tuberculosis (TB) treatment success, medication adherence, alcohol use and tobacco smoking.

53 **Design:** Multicentre, individual, randomised controlled trial where participants were assigned (1:1)

54 to the ProLife intervention or usual care.

55 **Setting:** 27 primary care clinics in South Africa.

56 **Participants:** 574 adults starting treatment for drug-sensitive pulmonary TB who smoked tobacco or

57 reported harmful/hazardous alcohol use.

58 **Interventions:** The intervention, delivered by lay health workers (LHWs), consisted of 3 brief

59 motivational interviewing (MI) sessions, augmented with Short Message Service (SMS) messages,

60 targeting medication adherence, alcohol use and tobacco smoking.

61 **Outcome measures:** The primary outcome was successful versus unsuccessful TB treatment at 6 to 9

62 months, from TB records. Secondary outcomes were biochemically confirmed sustained smoking

63 cessation, reduction in the Alcohol Use Disorder Identification Test (AUDIT) score, improved TB and

64 antiretroviral treatment (ART) adherence and ART initiation, each measured at 3 and 6 months by

65 questionnaires; and cure rates in patients who had bacteriology-confirmed TB at baseline, from TB

66 records.

67 **Results:** Between 15 November 2018 and 31 August 2019, 574 participants were randomised to

68 receive either the intervention (n=283) or usual care (n=291). TB treatment success rates did not

69 differ significantly between intervention (67.8%) and control (70.1%; OR=0.9 (95% CI: 0.64,1.27)).

70 There was no evidence of an effect at 3- and 6-months respectively on continuous smoking

71 abstinence (OR=0.65 (95% CI: 0.37,1.14); OR=0.76 (95% CI: 0.35,1.63)), TB medication adherence

72 (OR=1.22 (95%CI: 0.52,2.87); OR=0.89 (95%CI: 0.26,3.07)), taking ART (OR=0.79 (0.38,1.65), OR=2.05

73 (0.80,5.27)) or AUDIT scores (mean score difference 0.55 (95% CI: -1.01,2.11); -0.04 (95% CI: -2,1.91);

74 and adjusting for baseline values. Cure rates were not significantly higher (OR=1.16 (0.83,1.63)).

75 **Conclusions:** Simultaneous targeting of multiple health risk behaviours with MI and SMS using LHWs

76 may not be an effective approach to improve TB outcomes.

77

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

78   **Trial registration:** ISRCTN62728852, Registered on 13th April 2018.

79   **Key words:** Tuberculosis, smoking, alcohol, motivational interviewing, mHealth, anti-retroviral

80   therapy, adherence

81

82   **STRENGTHS AND LIMITATIONS OF THIS STUDY**

83   • The use of motivational interviewing combined with Short Text Messaging to address the

84   effect of multiple risk behaviours (smoking, drinking and poor adherence) on tuberculosis

85   treatment outcomes is a novel and much needed intervention.

86   • Our study design was strong: this was a multi-site individually randomised controlled trial

87   with a large sample size and a high follow up rate for the primary outcome.

88   • We used validated measurement tools; furthermore, data analysis and primary outcome

89   assessment were blinded, thereby limiting measurement bias.

90   • However, the study was underpowered for secondary outcomes, and low intervention

91   uptake may have diluted any potential intervention effects.

92

3

93 **INTRODUCTION**

94 Tuberculosis (TB) is among the most common chronic infectious diseases in the world today. In 2019,

95 1.4 million deaths worldwide were attributed to TB, and the majority of these occurred in low-

96 income and middle-income countries (LMICs).(1) South Africa not only has one of the highest TB

97 burdens in the world; it is faced with high TB treatment interruption and loss to follow-up rates. It

98 also has a high prevalence of human immunodeficiency virus (HIV) co-infection in patients with TB

99 and a relatively high mortality in these co-infected patients.(1) Studies of interventions to advance

100 the goal of ending the TB epidemic and improving treatment outcomes are therefore research

101 priorities in South Africa and other LMICs.(2)

102 Mortality and morbidity from TB is strongly associated with health risk behaviours, particularly

103 smoking and hazardous or harmful alcohol use, both of which are prevalent and often co-occur in

104 patients with TB.(3–10) Strategies are also required to improve TB medication adherence in patients

105 with TB and adherence to TB medication and anti-retroviral therapy (ART) in patients co-infected

106 with TB and HIV, both of which may be negatively influenced by excessive alcohol use.(1) There is

107 very limited research on how to concurrently tackle these three risk behaviours - namely smoking,

108 harmful alcohol use and poor medication adherence - in patients with TB, particularly in LMICs.

109 Motivational Interviewing (MI) has been shown to support reduced drinking, smoking cessation in TB

110 patients and TB treatment and/or antiretroviral therapy (ART) medication adherence.(11–13) MI

111 interventions can be effectively delivered by lay health workers (LHWs).(14) The more widespread

112 use of LHWs and the increased use of mobile health (mHealth) digital technologies represent

113 promising ways to increase the scalability of MI interventions. Indeed, the World Health

114 Organisation (WHO) has called for researchers to capitalise on advances in mobile phone

115 technology, network coverage and the increased use of common and widely available digital

116 technologies (including the mobile phone short message service (SMS)) to improve TB care.(15)

117 There is evidence that mHealth technologies can have modest beneficial effects on a range of health

118 outcomes, including medication adherence.(16,17) Mobile phone messaging also shows a modest

119 effect in improving TB treatment success rates.(18,19) The evidence is however stronger for two-

120 way messaging and interactive systems for which smart phones are required.(18) These are often

121 not available to patients with TB in Africa.(20)

122

123 A limitation of existing MI and mHealth interventions is that they have been studied in the context of

124 modifying a single lifestyle factor. Integrated interventions are likely to be better accepted and more

125 effective than multiple interventions targeting different health risk factors.(21,22) In the case of TB,

4

126   there is a need for an intervention that has the flexibility to target multiple lifestyle factors as

127   appropriate and in line with patient preferences. This could be achieved through increased

128   integration of TB and non-communicable disease services.(23)

129

130   Recent re-engineering of primary health care in South Africa has seen the introduction of municipal

131   ward-based primary healthcare outreach teams of community health workers (CHWS). CHWs work

132   in an integrated, team-based manner, supported by nurses, and take responsibility for health

133   education and promotion, counselling and support for a range of health conditions.(24,25) Task

134   shifting in this context has been shown to improve population health in LMICs (26) and these teams

135   can be trained and supported to take responsibility for TB/HIV care.(27) Integrated interventions

136   could be implemented within this framework in a feasible and scalable way to improve outcomes for

137   patients with TB across South Africa and beyond.

138

139   Building on previous successes with MI and mHealth interventions, we developed a complex

140   behavioural intervention (ProLife) comprising MI-based counselling and SMS, targeting three

141   lifestyle risk behaviours for poor TB outcomes (smoking, hazardous/harmful alcohol consumption

142   and poor medication adherence), and delivered by LHWs. We then conducted a randomised

143   controlled trial (RCT) to assess the effectiveness of the ProLife intervention on improving TB

144   treatment outcomes, smoking abstinence, reducing alcohol consumption and improving adherence

145   to TB and ART medication compared to usual care. The cost-effectiveness of the intervention was

146   also assessed but only the costing results will be presented in this paper.

147

148   **METHODS**

149

150   **Study design and participants**

151   This was a prospective, two-arm, multicentre, individual RCT, which took place across 27 primary

152   care clinics in 3 districts in South Africa (Lejweleputswa in the Free State province; Bojanala in the

153   North West province; and Sedibeng in Gauteng province). Adult patients (18 years or older) were

154   eligible for the study if they had drug-sensitive Pulmonary TB (PTB), and were initiating TB treatment

155   or had been on TB treatment for less than a month for this treatment episode (both "new" and

156   "retreatment patients"). They had to be tobacco smokers (defined as smoking daily or non-daily in

157   the last four weeks on the Global Adult Tobacco Survey questionnaire)(28) and/or

158   hazardous/harmful drinkers who were not alcohol dependent (Alcohol Use Disorders Identification

159   Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20).(29) They also had to have access to a

5

160 mobile phone and understand one of the 4 languages used for the trial (English, IsiZulu, SeSotho and

161 Setswana). Potential participants were recruited consecutively at the participating clinics between

162 15 November 2018 and 31 August 2019. Trained field workers identified those interested in the

163 study and screened them for eligibility. If eligible and willing to be enrolled into the trial, written

164 informed consent was obtained. The RCT received ethics approval from the Research Ethics

165 Committees of the five participating research institutions and the trial protocol was previously

166 published.(30)

167

168 **Randomisation and blinding**

169 Patients were centrally randomised (1:1) to the ProLife intervention or control group using a

170 randomised sequence generator by the trial statistician (MK) who was blind to the arm allocation.

171 We used block randomisation with varying block sizes stratified by clinic so as to achieve equal

172 numbers in intervention and control groups within each clinic. Fieldworkers used sequentially

173 numbered, sealed, opaque envelopes to allocate participants to intervention or control. ProLife

174 involved a complex behavioural intervention therefore LHWs and participants could not be blinded

175 to the intervention. However, the determination of the primary outcome was done by the TB nurses

176 who were blinded to the intervention status of the participants, based on routinely collected data.

177 The statistician (MK) was blinded to the intervention or control arm allocation of participants during

178 the analysis.

179

180 **Intervention and procedures**

181 The ProLife intervention was developed based on a conceptual framework, following a review of

182 pre-existing evidence.(31) This framework assumed that smoking cessation, reducing harmful

183 alcohol use and improved adherence to TB and HIV treatment would result in improved TB

184 treatment outcomes.(30) The intervention consisted of 3 brief MI counselling sessions, lasting 15-20

185 minutes, one month apart, delivered by trained LHWs at their TB clinic. The first MI session took

186 place immediately or shortly after the randomisation and involved prioritisation and agenda setting,

187 wherein the participant determined which factor should be prioritised (either a plan to quit tobacco

188 smoking, or reduce or quit drinking, or deal with barriers relating to ART or TB medication

189 adherence). The second and third sessions built on the previous one until all relevant behavioural

190 problems had been addressed. These sessions were reinforced with follow-up SMS text messages,

191 twice a week over 12 weeks.(30) Study patients received 10 TB-related messages followed by seven

192 alcohol reduction- and/or seven smoking cessation-related messages, as appropriate. Messages

193 were aimed at giving information, and augmenting motivation or behavioural skills (we refer to the

6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

194 feasibility paper for more details).(31) Applicable SMS-messages were automatically activated after

195 the first MI had taken place. Thereafter remaining messages were delivered even if the participant

196 did not attend the second or third MI session.

197

198

199 Participants randomised to the ProLife intervention also received the same "usual care" as those in

200 the control group. The control group received the usual care and routine treatment and support

201 offered to patients with TB in South Africa, which varies by district but includes: health education;

202 dietetic input; social support; point of care biochemical testing; and HIV testing with pre- and post-

203 test HIV test counselling.

204

205 Data were collected at baseline, 3- and 6-months and recorded by fieldworkers equipped with

206 mobile phones with the ProLife mobile data collection application (built with CommCare)(32)

207 installed. They used a standardised electronic case report form (CRF) and followed standard

208 operating procedures (SOPs) to ensure quality. Details of data collection, protection and storage

209 procedures have been reported elsewhere.(30)

210

211 **Patient and public involvement**

212 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination

213 plans of our research.

214

215 **Outcomes**

216 Primary Outcome

217 The primary outcome of TB treatment success at 6 to 9 months follow-up (depending on when it was

218 recorded) was as per the WHO definitions adopted in South Africa,(10) that is, either successful

219 treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss

220 to follow-up (defined as treatment interruption of more than 2 months), or outcome not evaluated.

221 It was measured using the routinely collected TB treatment outcomes in patients' individual files.

222

223 Secondary Outcomes

224 For those participants with bacteriologically confirmed PTB at baseline (either sputum acid fast

225 bacilli (AFB) positive, culture positive or GeneXpert positive PTB), sputum conversion at the end of

226 treatment ("cure rate") was measured as a secondary outcome.(10) Continuous smoking abstinence

227 was assessed at 3- and 6-months follow-up in those participants who were current cigarette smokers

7

228 at baseline. It was defined as having quit smoking completely and a self-report of not smoking more

229 than 5 cigarettes from the start of the study, in addition to a negative biochemical test (exhaled

230 Carbon Monoxide (CO) < 7 ppm).(33,34) Changes in alcohol consumption were computed using the

231 AUDIT questionnaire scores measured at 3- and 6-months follow-up in those participants who were

232 hazardous/harmful drinkers at baseline.

233 HIV positive participants were asked about ART status at baseline, 3- and 6-months using

234 standardised questions on the CRF and change in ART status as measured at the 2 follow-up times.

235 TB and ART medication adherence was measured using modified versions of the AIDS Clinical Trials

236 Group Adherence Questionnaire, a validated tool for measuring adherence specifically to ART.(35)

237 Adherence was measured using an adherence index calculated by the formula (using the 4-day

238 recall): [Total number of doses taken/Total number of doses prescribed] x 100. Patients with at least

239 95% adherence were classed as having optimal adherence and those with less than 95% were

240 classed as having low (or suboptimal) adherence. This was assessed at 3- and 6-months.

241 During COVID-19 lockdown (in the second term of 2020) we switched to telephonic follow-up of

242 participants using a shortened questionnaire whereby only strictly needed information for the

243 measurement of outcomes was inquired about.

244 Training and Intervention Fidelity Monitoring

245 The training and intervention fidelity monitoring is described in more detail in previous

246 papers.(30,31) In brief, 18 LHWs, 3 district coordinators and 1 research assistant who focused on

247 counselling supervision underwent MI training over 5 days. LHWs completed a post-session semi-

248 structured form onto which they indicated the extent to which they implemented each element of

249 MI, as well as their general qualitative impressions of that particular session. In addition, we

250 assessed MI intervention fidelity based on ratings of the counsellors' recorded MI sessions, as

251 described below and in footnotes to the relevant supplementary table. SMS-message delivery was

252 also assessed.

253

254 Economic evaluation

255 The ProLife intervention costs consisted of the costs of training and the delivery of the ProLife

256 intervention, including relevant personnel involvement (trainers and LHWs), materials used, travel,

257 accommodation and refreshments, and digital infrastructure for the intervention. These were

258 estimated based on research team records. Usual care costs consisted of TB medication costs,

259 biochemical investigations, and ART costs if applicable. These were estimated based on information

8

260   obtained through routine records. The country specific version of Euroqol with 5 dimensions and 3

261   levels of response categories (EQ-5D-3L) for South Africa was administered to participants at

262   baseline, 3- and 6-months follow-up to measure health-related quality of life.(36,37)

263

264   **Statistical analysis**

265   The sample size was estimated at 696 in total (348 participants per arm), to detect a 10% difference

266   in TB treatment success rates (0.86 vs. 0.76) in the ProLife arm (intervention) vs. the control arm

267   with 80% power, a significance level of 0.05 and 25% attrition rate. The assumed success rates in the

268   control group were based on actual success rates in patients with TB in the studied provinces

269   obtained from TB managers at the time of the grant application for this study.

270   We summarised baseline data descriptively by trial arm. For the primary outcome, we conducted

271   statistical analysis on an intention-to-treat basis. We used binary logistic regression to compare the

272   main outcome (TB treatment success rate) between the intervention and the usual care arm. Where

273   treatment outcome data were missing, the outcome was coded as unsuccessful. TB treatment

274   outcomes recorded by the TB nurse were taken on face value as inconsistencies in the dates of

275   bacteriological results did not permit us to verify the correctness of the nurse assessment. We

276   carried out similar statistical analyses for the secondary outcomes with appropriate regression

277   techniques. For the reduction in harmful or hazardous drinking, we used linear regression to

278   estimate the difference in total AUDIT score between control and intervention groups accounting for

279   the baseline AUDIT score as covariate. Separate analyses at 3- and 6-months were performed.

280   For our main analyses we adjusted for baseline characteristics if these differed between trial arms at

281   baseline. The covariates that we controlled for in each model are specified when a model is

282   presented. The statistical packages STATA (38) and R (39) were used to carry out the analyses, with a

283   P-value < 0.05 considered statistically significant.

284   The validated Motivational Interviewing Treatment Integrity (MITI) coding tool (version 4.2.1) was

285   used to assess MI intervention fidelity.(40) The coding entailed making 'Global Ratings' (on 4

286   dimensions: Cultivating change talk, Softening sustain talk, Partnership and Empathy) and

287   'Behaviour' counts (with respect to the items: giving information, persuade, persuade with

288   permission, question, simple reflection, complex reflection, affirm, seeking collaboration,

289   emphasising autonomy and confront). A score was assigned to each of these items and the scores

290   compared against the competency and proficiency thresholds that are specified in the MITI manual.

9

291

292　For the analysis of the costs, all costs were collected in South Africa Rand (ZAR) except for the data

293　management system subscription. Results are presented in both ZAR and US dollar ($) using the

294　2019 OECD exchange rate (1 USD = 14.448 Rand).(36) No South African specific valuation set was

295　available for EQ-5D-3L. The valuation set of Argentina, based on a Visual Analogue Scale, was used to

296　derive utility values, because the GDP per capita in international dollars was the closest between the

297　two countries at the time of analysis.(37,41) Quality-adjusted life years (QALYs) were derived from

298　the utility values at the time points by calculating the area under the curve.(42) No missing data

299　imputation was performed.

300

301

302　**RESULTS**

303

304　**Participant enrolment and follow-up**

305　A total of 2099 patients with TB were screened for eligibility out of which 574 consenting and eligible

306　participants were randomised: 291 to control and 283 to intervention. Trial recruitment was

307　terminated on 31 August 2019 before the planned sample size was reached because of budget and

308　time constraints. In the intervention arm, 227 (80.2%) participants completed the first MI (MI 1)

309　session, 199 (70.3%) MI 2 and 150 (53.0%) MI 3. In the intervention arm, at least one message was

310　delivered to 208 (73.5%) participants, while 99 (35.0%) received all messages. Of those randomised

311　to the control and intervention groups, the primary outcome was recorded in 244 (83.8%) and 253

312　(89.4%) participants, respectively. (Figure 1)

313

314　**Figure 1 Consort flow diagram**

315

316　**Baseline participant characteristics of the intervention and control arm**

317　Socio-demographic; socio-economic and clinical characteristics

318　Baseline characteristics were distributed similarly in the intervention and control arms for most

319　variables but with some imbalances in educational level. A total of 513 (91.3%) participants were

320　new patients with TB, 129 (22.5%) women, and nearly all had PTB (International Classification of

321　Diseases-10 A15) without extrapulmonary TB manifestations (553 (98.9%)). About half of the

322　participants were HIV positive (305 (53.2%)), of whom 204 (65.4%) were on cotrimoxazole and 257

323　(82.4%) were on ART. (Table 1) Details of marital status, employment, wealth, depression status and

324　co-morbidities are presented in Supplementary table 1.

10

1
2
3   325
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11

Table 1 Baseline descriptive socio-economic statistics and clinical characteristics by study arm			
	Control (N = 291) n (%)*	Intervention (N = 283) n (%)*	Total (N=574) n (%)*
Age in years: mean (SD)	39.37 (12.60)	38.56 (11.15)	
Female Sex	69 (23.7)	60 (21.2)	129 (22.5)
Education			
No education	7 (2.4)	5 (1.8)	12 (2.1)
Grades 1-5	23 (7.9)	20 (7.1)	43 (7.5)
Grades 6-7	32 (11.0)	35 (12.4)	67 (11.7)
Grades 8-11	96 (33.0)	128 (45.2)	224 (39.0)
Grade 12	87 (29.9)	70 (24.7)	157 (27.4)
Higher	24 (8.2)	8 (2.8)	32 (5.6)
Declined to answer**	22 (7.6)	17 (6.0)	39 (6.8)
TB Patient category			
New patient	264 (92.3)	249 (90.2)	513 (91.3)
Relapse	10 (3.5)	9 (3.3)	19 (3.4)
Re-treatment after default	9 (3.1)	14 (5.1)	23 (4.1)
Re-treatment after failure	1 (0.3)	2 (0.7)	3 (0.5)
Other	2 (0.7)	2 (0.7)	4 (0.7)
TB Site of disease Pulmonary only (ICD-10 A15)	281 (98.9)	272 (98.9)	553 (98.9)
TB Sputum smear, Gene XPert, or culture result available N=	236	227	463
At least one Sputum smear, Gene XPert, or culture result positive	208 (88.1)	195 (85.9)	403 (87.0)
HIV status			
Negative	118 (40.7)	125 (44.2)	243 (42.4)
Positive	163 (56.2)	142 (50.2)	305 (53.2)
Unknown	9 (3.1)	16 (5.7)	25 (4.4)
HIV positive patients			
Using Cotrimoxazole	104 (63.8)	100 (67.1)	204 (65.4)
Using anti-retroviral	139 (85.3)	118 (79.2)	257 (82.4)

12

1
2
3   326   * Frequencies and (percentages) are presented unless otherwise stated
4   327   **More variables with the option "declined to answer" are listed in the Supplementary table 1
5   328
6
7
8   **Table 2** Baseline descriptive alcohol and smoking characteristics by study arm
9

	Control (N=291)	Intervention (N=283)	Total (N=574)
	n (%)*	n (%)*	n (%)*
In the past month, smoked tobacco			
Not at all**	110 (37.8)	92 (32.5)	202 (35.2)
Daily	149 (51.2)	149 (52.7)	298 (51.9)
Less than Daily	32 (11.0)	42 (14.8)	74 (12.9)
Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)
AUDIT Score (males) : mean (SD) [max: 19]†	12.27 (3.98)	13.02 (3.78)	12.66 (3.89)
AUDIT Score (females): mean (SD) [max: 19]†	11.32 (4.02)	10.98 (4.02)	11.15 (4.0)
Hazardous/harmful drinking and Smoking Combined (Constructed)			
Hazardous/harmful drinking Only‡	110 (37.8)	92 (32.5)	202 (35.2)
Smoking Only	103 (35.4)	77 (27.2)	180 (31.4)
Smoking and hazardous/harmful drinking‡	78 (26.8)	114 (40.3)	192 (33.4)

28   329   * Frequencies and (percentages) are presented unless otherwise stated
29   330   **Non-smokers were only included if they were harmful or hazardous drinkers
30   331   †Only hazardous/harmful drinkers and/or current smokers were included in the study. Therefore, patients with TB were excluded if they were non-current smokers and had an AUDIT score
31   332   <7 (females) or <8 (males) or >19; however, they were included if they were smokers independent of whether they had a drink in the past year and therefore independent of the AUDIT
32   333   score. These AUDIT scores are thus representative of the mean AUDIT scores in the entire study sample and differ from the AUDIT score in the harmful/hazardous drinkers whose change in
33   334   AUDIT score was measured at 3 and 6-months follow-up
34   335   ‡Harmful/hazardous drinking is defined as Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20
35   336

36
37
38
39
40
41   13
42
43
44
45
46

337 There were 372 current smokers (298 daily, 74 less than daily). Seventy eight participants (26.8 %) in

338 the control arm were dual smokers *and* drinkers compared to 114 (40.3 %) in the intervention arm.

339 In the control arm, 110 (37.8%) were hazardous/harmful drinkers only and 103 (35.4%) were

340 smokers only, compared to 92 (32.5%) and 77 (27.2) respectively, in the intervention arm. (Table 2)

341 More details of smoking and drinking history, forms of tobacco use, addiction and quit attempts are

342 presented in Supplementary Table 2.

343

344 **Primary outcome**

345 Overall, 396 (70%) of participants were classified as treated successfully (treatment completed or

346 cured). The remainder either interrupted treatment, failed treatment, developed drug resistance,

347 were transferred out or had an unknown treatment outcome.(Supplementary table 3) The

348 percentage of successful TB treatment did not differ significantly between the control and

349 intervention arm (70.1% vs. 67.8%), odds ratio (OR) for successful TB treatment 0.90 (95%CI:

350 (0.64,1.27)) comparing the intervention arm to the control arm; and was similar to adjusted ORs

351 (Tables 3 and 4).

352

353 **Secondary outcomes**

354 Cure rates

355 Among the 403 participants who had at least one positive bacteriological result at baseline, 168

356 (41.7%) were recorded as cured; of these, 83/205 (39.9%) were in the control arm compared to

357 85/195 (43.6%) in the intervention arm. The OR of being cured was 1.16 (95% CI: 0.83,1.63) in the

358 intervention versus the control arm; and was similar to the adjusted OR. (Tables 3 and 4)

359

360 Continuous smoking abstinence

361 Among those who identified as cigarette smokers at baseline (345 (60.1%)), 27 had information (self-

362 report plus biochemical verification) to enable the identification of continuous abstinence at 6-

363 months of which 22 had continuously abstained from smoking. These were similarly distributed

364 across the two study arms: 10 (5.59%) participants in the intervention arm compared to 12 (7.23%)

365 in the control arm, OR 0.76 (95% CI: 0.35,1.63). (Tables 3 and 4) At the 3-month follow-up 20 (11.2%)

366 participants in the intervention arm compared to 27 (16.3%) in the control arm continuously

367 abstained from smoking, OR 0.65 (95% CI: 0.37,1.14). (Tables 3 and 5)

368

14

TABLE 3 Descriptive statistics for primary and secondary outcomes by study arm at baseline (where available), 3-months (where available) and 6-months

	Baseline n (%)*			3-months follow-up n (%)*			6-months follow-up n (%)*		
	Control	Intervention	Total	Control	Intervention	Total	Control	Intervention	Total
TB treatment status[a]									
Successful**							204 (70.1)	192 (67.8)	396 (69.0)
Not Successful							87 (29.9)	91 (32.16)	178 (31.01)
Cured [a, *]**									
Yes							83 (39.9)	85 (43.6)	168 (41.7)
No							125 (60.1)	110 (56.4)	235 (58.3)
Continuous smoking abstinence[b]									
Yes				27 (16.3)	20 (11.2)	47 (13.6)	12 (7.2)	10 (5.6)	22 (6.4)
No				139 (83.7)	159 (88.8)	298 (86.4)	154 (92.8)	169 (94.4)	323 (93.6)
Harmful/hazardous drinkers[i]: N =	188†	206†	394†	141†	130†	271†	112†	127†	239†
AUDIT score: mean (SD)	12.76 (3.42)	13.12 (3.47)	12.94 (3.45)	8.28 (6.18)	8.84 (5.38)	8.55 (5.81)	8.79 (6.66)	8.70 (5.83)	8.74 (6.22)
Difference from baseline: mean (SD)				-4.61 (6.26)	-4.07 (5.33)	-4.35 (5.83)	-4.25 (6.56)	-4.17 (6.61)	-4.21 (6.57)
HIV positive patients:	163† (56.2)	142† (50.2)	305† (53.2)	122†	83†	205†	100†	83†	183†
Taking ART medication if HIV positive‡	139 (85.3)	115 (81.0)	254 (83.3)	91 (74.6)	58 (69.9)	149 (72.7)	80 (80.0)	74 (89.2)	154 (84.2)

15

ART medication adherence[b]						
Optimal adherence	101 (99.0)	64 (98.5)	165 (98.8)	75 (97.4)	64 (97.0)	139 (97.2)
Suboptimal adherence	1 (1.0)	1 (1.54)	2 (1.2)	2 (2.6)	2 (3.0)	4 (2.8)
TB medication adherence						
Optimal adherence	181 (92.3)	138 (90.8)	319 (91.7)	61 (89.7)	59 (90.8)	120 (90.2)
Suboptimal adherence	15 (7.6)	14 (9.2)	29 (8.3)	7 (10.3)	6 (9.2)	13 (9.8)

a: only assessed at 6-months

b: assessed at 3 and 6-months; this table refers to *cigarette* smokers only (other forms of tobacco smoking are excluded)

* Frequencies and (percentages) are presented unless otherwise stated

**Primary Outcome: This is a binary variable defined as either successful treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss to follow-up or treatment interrupted for more than 2 months, or outcome not evaluated/unknown.

***Based on having a cured treatment outcome among those who were bacteriologically positive at baseline.

! hazardous/harmful drinkers who are not alcohol dependent= AUDIT score ≥ 8 for men or ≥ 7 for women but < 20; *! Important distinction at baseline for eligibility purposes.

†Denominator for the mean (SD) or denominator for %

‡ Information on HIV-positivity was obtained from information from TB records combined with patient self-report at baseline. True HIV-positivity rates may have been higher.

16

TABLE 4 Regression analysis results for the primary and secondary outcomes at 6-months

	Crude Odds Ratio (95% CI)*	P Value*	Adjusted Odds Ratio (95% CI)*	P Value*
Primary outcome				
TB treatment status: Successful (Ref: Not successful)	0.90 (0.64,1.27)	0.548	0.86‡ (0.60,1.24)	0.421
Secondary outcomes				
Cured (Ref: Not Cured)	1.16 (0.83,1.63)	0.374	1.07‡ (0.76,1.51)	0.684
Continuous smoking abstinence (Ref: No)***	0.76 (0.35,1.63)	0.482		
TB medication adherence (Ref: Optimal)	0.89 (0.26,3.07)	0.849		
ART medication adherence (Ref: Optimal)	1.17 (0.14,9.94)	0.884		
Taking ART medication (Ref: No)	2.05! (0.80,5.27)	0.136		
AUDIT	-0.04** (-2,1.91)	0.966	0.02!! (-1.55,1.6)	0.976

* Analyses accounted for potential clustering by centre.

‡ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline. It is worth noting that of the variables in the adjusted model; the only statistically significant result is for the district variable.

! Adjusting for art status at baseline

**Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.

!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.

***Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.73 and 0.76 with similar confidence limits as for the crude estimate.

17

TABLE 5 Regression analysis results for secondary outcomes measured at 3-months

Secondary outcome	Crude Odds Ratio (95% CI)*	P Value*	Adjusted Odds Ratio (95% CI)*	P Value*
Continuous smoking abstinence (Ref: No)**	0.65 (0.37,1.14)	0.135		
TB medication adherence (Ref: Optimal)	1.22 (0.52,2.87)	0.641		
ART medication adherence (Ref: Optimal)	1.58 (0.10,26.12)	0.750		
Taking ART medication (Ref: No)	0.79! (0.38,1.65)	0.53	0.74‡ (0.35,1.58)	0.443
AUDIT	0.55† (-1.01,2.11)	0.474	0.74!! (-0.62,2.1)	0.273

*Analyses accounted for clustering.

! Adjusting for art status at baseline

‡ Adjusted for art status at baseline, district, sex, and smoking/drinking status and HIV status at baseline.

†Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.

!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.

** Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.63 and 0.66 with similar confidence limits as for the crude estimate.

18

369   Change in harmful/hazardous drinking

370   AUDIT scores were about 4 points lower at both follow-up times than at baseline, independent of

371   the intervention.(Table 3) In the intervention arm, participants had, on average, a reduction of 0.04

372   points (95% CI: -2,1.91) on the AUDIT score at 6-months, compared to those in the control arm

373   controlling for baseline scores; whereas an average increase of 0.55 (95% CI: -1.01,2.11) was

374   observed at 3-months. (Tables 4 and 5)

375

376   Medication adherence and ART uptake

377   At 6-months, the OR of taking ART medication was 2.05 (95% CI: 0.80,5.27) comparing the

378   intervention arm to the control arm and controlling for ART baseline medication status; whereas it

379   was 0.79 (95% CI: 0.38,1.65) at 3-months. The proportion of participants who had optimal TB

380   medication adherence was 90.2% (120/133) at 6-months and 91.7% (319/348) at 3-months.

381   Suboptimal TB medication adherence ORs were 0.89 (95%CI: 0.26,3.07) and 1.22 (95%CI: 0.52,2.87)

382   comparing intervention arm to the control arm at 6-months and 3-months, respectively. The

383   proportions of participants on ART who had optimal ART medication adherence were high at both 3-

384   months (165/167, 98.8%) and 6-months follow-up (139/143, 97.2%). Suboptimal ART medication

385   adherence ORs were 1.17 (95%CI: 0.14,9.94) and 1.58 (95%CI: 0.10,26.12) comparing the

386   intervention arm to the control arm at 6-months and 3-months, respectively. (Tables 3, 4 and 5)

387

388   **Intervention fidelity**

389   Motivational interviewing fidelity

390   The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In terms

391   of the global ratings, the LHWs' counselling sessions were above proficiency levels on all items,

392   namely, cultivating change talk, softening sustain talk, partnership, and empathy (as the mean scores

393   were all above 2). In terms of the summary measures, the LHWs' counselling sessions did not

394   achieve the basic proficiency threshold of 3.5 for the Relational component (Partnership + Empathy)

395   as their mean score was 3.1 (SD=1.19). However, their mean score on the Technical component

396   (Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For

397   behavioural counts, "Asking Questions" had the highest mean score (24.2; SD=10.42), followed by

398   "Affirm" with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the

399   following: Persuade with permission and emphasising autonomy. The mean Reflections to Questions

400   Ratio was 0.23 (SD=0.24). The LHWs made on average 9.3 (SD=4.74) MI adherent (Affirm, Emphasize

401   Autonomy and Seek Collaboration) and 1.2 (SD=2.28) MI non-adherent (Confront and Persuade)

402   statements per session. (Supplementary Table 4)

19

403

404   SMS-delivery

405   Of the total number of Information-Motivation-Behaviour messages triggered, 3583 (80.4%) were

406   delivered. All due SMS messages were delivered to 95 (41.9%) of the participants who completed

407   the first MI, See Supplementary Table 5 for more details.

408

409   **Costs and health related quality of life**

410   Unit costs used to estimate the mean costs are presented in the Supplementary Table 6. Incremental

411   cost-utility ratios are not presented since the intervention was not clinically effective. The mean cost

412   of the ProLife intervention was ZAR 2601 (SD 6) ($180.02 (SD $0.42)) per participant in the

413   intervention arm (n=283). The mean cost of usual care was ZAR 681 (SD 357) ($47.13 (SD $24.71)) in

414   the intervention arm (n=122) versus ZAR 706 (SD 302) ($48.86 (SD $20.90)) in the control arm

415   (n=131). The total mean cost of care including the intervention was ZAR 3285 (SD R357) ($227.37 (SD

416   24.71)) in the intervention arm (n=122). EQ-5D-3L data were available at the 3 time points for 137

417   intervention and 159 control arm participants. The mean QALYs estimated over six months were

418   0.442 (SD 0.061) in the intervention arm versus 0.430 (SD 0.074) in the control arm (adjusted mean

419   difference 0.006 (95% CI -0.001 to 0.013)).

420

421   **DISCUSSION**

422

423   This RCT did not provide evidence for improved TB treatment success rates in those receiving the

424   ProLife intervention compared to those receiving usual care. We could also not demonstrate

425   significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption,

426   medication adherence and ART initiation. To our knowledge there are no other published studies of

427   similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or

428   drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex

429   interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of

430   increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused

431   on a single behaviour, namely smoking or drinking.(45,46). Of the latter studies, a brief smoking

432   cessation intervention was effective in inducing smoking cessation in patients with TB but did not

433   improve TB outcomes.(45) Conversely, in another study in India, intensive counselling for alcohol

434   disorders led to significantly better TB treatment outcomes in the intervention group compared to

435   the control group.(46) Smoking cessation also led to better TB treatment outcomes in a secondary

436   analysis of a large tobacco cessation trial in patients with TB in Bangladesh and Pakistan.(47) Our

20

437   non-significant result for smoking-related outcomes is not consistent with findings from our previous

438   TB study, which used a single MI session and found that the chance of sustained smoking cessation

439   was twice as high in the MI intervention group compared to the control group,(14) albeit with a less

440   stringent exhaled CO cut-off point. Evidence on the effectiveness of MI for smoking abstinence in

441   non-TB settings has been equivocal.(48) Self-reported alcohol consumption decreased with about 4

442   points in both intervention and control arms in our study at both follow-up times. Answering

443   questions on drinking in brief intervention trials may alter subsequent self-reported behaviour:

444   exposing non-intervention control groups to an integral component of the intervention may

445   therefore underestimate the effect of the intervention.(49) There have been few previous studies

446   looking at MI and SMS interventions for the modification of hazardous/harmful drinking in the

447   context of TB. A previous trial of a brief counselling intervention to reduce alcohol consumption in

448   patients with TB did not find a significant effect on alcohol reduction.(50) Outside a TB setting,

449   results have been mixed. A meta-analysis showed a small but significant improvement in outcomes

450   when MI was used in conjunction with cognitive behavioural therapy for co-morbid alcohol use and

451   depression.(51) Self-reported TB and ART medication adherence was high overall in our study

452   population, which is consistent with other studies conducted in South Africa.(52,53) It is possible

453   that we did not find a difference in treatment adherence due to a ceiling effect.

454

455   There were several key strengths in this RCT. This was an individually RCT with a relatively large

456   sample size and a high follow up rate (87%) for the primary outcome. Primary outcome assessment

457   was blinded. This was a novel intervention, which built on previous successes with both MI and

458   mHealth interventions and was aligned with the WHO's call to increase the use of digital

459   technologies to improve TB care.(15) We utilized a validated alcohol consumption questionnaire

460   (AUDIT) (29) and a four-day timeline follow-back for medication adherence to reduce recall bias as

461   self-reports tend to underreport drinking while overestimating adherence behaviour compared

462   with.(54) (35) Smoking cessation was confirmed with exhaled CO using strict cut-off points. Overall,

463   the quality of the counselling was acceptable. The results of our MI analyses suggest that the LHWs

464   trained as counsellors were more proficient in MI than during the feasibility stage, as observed by

465   their global rating scores on cultivating change talk, softening sustain talk, partnership and empathy.

466   (Supplementary Table 4) These results were achieved by ongoing monitoring and training of LHWs

467   during the trial and adapting the training based on feedback from the feasibility stage. Extra

468   counsellors were also appointed to minimise travel distances to clinics. There were some limitations

469   associated with this RCT. Trial recruitment had to be terminated before the planned sample size

470   because of funding and time constraints. Nevertheless, the calculation of sample size was based on

21

471   an anticipated 25% LTFU for the primary outcome, while in reality only 13.4 %, of the TB outcomes

472   were not available. As a result, we achieved a slightly higher power to detect the a 10% difference in

473   primary outcomes, than we had aimed for (83% vs. 80%). The smaller sample size did however

474   reduce the power to detect a difference for secondary outcomes for which the LTFU was much

475   higher than 25%. Also, the calculated sample size was not powered for subgroup analysis which was

476   the case for outcomes relating to smoking, drinking, ART and cure rates. In addition, due to COVID-

477   19 lockdown in March 2020, we had to switch to telephonic follow-up of participants using a

478   shortened questionnaire (22 participants) and could not access clinics to retrieve outstanding TB

479   treatment outcomes. The low intervention uptake meant that half of the participants received only

480   one or two MI sessions combined with SMS messages. SMS messages were only used for the first

481   half of the study period, and one quarter of participants did not receive their messages, a commonly

482   occurring problem in developing countries.(20,55) It could be argued that in the absence of ongoing

483   text messages, the MI and associated text messages were not enough to keep participants focussed

484   for the second three months of the trial. The 2-arm study design did not permit the untangling of the

485   individual effects of SMS and MI. Understanding their separate effects could have important cost

486   implications as SMS-communication would be cheaper and easier to organise than individual

487   counselling.

488

489   The lack of effectiveness of our intervention on the primary outcome (TB treatment success) can

490   have a number of possible explanations. Although intervention uptake was high (80.2%) for the first

491   counselling session, many participants did not return for the second (29.7%) and third (47%)

492   sessions. As a result of this only about half of the intervention arm participants received all three MI

493   sessions. Furthermore, about one quarter of all participants did not receive any SMS-messages. Low

494   intervention uptake leads to a dilution of any potential effects. The lack of effectiveness on TB

495   treatment success could perhaps also be explained by the complexity of the ProLife intervention

496   itself: counsellors had to address multiple behaviours, namely medication adherence, tobacco

497   smoking and hazardous/harmful drinking. Despite having established the feasibility and acceptability

498   of this approach (31) and ongoing on site performance monitoring and feedback of counsellors, it is

499   possible that MI for multiple behaviour change in the ProLife study was counterproductive as

500   counsellors may have ended up not focusing on any of the behaviours at optimal levels. Similarly,

501   patients might have found it difficult to change multiple behaviours simultaneously, especially

502   because smoking and drinking are mutually reinforcing. This integrated approach was nevertheless

503   adopted to avoid the need for multiple vertical counselling services (in addition to TB treatment and

504   HIV treatment), to allow the different elements of the programme to reinforce one another, and to

505   improve the affordability, feasibility and acceptability for a future roll-out of the programme. It is

22

506 also possible that sequential interventions may be better, at least for smoking cessation.(56) More

507 intensive counselling (more sessions) or a modified counselling method may have been more

508 appropriate, even more so since a recent review of reviews of MI casts doubt on its

509 efficacy.(48,57,58) For example, more emphasis on increasing patient knowledge in addition to

510 increasing self-efficacy may have been more effective.(59) The cause of the mobile health message

511 delivery problems (such as poor network coverage, no electricity to charge phones) (60) would need

512 to be investigated in order to increase the effectiveness of future mHealth interventions. Messages

513 may also have to be intensified or modified to be more interactive and/or tailored to specific

514 circumstances of each individual. This would improve the personal value of the intervention to the

515 individual, which is likely to increase the chances of their participation in the intervention.(61)

516 Consistent with the normalisation process theory,(62) cognitive participation in the intervention

517 might have been higher had we been deliberate in the implementation to ensure the TB nurse who

518 would have routinely seen the participants, provided additional support and motivated participants

519 to attend MI sessions with the counsellor. In this way, the intervention would have gained

520 'legitimacy' but this would have led to unblinding of the nurses to the intervention arm.

521

522 In conclusion, we could not demonstrate that the ProLife intervention was effective in improving TB

523 treatment outcomes. This may be due to the lack of effect of the intervention, but the study may

524 also have been underpowered for the intermediary secondary outcomes. Valuable lessons were

525 learnt on challenges relating to training LHWs in MI counselling and delivery, SMS-delivery in a

526 challenging socio-economic context and the reasons for loss to follow-up of TB participants with

527 multiple health problems. Further research is needed to provide answers on how to increase

528 intervention uptake in poor resource settings and whether our complex intervention should have

529 been more intensive. Other important questions are whether another counselling method would

530 have been more effective. Lastly, in the light of the already existing evidence of SMS and the costs

531 and implementation challenges relating to MI, intervention studies limited to an mHealth

532 intervention but using different intensities, duration and type of interventions (one-way, two-way,

533 interactive) are needed.

534

23

Contributors

MK contributed to study design and the manuscript, led on the sample size determination and did the statistical analysis. NKM contributed to study design, particularly with respect to development of the MI intervention, did the analysis of the MI data and contributed to the manuscript writing. AVZ led the data management and SMS-system, monitored data quality and contributed to data analysis and manuscript writing. ASM contributed to study design and led on the preparation of the manuscript. NDM contributed to study design, intervention development and manuscript preparation. JL and SP led on the economic evaluation. AT contributed to the economic evaluation. JT was site lead for the Bojanala sub-district. OBO was site lead for the Sedibeng sub-district. MOB contributed to study design, data interpretation and the manuscript. KS and OAA are co-principal investigators. Both contributed to study design, data interpretation and manuscript writing. All authors read and approved the final draft of the manuscript.

1
2
3   568
4
5   569   **Competing interests**
6
7   570   OA Ayo-Yusuf, the principal investigator, received a research grant (MRC-RFA-02: TB -
8
9   571   05-2015) which was allocated to Sefako Makgatho Health Sciences University to pay
10
11   572   for the expenses related to the research project. As co-prinicipal investigator K Siddiqi
12
13   573   received part of the MRC-Newton research grant (MRC-RFA-02: TB -05-2015) which
14
15   574   was allocated to the University of York to support the research by the authors
16
17   575   affiliated to the University of York (K Siddiqi, ND Mdege, M Kanaan, S Parrot, J Lee).
18
19   576   Goedele Louwagie received a small monthly remuneration per month from 1 October
20
21   577   2018 until 30 June 2020 as academic research coordinator. André van Zyl was
22
23   578   employed as a research data manager on a part-time basis from 1 September 2017
24
25   579   and 30 June 2020. OA Ayo-Yusuf received support for attending meetings and for
26
27   580   travel by Tax Justice Network Africa. He is the Vice Chair of the Standing Committee on
28
29   581   Health, Academy of Science, SA (not remunerated). The remaining authors declare no
30
31   582   competing interests.

         583

         584   **Ethical considerations**

         585   This study received ethics approval from the Research Ethics Committees of: Sefako

         586   Makgatho Health Sciences University (SMU; Ref: SMUREC/D/234/2017: IR); the South

         587   African Medical Research Council (with the SMU Ethics Committee serving as the

         588   Research Ethics Committee Record); the University of Pretoria (Ref: 434/2017); the

         589   University of Witwatersrand (M160455); and the University of York (no reference

         590   number, approval date 15 January 2017 (29).

         591

         592   **Patient Consent for publication**

         593   Not applicable

         594

         595   **Data availability statement**

         596   The study protocol was previously published.(30) The de-identified participant and

         597   SMS data sets are stored in labelled Stata files and are accompanied by a statistical

         598   analysis plan and metadata explaining each variable. Although data can be viewed

         599   immediately, data will be embargoed for data analysis until 30 June 2023. Thereafter,

         600   permission must be obtained from the principal investigators (OA and KS) for any data

25

601 analysis not yet performed by the primary research group. Data are stored in the

602 institutional data repository at Sefako Makgatho Health Sciences University called

603 Discover research (https://smu-za.figshare.com/) with a CC-BY 4.0 (Attribution) license

604 (Creative Commons — Attribution 4.0 International — CC BY 4.0). The statistical

605 analysis plan is available as supplementary material.

606

607 **Open access**

608 This is an open access article distributed in accordance with a Creative Commons

609 Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix,

610 transform and build upon this work for any purpose, provided the original work is

611 properly cited, a link to the licence is given and indication of whether changes were

612 made. See: https://creativecommons.org/licenses/by/4.0/.

613

614 **References**

615

616 1. World Health Organisation. Global tuberculosis report 2020. Available:

617 https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf

618 [Accessed 4 Aug 2021].

619 2. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the

620 Sustainable Development Goals. *Trans R Soc Trop Med Hyg* 2016;110:145–7.

621 3. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis

622 treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. *PLoS ONE*

623 14(7):e0220507.

624 4. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis:

625 meta-analyses and burden of disease. *Eur Respir J* 2017;50: 1700216.

626 5. Ogbo FA, Ogeleka P, Okoro A, et al. Tuberculosis disease burden and attributable risk factors

627 in Nigeria, 1990–2016. *Tropical Medicine and Health* 2018;46:34.

628 6. Azeez A, Mutambayi R, Odeyemi A, et al. Survival model analysis of tuberculosis treatment

629 among patients with human immunodeficiency virus coinfection. *Int J Mycobacteriol*

630 2019;8:244-51.

631 7. Mollel EW, Chilongola JO. Predictors for Mortality among Multidrug-Resistant Tuberculosis

632 Patients in Tanzania. J Trop Med 2017;2017:9241238. doi: 10.1155/2017/9241238.

633 8. Peltzer K. Conjoint alcohol and tobacco use among tuberculosis patients in public primary

634 healthcare in South Africa. *S Afr J Psychiatr* 2014;20(1):21–6.

26

635   9.   Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis

636   treatment outcomes: a systematic review and meta-analysis. *Int J Tuberc Lung Dis*

637   2020;24(1):73–82.

638   10. Department of Health of South Africa. National Tuberculosis Management Guidelines.

639   Pretoria: 2014. Available from:

640   http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-

641   27.5.2014.pdf [Accessed 4 Aug 2021].

642   11. Harder VS, Musau AM, Musyimi CW, et al. A randomized clinical trial of mobile phone

643   motivational interviewing for alcohol use problems in Kenya. *Addiction* 2020 ;115:1050-1060.

644   12. Palacio A, Garay D, Langer B, et al. Motivational Interviewing Improves Medication

645   Adherence: a Systematic Review and Meta-analysis. *Gen Intern Med.* 31:929–40. DOI:

646   10.1007/s11606-016-3685-3.

647   13. Madhombiro M, Kidd M, Dube B, et al. Effectiveness of a psychological intervention delivered

648   by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster

649   randomized controlled trial. *J Int AIDS Soc* 2020 Dec;23:e25641.

650   14. Louwagie GMC, Okuyemi KS, Ayo-Yusuf OA. Efficacy of brief motivational interviewing on

651   smoking cessation at tuberculosis clinics in Tshwane, South Africa: a randomized controlled

652   trial. *Addiction* 2014;109:1942–52

653   15. World Health Organization. Handbook for the use of digital technologies to support

654   tuberculosis medication adherence, 2017. Available:

655   https://apps.who.int/iris/handle/10665/259832 [Accessed 4 Aug 2021].

656   16. Hirsch-Moverman Y, Daftary A, Yuengling KA, et al. Using mhealth for HIV/TB treatment

657   support in lesotho: Enhancing patient-provider communication in the start study. *J Acquir*

658   *Immune Defic Syndr* 2017;74:S37–43.

659   17. Shah R, Watson J, Free C. A systematic review and meta-analysis in the effectiveness of

660   mobile phone interventions used to improve adherence to antiretroviral therapy in HIV

661   infection. *BMC Public Health* 2019;19:915.

662   18. Gashu KD, Gelaye KA, Mekonnen ZA, et al. Does phone messaging improves tuberculosis

663   treatment success? A systematic review and meta-analysis. *BMC Infect Dis* 2020;20:42.

664   19. Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on

665   tuberculosis treatment: a systematic review. Eur Respir J. 2018 11;51(1):1701596. doi:

666   10.1183/13993003.01596-2017

667   20. Ggita JM, Ojok C, Meyer AJ, et al. Patterns of usage and preferences of users for tuberculosis-

668   related text messages and voice calls in Uganda. *Int J Tuberc Lung Dis* 2018;22:530-536.

27

669   21.   Oosterveen E, Tzelepis F, Ashton L, et al. A systematic review of eHealth behavioral

670   interventions targeting smoking, nutrition, alcohol, physical activity and/or obesity for young

671   adults. *Prev Med* 2017;99:197–206.

672   22.   Haug S, Paz Castro R, Kowatsch T, et al. Efficacy of a technology-based, integrated smoking

673   cessation and alcohol intervention for smoking cessation in adolescents: Results of a cluster-

674   randomised controlled trial. *J Subst Abuse Treat* 2017;82:55–66.

675   23.   Siddiqi K, Stubbs B, Lin Y, et al. TB multimorbidity: a global health challenge demanding

676   urgent attention. *Int J Tuberc Lung Dis* 2021;25:87–90.

677   24.   Moosa S, Derese A, Peersman W. Insights of health district managers on the implementation

678   of primary health care outreach teams in Johannesburg, South Africa: A descriptive study

679   with focus group discussions. *Hum Resour Health* 2017;15:1–9.

680   25.   Marcus TS, Hugo J, Jinabhai CC. Which primary care model? A qualitative analysis of ward-

681   based outreach teams in South Africa. *African J Prim Heal Care Fam Med* 2017;9:1–8.

682   26.   Seidman G, Atun R. Does task shifting yield cost savings and improve efficiency for health

683   systems? A systematic review of evidence from low-income and middle-income countries.

684   *Hum Resour Health* 2017;15:1–13.

685   27.   Heunis C, Wouters E, Kigozi G, et al. TB/HIV-related training, knowledge and attitudes of

686   community health workers in the Free State province, South Africa. *African J AIDS Res*

687   2013;12:113–9.

688   28.   World Health Organization & Centers for Disease Control (U.S.). Tobacco questions for surveys: a

689   subset of key questions from the Global Adult Tobacco Survey (GATS): global tobacco surveillance

690   system. *World Health Organization* 2011. Available from:

691   https://apps.who.int/iris/handle/10665/87331 [Accessed 16 Nov 2021]

692   29.   Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT):

693   validation of a screening instrument for use in medical settings. *J Stud Alcohol* 1995;56:423–

694   32.

695   30.   Moriarty AS, Louwagie GM, Mdege ND, et al. ImPROving TB outcomes by modifying LIFE-style

696   behaviours through a brief motivational intervention followed by short text messages

697   (ProLife): Study protocol for a randomised controlled trial. *Trials* 2019;20:1–12.

698   31.   Louwagie GM, Morojele N, Siddiqi K, et al. Addressing tobacco smoking and drinking to

699   improve TB treatment outcomes, in South Africa: A feasibility study of the ProLife program.

700   *Transl Behav Med* 2020; 10: 1491–1503.

701   32.   CommCare. Cambridge, MA: Dimagi; 2017. Available from:

702   https://play.google.com/store/apps/details?id=org.commcare.dalvik&hl=en_US&gl=US.

703   [Accessed 15 June 2021].

28

704   33.   Siddiqi K, Khan A, Ahmad M, et al. Action to stop smoking in suspected tuberculosis (ASSIST)

705   in Pakistan: a cluster randomized, controlled trial. *Ann Intern Med* 2013;158:667–75.

706   34.   West R, Hajek P, Stead L, et al. Outcome criteria in smoking cessation trials: proposal for a

707   common standard. *Addiction* 2005;100:299–303.

708   35.   van den Boogaard J, Lyimo RA, Boeree MJ, et al. Electronic monitoring of treatment

709   adherence and validation of alternative adherence measures in tuberculosis patients: A pilot

710   study. *Bull World Health Organ* 2011;89:632–9.

711   36.   OECD [Internet]. Available from: https://data.oecd.org/conversion/exchange-rates.htm

712   [Accessed 26 Oct 2021]

713   37.   Augustovski FA, Irazola VE, Velazquez AP, et al. Argentine valuation of the EQ-5D health

714   states. *Value Heal* 2009;12:587–96.

715   38.   StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 2017.

716   39.   Team RC. R: A language and environment for statistical computing. Vienna, Austria: R

717   Foundation for Statistical Computing; 2017. Available from: https://www.r-project.org/

718   [Accessed 04 Aug 2021]

719   40.   Moyers TB, Rowell LN, Manuel JK, et al. The Motivational Interviewing Treatment Integrity

720   Code (MITI 4): Rationale, Preliminary Reliability and Validity. *J Subst Abuse Treat* 2016;65:36-

721   42. doi:10.1016/j.jsat.2016.01.001

722   41.   International Monetary Fund. IMF DataMapper - GDP per capita, current prices (Purchasing

723   power parity; international dollars per capita), 2018. Available from:

724   https://www.imf.org/external/datamapper/datasets [Accessed 04 Aug 2021]

725   42.   Richardson GMA. Calculation of quality adjusted life years in the published literature: a

726   review of methodology and transparency. *Health Econ* 2004;13:1203–10.

727   43.   Khachadourian V, Truzyan N, Harutyunyan A, et al. People-centred care versus clinic-based

728   DOT for continuation phase TB treatment in Armenia: a cluster randomized trial. *BMC Pulm

729   Med* 2020;20:105.

730   44.   Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a strategy to improve adherence to

731   tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. *JAMA*

732   2007;297:380–6.

733   45.   Goel S, Kathiresan J, Singh P SR. Effect of a brief smoking cessation intervention on adult

734   tobacco smokers with pulmonary tuberculosis: A cluster randomized controlled trial from

735   North India. *Indian J Public Heal* 2017;61(Suppl 1):S47–53

736   46.   Manogaran C, Nagarajan K, Ovung S, et al. Alcohol intervention strategy among tuberculosis

737   patients: a pilot study from South India. *Int J Tuberc Lung Dis* 2017;21:947–52

29

738 47. Siddiqi K, Keding A, Marshall AM, et al. Effect of quitting smoking on health outcomes during

739   treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial. *Thorax* 2021

740   Published Online First Jul 16:thoraxjnl-2020-215926. doi: 10.1136/thoraxjnl-2020-215926.

741 48. Lindson N, Thompson TP, Ferrey A, et al. Motivational interviewing for smoking cessation.

742   *Cochrane Database Syst Rev*. 2019;2019(7).

743 49. McCambridge J, Kypri K. Can simply answering research questions change behaviour?

744   Systematic review and meta analyses of brief alcohol intervention trials. *PLoS One*

745   2011;6(10):e23748.

746 50. Peltzer K, Naidoo P, Louw J, et al. Screening and brief interventions for hazardous and

747   harmful alcohol use among patients with active tuberculosis attending primary public care

748   clinics in South Africa: results from a cluster randomized controlled trial. *BMC Public Health*

749   2013;13:699.

750 51. Riper H, Andersson G, Hunter SB, et al. Treatment of comorbid alcohol use disorders and

751   depression with cognitive-behavioural therapy and motivational interviewing: a meta-

752   analysis. *Addiction* 2014;109:394–406.

753 52. Moosa A, Gengiah TN, Lewis L, et al. Long-term adherence to antiretroviral therapy in a South

754   African adult patient cohort: a retrospective study. *BMC Infect Dis* 2019;19(1):775. doi:

755   10.1186/s12879-019-4410-8.

756 53. Webb Mazinyo E, Kim L, Masuku S, et al. Adherence to Concurrent Tuberculosis Treatment

757   and Antiretroviral Treatment among Co-Infected Persons in South Africa, 2008–2010. *PLoS*

758   *One* 2016;11(7): e0159317. https://doi.org/10.1371/journal.pone.0159317.

759 54. Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence

760   behavior: recommendations on optimal use. *Transl Behav Med* 2015;5:470–82.

761 55. Wanyama JN, Nabaggala SM, Kiragga A, et al. High mobile phone ownership but low internet

762   access and use among young adults attending an urban HIV clinic in Uganda. *Vulnerable Child*

763   *Youth Stud* 2018;13:3,207-20.

764 56. Meader N, King K, Wright K et al. Multiple risk behavior interventions: Meta-analyses of RCTs.

765   *Am J Prev Med* 2017;53:e19–e30.

766 57. Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions.

767   *Health Psychol* 2008;27:379-87.

768 58. Frost H, Campbell P, Maxwell M, et al. Effectiveness of Motivational Interviewing on adult

769   behaviour change in health and social care settings: A systematic review of reviews. *PLoS One*

770   2018;18:13(10):e0204890

771 59. Kahwati L, Viswanathan M, Golin CE, et al. Identifying configurations of behavior change

30

772   techniques in effective medication adherence interventions: a qualitative comparative

773   analysis. *Syst Rev* 2016;5(83).

774 60.   Telerivet. Message Statuses . User Guide, 2021. Available from:

775   https://guide.telerivet.com/hc/en-us/articles/360038959611-Message-Statuses. [Accessed

776   21 June 2021]

777 61.   Lustria MLA, Noar SM, Cortese J, et al. A meta-analysis of web-delivered tailored health

778   behavior change interventions. *Journal of Health Communication* 2013;18:1039–69.

779 62.   Gallacher K, May CR, Montori V, et al. Understanding Patients' Experiences of Treatment

780   Burden in Chronic Heart Failure Using Normalization Process Theory. *Ann Fam Med*

781   2011;9:235-243.

31

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Enrolment

1
2
3

Assessed for basic eligibility (n=2099)

4
5
6
7

Excluded
Participants
• Not meeting inclusion criteria (862)
• Declined to participate (358)

8
9
10

Assessed for eligibility (n=879)

11
12
13
14
15
16
17

Excluded
Participants
• Not meeting inclusion criteria (294)
• Declined to participate in screening (4)
• Did not consent to RCT (4)
• Did not complete baseline and randomization (3)

18
19

Randomized (n=574)

20

Allocation

21
22
23
24
25
26
27

Allocated to control (n=291)
• Received intervention
  • MI 1 (n=0)
  • MI 2 (n=0)
  • MI 3 (n=0)
  • SMS (n=1)

Allocated to intervention (n=283)
Received allocated intervention
• MI 1 (n=227)
• MI 2 (n=199)
• MI 3 (n=150)
• All SMS (99), 1% to 60% of SMS (34), 61% to 99% of SMS (75)
Did not receive allocated intervention:
• MI 1 (n=56): Unable to get hold of (n=18), Discontinued intervention (n=15), Working or relocated (n=6), Deceased (n=3), Other (n=14)
• MI 2 (n=84): MI 1 Incomplete (n=56), Unable to get hold of (n=10), Working or relocated (n=3), Deceased (n=2), Other (n=13)
• MI 3 (n=133): MI 2 Incomplete (n=84), Unable to get hold of (n=19), Working or relocated (n=6), Discontinued intervention (n=6), Other (n=18)
• SMS (n=75)

28
29
30
31
32
33
34
35
36
37
38
39

Follow-Up

40
41
42
43
44
45
46
47
48
49
50
51
52

Month 3 (n=213)
• Lost to follow-up (n=78): Unable to get hold of (n=36), Working or relocated (n=14), Deceased (n=5), Discontinued intervention (n=3), Other (n=20)
Month 6 (n=173)
• Lost to follow-up (n=118): Unable to get hold of (n=49), Working or relocated (n=16), Deceased (n=7), Discontinued intervention (n=14), Other (n=32)
Month 6-9 TB outcome (n=244)

Month 3 (n=168)
• Lost to follow-up (n=115): Unable to get hold of (n=34), Working or relocated (n=21), Deceased (n=10), Discontinued intervention (n=14), Other (n=36)
Month 6 (n=165)
• Lost to follow-up (n=118): Unable to get hold of (n=49), Working or relocated (n=20), Deceased (n=13), Discontinued intervention (n=10), Other (n=26)
Month 6-9 TB outcome (n=253)

53
54

Analysis

55
56
57

Analysed
TB treatment outcome (n=291)

Analysed
TB treatment outcome (n=283)

58
59
60

SUPPLEMENTARY TABLES

Supplementary table 1 Detailed baseline descriptive statistics for socio-demographic, socio-economic, and clinical characteristics by study arm			
	Control (N = 291) n (%)*	Intervention (N = 283) n (%)*	Total (N=574) n (%)*
Marital status			
Married or living together	102 (35.1)	95 (33.6)	197 (34.3)
Divorced/separated	20 (6.9)	18 (6.4)	38 (6.6)
Widowed	10 (3.4)	7 (2.5)	17 (3.0)
Never married and never lived together	144 (49.5)	150 (53.0)	294 (51.2)
Declined to answer	15 (5.2)	13 (4.6)	28 (4.9)
Employment			
Self-employed (full-time)	30 (10.3)	36 (12.7)	66 (11.5)
Employed full-time (30 hrs a week or more)	62 (21.3)	54 (19.1)	116 (20.2)
Employed part-time (less than 30 hrs a week)	19 (6.5)	29 (10.2)	48 (8.4)
Retired	17 (5.8)	16 (5.7)	33 (5.7)
Unemployed (but able to work)	125 (43.0)	120 (42.4)	245 (42.7)
Unable to work because of long-term disability or ill health	9 (3.1)	8 (2.8)	17 (3.0)
Full-time student	12 (4.1)	4 (1.4)	16 (2.8)
Caring from my home and family/doing household work/housewife	0 (0.0)	2 (0.7)	2 (0.3)
Occasional work ("piece job")	17 (5.8)	12 (4.2)	29 (5.1)
Declined to answer	0 (0.0)	2 (0.7)	2 (0.3)
Ever worked or spent time in mines			
No	244 (83.8)	237 (83.7)	481 (83.8)
Yes	46 (15.8)	45 (15.9)	91 (15.9)
Household items (Yes is displayed)			
A radio	249 (85.6)	234 (82.7)	483 (84.1)
A television	255 (87.6)	255 (90.1)	510 (88.9)
A landline telephone	21 (7.2)	22 (7.8)	43 (7.5)
A desktop or laptop computer	67 (23.0)	48 (17.0)	115 (20.0)
A refrigerator	248 (85.2)	240 (84.8)	488 (85.0)
A vacuum cleaner or floor pol	49 (16.8)	35 (12.4)	84 (14.6)
A microwave oven	198 (68.0)	189 (66.8)	387 (67.4)
An electric or gas stove	254 (87.3)	238 (84.1)	492 (85.7)
A washing machine	153 (52.6)	136 (48.1)	289 (50.3)
Total number of assets: mean (SD)	5.14 (1.96)	4.94 (1.77)	5.04 (1.87)
In the past month, number of days you or people in the household went to bed hungry because there was no food to eat			
0 days	244 (83.8)	238 (84.1)	482 (84.0)
1-7 days	45 (15.5)	34 (12.0)	79 (13.8)
More than 7 days	2 (0.7)	9 (3.2)	11 (1.9)
Declined to answer	0 (0.0)	2 (0.7)	2 (0.3)
Number of pre-treatment smear tests recorded?			

	One	197 (92.1)	169 (87.6)	366 (89.9)
	Two	17 (7.9)	24 (12.4)	41 (10.1)
Number of Gene XPert results recorded				
	One	225 (97.8)	210 (97.2)	435 (97.5)
	Two	5 (2.2)	6 (2.8)	11 (2.5)
Number of culture results recorded on the TB Treatment record				
	One	54 (94.7)	42 (97.7)	96 (96.0)
	Two	3 (5.3)	1 (2.3)	4 (4.0)
Co-morbidities				
	Hypertension	19 (6.93)	11 (4.1)	30 (5.54)
	Diabetes	5 (1.84)	4 (1.49)	9 (1.66)
	Epilepsy	3 (1.09)	4 (1.49)	7 (1.29)
	Mental illness	3 (1.09)	0 (0)	3 (0.55)
	Liver disease	1 (0.36)	1 (0.38)	2 (0.37)
	Renal insufficiency	1 (0.36)	1 (0.38)	2 (0.37)
	Allergies	2 (0.76)	0 (0)	2 (0.38)
	Other	1 (0.36)	1 (0.38)	2 (0.37)
Depression score (CESD 10): mean (SD)		8.44 (4.38)	8.74 (4.8)	8.59 (4.59)

*Counts and percentages unless otherwise indicated

	Control n (%)*	Intervention n (%)*	Total n (%)*
Smoking History (current smokers only) N=	181	191	372
On the days that you smoke, how soon after you wake up do you have your first cigarette?			
After 60 minutes	30 (16.6)	28 (14.7)	58 (15.6)
31-60 minutes	24 (13.3)	16 (8.4)	40 (10.8)
6- 30 minutes	60 (33.1)	65 (34.0)	125 (33.6)
Within 5 minutes	67 (37.0)	82 (42.9)	149 (40.1)
Duration of smoking in months: mean (SD)	212.09 (134.03)	224.93 (127.82)	218.68 (130.86)
Duration of smoking in months: median (IQR)	186 (110, 282)	206 (135, 294)	200.5 (123, 287)
Age started smoking in years: mean (SD)	19.2 (6.3)	19.3 (6.3)	19.3 (6.3)
Age started smoking in years: median (IQR)	18 (15-20)	18 (16-21)	18 (15.5-20.5)
Form of tobacco used			
Manufactured cigarettes (Yes)	166 (91.7)	179 (93.7)	345 (92.7)
Number of days you smoked in the past 7days: mean (SD)	5.3 (2.65)	5.53 (2.33)	5.42 (2.49)
Average number of cigarettes smoked daily: mean (SD)	6.18 (6.43)	6.48 (8.21)	6.34 (7.39)
Hand-rolled cigarettes (Yes)	14 (7.7)	21 (11.0)	35 (9.4)
Number of days you smoked in the past 7days: mean (SD)	4.71 (2.84)	3.71 (2.95)	4.11 (2.91)
Average number of handrolled cigarettes smoked daily: mean (SD)	3.71 (3.97)	3.81 (2.82)	3.77 (3.27)
Pipe (Yes)	4 (2.2)	2 (1.0)	6 (1.6)
Number of days in the past 7days you smoked: median (IQR)	1 (0, 2.5)	4.5 (2, 7)	2 (0, 3)
Average number of daily sessions: median (IQR)	1 (0, 3.5)	3 (1, 5)	1.5 (0, 5)
Length of one session (on average) in **minutes**: median (IQR)	90 (60, 107.5)	60 (30, 90)	90 (30, 90)
Cigars, cheroots or cigarillos (Yes)	1 (0.55)	0 (0)	1(0.27)
Water pipe (Yes)	3 (1.7)	2 (1.0)	5 (1.3)
Other	10 (5.5)	4 (2.1)	14 (3.8)
Heaviness of smoking index >= 4	134(74.03)	158(82.72)	292(78.49)
Smoking inside your home restrictions			
Total: Not allowed	96 (53.0)	108 (56.5)	204 (54.8)
Some rules: where/when it is allowed	61 (33.7)	58 (30.4)	119 (32.0)
No rules	24 (13.3)	25 (13.1)	49 (13.2)

Supplementary table 2 Detailed descriptive statistics for smoking history, alcohol history at baseline by study arm

Attempts to quit smoking (current smokers only)			
Ever attempted to quit in the past (Yes)	52 (28.7)	64 (33.5)	116 (31.2)
Number of attempts to quit: mean (SD)	2.46 (2.98)	2.64 (1.62)	2.56 (2.32)
Time elapsed since attempt to quit last time, in months: mean (SD)	36.65 (94.62)	25.13 (37.91)	30.29 (69.22)
Longest duration abstinent in previous quit attempts: mean (SD)	6.15 (13.48)	4.22 (8.9)	5.09 (11.18)
Likelihood to TRY TO QUIT smoking completely and permanently in the next three months			
Definitely will not	6 (3.3)	5 (2.6)	11 (3.0)
Probably will not	10 (5.5)	12 (6.3)	22 (5.9)
Probably will	104 (57.5)	109 (57.1)	213 (57.3)
Definitely will	61 (33.7)	65 (34.0)	126 (33.9)
Likelihood that I WILL QUIT smoking completely and permanently in the next three months			
Definitely will not	6 (3.3)	5 (2.6)	11 (3.0)
Probably will not	11 (6.1)	13 (6.8)	24 (6.5)
Probably will	103 (56.9)	104 (54.5)	207 (55.6)
Definitely will	61 (33.7)	69 (36.1)	130 (34.9)
Ever used any methods to help you stop smoking tobacco in the past 3-months? (Yes)	23 (12.7)	16 (8.4)	39 (10.5)
Smokeless tobacco use (all participants)			
In the past month, have you used smokeless tobacco (Snuff) on a daily basis			
Not at all	275 (94.5)	275 (97.2)	550 (95.8)
Daily	12 (4.1)	6 (2.1)	18 (3.1)
Less than Daily	4 (1.4)	2 (0.7)	6 (1.0)
Duration of using ST in months: mean(SD)	113.69 (112.7)	152 (91.16)	126.46 (105.61)
Age started using ST in years: mean (SD)	27.56 (10.57)	25.88 (13.43)	27 (11.33)
Form of ST used (for SLT users)			
Snuff (by mouth)	2 (12.5)	0 (0.0)	2 (8.3)
Snuff (by nose)	11 (68.8)	5 (62.5)	16 (66.7)
Chewing tobacco leaves	0(0)	0(0)	0(0)
Other	1 (6.3)	0 (0.0)	1 (4.2)
Help to stop drinking (N= , had a drink in past 12 months)	208	223	431
Ever used any methods to stop drinking alcohol in the past 3-months	21 (11.2)	22 (10.7)	43 (10.9)

* Frequencies and (percentages) are presented unless otherwise stated

Supplementary table 3 Detailed descriptive statistics for primary outcome by study arm at 6-months			
TB treatment status detailed	Control n (%)	Intervention n (%)	Total n (%)
Cured	108 (37.1)	105 (37.1)	213 (37.1)
Treatment completed	96 (33.0)	87 (30.7)	183 (31.9)
Treatment interrupted > 2 months	15 (5.2)	29 (10.2)	44 (7.7)
Treatment failure	5 (1.7)	2 (0.7)	7 (1.2)
Acquired drug resistance	1 (0.3)	4 (1.4)	5 (0.87)
Died	11 (3.8)	15 (5.3)	26 (4.5)
Transfer out	8 (2.75)	11 (3.9)	19 (3.31)
Unknown	42 (14.4)	25 (8.8)	67 (11.7)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary table 4 MI treatment fidelity scores of counselling sessions delivered by 17 lay health workers*

Ratings	Mean (SD)	Range
Global ratings**		
Cultivating change talk	3.2 (1.17)	1-5
Softening sustain talk	3.4 (0.96)	1-4
Partnership	3.4 (1.12)	2-5
Empathy	2.9 (1.34)	1-5
Behaviour counts&		
Giving information	4.8 (8.13)	0-5
Persuade	0.8 (1.48)	0-5
Persuade with permission	0.1 (0.24)	0-1
Question	24.2 (10.42)	12-51
Simple reflection	4.1 (3.21)	0-10
Complex reflection	1.6 (2.69)	0-9
Affirm	5.5 (3.47)	1-12
Seeking collaboration	2.4 (1.46)	0-6
Emphasising autonomy	1.4 (1.37)	0-4
Confront	0.4 (0.74)	0-3
Summary measures		
Total MI non-adherent †	1.2 (2.28)	0-7
Total MI adherent†	9.3 (4.74)	1-16
Technical global ratings**	3.3 (0.97)	1.5-4.5
Relational global ratings**	3.1 (1.19)	1.5-5
Reflection to question ratio††	0.23 (0.24)	0-0.83
Percentage of complex reflections***	20.4 (21.9)	0-67

*The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In order to assess the fidelity of the counsellors' delivery of motivational interviewing during the trial, we are used the validated Motivational Interviewing Treatment Integrity Coding Manual 4.2.1 (MITI) tool. The table shows the results of the fidelity assessment that was conducted by one rater who is proficient in English, seSotho and seTswana and in motivational interviewing. The rater listened to the recordings and coded a randomly selected 20-min portion of the written transcript. In the case of shorter counselling sessions, the entire recording was assessed.

**The "global ratings" involve assessing, on a 5-point Likert scale (1 for low and 5 for high), how well or poorly the counsellor adheres to the MI practice. Ratings are conducted on four items, two each making up Technical Components (Cultivating change talk and Softening sustain talk) and Relational Components (Partnership and Empathy).

**Scores on Cultivating Change Talk and Softening Sustain Talk are averaged to obtain the Technical global scores.

***Scores on Partnership and Empathy are averaged to obtain Relational global scores. The basic competency threshold scores for fair and good proficiency are 3 and 4, respectively for Technical scores and 3.5 and 4, respectively for Relational scores.

&The "behaviour counts" involve counting 10 verbal behaviours of the counsellor during the intervention.

† "MI adherence" is determined by adding up the following verbal behaviours: Seeking Collaboration, Affirm and Emphasising autonomy. "MI non-adherence" is determined by summing instances of Confront and Persuade. No thresholds for MI adherence or non-adherence are specified in the MITI 4.2.1.

††The Reflection-to-Question (R:Q) ratio is the total reflections divided by the total questions asked. One reflection to each question is considered a "fair" practice level while two reflections to each question is considered a "good" practice level.

*** The Percentage of Complex Reflections (% CRs) is calculated by dividing the number of complex reflections by the sum of complex reflections and simple reflections. A fair and a good % CRs are 40% and 50%, respectively.

Supplementary table 5 SMS delivery				
			Intervention (N=283)	Control (N=291)
No. of participants who received ALL due IMB messages INDEPENDENT OF WHETHER they completed MI 1			99/283 (35%)	1/291 (0.3%)
Completion of first MI and initiation of SMS-sequence				
Completed first MI			227/283 (80.2%)	0/291 (0%)
No. of participants who received ALL due messages after receipt of MI1			95/227 (41.9%)	0/0 (0%)
SMS delivery for participants for whom the SMS-sequence was initiated (after receipt of first MI)				
	Mean (SD)	Median (IQR) Range	Mean (SD)	Median (IQR) Range
Average no. adherence messages received per participant (n=227)	7.9 (3.5)	10 (8-10) 0-11	0	0
Average no. tobacco-related messages received (n=153)	5.4 (2.5)	7 (5-7) 0-7	0	0
Average no. alcohol related messages received (n=171)	5.5 (2.5)	7 (5-7) 0-7	0	0
Average no. IMB messages received (n= 227)	15.7 (7.3)	17 (13-22) 0-25		

Page 7

1
2
3
4
5
6
7

Supplementary table 6 Unit costs used in the analysis (Presented in Rand as sources, $1=R14.448 in 2019)	
Item	Unit costs
Personnel	LHWs: R3000/month, 160 hours/month, R18.75/hour; District coordinators: R7500/month, 160 hours/month, R46.88/hour; MRC appointed supervisor: R205.79/hour; Trainers: R373.17/hour; Administrative staff: R333.24/hour
Materials	Training manual: R3250; Printing: R3000; Additional printing & stationary: R500
Accommodation / Travel / Refreshments	LHWs accommodation: R540 000; Trainers accommodation/travel: R36 000; Supervision accommodation/travel: R30 000; Refreshment: R12 500
SMS system	Monthly subscription at R433.44 ($30) for 3-months: R1300
MI sessions	Session 1 (17 minutes): R5.31; Session 2 (16 minutes): R5.00; Session 3 (17 minutes): R5.31
Biochemical investigations	Cost of TB smear microscopy: R28.37; culture: R79.22 and GeneXpert: R201.56 (Source: 2019/20 National Health Laboratory Service pricing schedule)*
ART	Atroiza: R3.78/dose; Dumiva: R5.55/dose; Tenemine: R2.34/dose; Zovilam: R1.72/dose; Kavimun: R1.89/dose; Ricovir: R1.36/dose; Zidomat: R1.38/dose; Lazena: R0.55/dose; Efrin:R0.63/dose; Efamat: R0.63/dose; Acriptaz: R0.61/dose (Source: Western Cape Department of Health. Antiretroviral and TB Stockmaster Worksheet. 2019)
TB medication	Month's supply of RHZE (intensive) @ R65.80; RH (continuation) @ R55.56 (Source: Western Cape Department of Health. Antiretroviral and TB Stockmaster Worksheet. 2019)

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

PROLIFE

Im*pro*ving TB outcomes by modifying *life*-style behaviours through a brief motivational intervention followed by short text messages (Phase II)

A multi-centre randomised controlled trial looking at the effect of a complex behavioural intervention on TB and lifestyle-related outcomes in South Africa

Version 1.2

Trial Registration number/registry: ISRCTN62728852/ISRCTN registry
http://www.isrctn.com/ISRCTN62728852

Version date: ~~14 Feb 2020~~ 25 Oct 2020
Author(s): Mona Kanaan

Department of Health Sciences
University of York
York, YO10 5DD

Principal Investigator: Olalekan Ayo-Yusuf and Kamran Siddiqi
Trial Coordinator: Goedele M Louwagie

STATISTICAL ANALYSIS PLAN
V1.2

Contents

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This analysis plan deals only with the statistical analysis of the trial.

1.   Definition of terms

Abbreviation	Expansion
ACTG	AIDS Clinical Trials Group
AE	Adverse Event
ART	Anti-retroviral therapy
AUDIT	Alcohol Use Disorders Identification Test
CI	Confidence Interval
CO	Carbon monoxide
CONSORT	Consolidated Standards of Reporting Trials
CRF	Case Report Form
EPTB	Extra-pulmonary TB
HIV	Human immunodeficiency virus
LHW	Lay health worker
MI	Motivational interviewing
PTB	Pulmonary TB
SMS	Short Message Service
SA	South Africa
SADHS	South Africa Demographic and Health Survey
SAE	Serious Adverse Event
SD	Standard deviation
SOPs	Standard Operating Procedures
TB	Tuberculosis

2.   Trial Objectives

The PROLIFE model is a complex behavioural intervention comprised of a brief motivational interviewing (MI) counselling strategy augmented with subsequent SMS messaging. To be delivered in three brief sessions, the MI intervention will target three main areas, as appropriate:

- Tobacco smoking
- Alcohol drinking
- Tuberculosis (TB) and Anti-retroviral therapy (ART) adherence or ART initiation

Primary objective:

- To assess the <u>effectiveness</u> of the PROLIFE model delivered by lay health workers (LWH) compared to usual care in improving Pulmonary TB (PTB) treatment outcomes

Secondary objective: (**this element will not be addressed in this SAP**)

- To estimate the <u>cost-effectiveness</u> of the PROLIFE model

3.   Design

This is a pragmatic, prospective, multicentre, two-arm, parallel, individual RCT taking place in 27 purposively selected primary care clinics with the highest TB case-load in three districts in South Africa: Welkom in the Free State; Bojanala in the North West province; and Sedibeng in Gauteng province. The intervention will be delivered by LHWs and three district coordinators who will each cover 1–2 clinics.

This is a pragmatic parallel superiority individually randomised controlled trial. There are two

treatment arms:

The control arm (Arm1): Intervention arm – participants will receive the PROLIFE

programme;

The intervention arm (Arm2): Control arm – participants will receive usual treatment and

support provided to TB patients in TB treatment clinics in South Africa ('usual care').

Full details of the background and design of the trial are presented in the protocol (version 1.2 Prolife Protocol_15 Dec 17_with markup) and the published protocol in Moriarty et al (2019) https://doi.org/10.1186/s13063-019-3551-9.

Participants

The inclusion criteria for participants are:
- adult patients (aged ≥ 18 years)
    - with drug-sensitive (bacteriologically or clinically confirmed) PTB;
- initiating TB treatment or on TB treatment for < 1 month (these include both 'new' and 'retreatment' patients);
- current smokers and/or
- hazardous/harmful drinkers who are not alcohol dependent (Alcohol Use Disorders Identification Test [AUDIT] score ≥ 8 for men or ≥ 7 for women but < 20);
- access to a functional mobile phone; and
- understand one of the four languages used for the trial (Sesotho, Setswana, Isizulu or English).

Exclusion criteria:
- alcohol-dependent participants (AUDIT score ≥ 20);
- Extrapulmonary TB without PTB; or
- Resistance to one or more TB drugs at baseline

4.   Sample Size

We will recruit 696 participants (348 per study arm). The sample size calculations were based on the following assumptions:

- Detection a 10% difference in TB treatment success rates (0.86 vs 0.76) in the ProLife group versus the control group
- 80% power,
- a significance level of 0.05, and
- 25% attrition.

The sample size per clinic was in the range of 14–74 participants per clinic with a median of 24. The assumed success rates in the control group are based on actual success rates in TB patients in the studied provinces that were available at the time of sample size calculations in 2015.

5.   Randomisation

Patients will be randomised using a randomised sequence generator performed by the trial statistician (MK) who will remain blind to the arm allocation. We will use block randomisation with varying block sizes stratified by the clinic to achieve equal numbers in intervention and control groups within each clinic. Allocation concealment will be done with consecutively numbered, sealed, opaque envelopes.

Lay health workers delivering the intervention, field researchers, and participants cannot be blinded to the intervention. However, the determination of the primary outcome will be completed by TB nurses who are blinded to the intervention status of the participants based on routinely collected data.

The statistician will be blinded to the intervention or control arm allocation of participants during the analysis stage.

6.   Outcomes

6.1 Primary outcome

The primary outcome is TB treatment success at six to nine months of follow-up. This is a binary variable defined as
- Success: cured or treatment completed
- Failure: failed treatment, death, acquired drug resistance, loss to follow-up or 'default', or not outcome evaluated.

The different mutually exclusive treatment outcomes are summarised here

Treatment outcome	Definition
Cure	Patient in whom baseline smear or culture was positive at beginning of treatment AND is smear/culture negative in the last month of treatment and on at least one previous occasion at least 30 days prior According to local protocol, a patient who is diagnosed using Gene Xpert and is sputum negative for TB at 11 and 23 weeks is considered 'Cured'.
Treatment completed	Patient whose baseline smear or culture was positive at the beginning and has completed treatment but does not have a negative smear/culture in the last month of treatment and on at least one previous occasion > 30 days prior. Patients diagnosed with PTB whose baseline smear (or culture) result was negative and who started treatment based on clinical and radiological findings who have shown clinical improvement and completed the prescribed course of treatment. *N.B. The smear examination may not have been done or the results may not be available at the end of treatment.*
Treatment failure	Patient whose baseline smear or culture was positive and remains or becomes positive again at 5 months or later during treatment. Patients who were negative at baseline but were later found to be positive. *N.B. This definition excludes those patients who are diagnosed with RR-TB or MDR-TB during treatment.*
Died	Patient who dies for any reason during the course of TB treatment.
Treatment default	Patient whose treatment was interrupted for two consecutive months or more during the treatment period.
Transfer out	Patient who was referred to a facility in another district to continue treatment and for whom the treatment outcome is not known.
Acquired resistance	Participants who are subsequently referred for MDR treatment.

6.2 Secondary outcomes

The following outcome measures will be recorded at the six-month follow-up:
- sputum conversion at the end of treatment in the group of participants who had bacteriology confirmed PTB at baseline [1]
- continuous smoking abstinence for identified smokers at baseline[2]

Whereas, the following will be assessed at three and six months follow-up:
- reduction in harmful or hazardous drinking[3]
- TB and ART medication adherence will be measured using a modified version of the AIDS Clinical Trials Group (ACTG) Adherence Questionnaire[4]; using an adherence index calculated by the formula (using the four-day recall table):

  [Total number of doses taken/Total number of doses prescribed] x 100

  Patients with at least 95% of adherence will be considered as having optimal adherence otherwise will be considered as having low (or suboptimal) adherence.
- increase in proportion of HIV-positive participants on ART at three and six months from baseline using standardised questions on the CRF.

6.2.1 Monitoring adverse events

Adverse events (AE) and serious adverse events (SAE) will be defined *apriori* and relevant information will be collected.

A **Serious Adverse Event (SAE)** is actually a special case of an adverse event where adverse outcomes are severe. It includes following events: Death of any of the participants associated with a clinical trial. **Examples of events**: Death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant.

An **adverse event (AE)** is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

The events are reported to ethics committee within 72 hours

---

[1] i.e. cure rates in intervention group versus control group for participants who initially had sputum AFB-positive, culture-positive or GeneXpert-positive PTB

[2] defined as a self-report of not smoking > 5 cigarettes six months from the start of the abstinence period, supported by a negative biochemical test CO < 7 ppm

[3] alcohol use will be measured using the AUDIT questionnaire. The questionnaire will be administered at screening (which will take place on the same day or shortly after the baseline assessment) and again at three months and six months.

[4] The questionnaire is a validated tool for measuring adherence specifically to ART and we will use an adapted version to also measure TB medication adherence [40].

The following information were collected to report the events:

Participants identification number, Gender, Age, Date of Enrollment, Arm (Control or intervention), Date of death notification to staff, Date of death , If death is related or not related to study.

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

6.3 Trial assessment schedule

Table 2 details the trial assessment schedule

Assessment	Items	Pre randomisation	Timeline (post randomisation)				
		Eligibility (Day 0)	*Baseline (Day 0)*	*2 months*	*3 months*	*6-9 months*	*Trial end*
Table 2: *Trial assessment schedule*							
ELIGIBILITY							
Smoking status		X					
Smoking profile			X				
Alcohol profile		X					
Medical eligibility		X					
Eligible, consenting		X					
MEASURES							
Trial ID, visit date			X				
Socio-demographic history			X				
Depression screen			X		X	X	
Clinical review of TB Treatment record for disease information			X				X
Smoking history			X				
Smoking abstinence (self-report)					X	X	
Exhaled CO					X	X	
Record sputum culture or smear or Gene Expert result			X	X	X	X	
HIV Status			X				
ART Status (if HIV positive)			X		X	X	
AUDIT		X			X	X	
Modified ACTG (Follow up)					X	X	
Economic evaluation			X		X	X	

6.4 Other important information

In addition to the above, the following information was collected at baseline. Socio-demographic history included age, gender, marital status, education, employment status, and comorbidities. For details about these variables, see Table 3.

6.5 Fidelity of the intervention

The main fidelity analysis will be published somewhere else. Some descriptive statistics regarding fidelity will be added here once the main analysis is completed and the statistician is unblinded to the treatment arm.

7.   Data

7.1 Data collection methods

The fieldworkers will screen all TB patients for eligibility immediately after the TB nurse at the clinic has initiated TB treatment and opened the TB "blue card". Consent will be obtained for this screening phase as the alcohol related questions are sensitive and the fieldworkers must gain insight in the patient files.

Eligible and consenting patients will be enrolled in the trial and the baseline questionnaire and record review completed. Patients will be given a unique Trial Number that will be used on all research documents. Data will be collected and recorded by field workers equipped with Android phones with a mobile data collection application installed.

Participants in the control arm will continue with the routine TB care. Intervention arm study participants will be referred by the fieldworker to the lay counsellor for motivational interviewing. The first MI session will be on the same day of the completion of the screening questionnaire, where possible (with a 2-week window period). The second and third MI session will be scheduled 4 weeks and 8 weeks from the first counselling session respectively each time with a 2-week window period.

MI counselling and data collection will take place in a well-ventilated private area inside or outside the clinic, and audio-recorded after consent obtained. Fieldworkers and LHWs will be provided with high particulate respirator masks to minimise the risk of infection.

Fieldworkers will follow-up all participants in both arms at 3 and 6 months within a window period of 2-weeks before and 2-weeks after the ideal 3 and 6-month visit. Participants will receive SMS reminders 3 days before each planned visit. Participants will also be in a position to send "please call me "messages to the fieldworkers or district coordinators, who will then call the participant to solve problems that may have arisen with the appointment.

Patients who did not return for the planned 3 and 6 months visit will be contacted by telephone up to 3-times, as needed. Home visits will also be undertaken by existing clinic "tracer teams" or Community Based Outreach teams -where feasible - for participants who cannot be traced by telephone. The data collection process is illustrated in Table 3.

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

Table 3: Data Collection Process by time-point and details of data collection method		
Time-point	**Information required at time-point**	**Data collection method**
Baseline interview	1. **Socioeconomic and demographic status (to include history of mine work)** ● Age ● Gender ● Marital status ● Educational level achieved ● Employment ● Mine work/type of mine work 2. Clinical information: ● Patient category (First episode vs recurrence) ● Site of disease ● Results of sputum smear, culture and Gene Xpert ● HIV status ● ART information ● Co-morbidities 3. Current smoking status and quit history, second hand smoke exposure 4. Alcohol history 5. Depression	TB Treatment Record CRF – Questions to participant – demographic details CRF – Questions to participant and information from the TB Treatment Record (as indicated in CRF) Questions adapted from Global Adult Tobacco Survey Questionnaire Baseline AUDIT score CES-D
3 months	1. ART information 2. TB and ART medication adherence (modified ACTCG) 3. Alcohol history (repeat AUDIT) 4. Smoking history 5. SLT use	CRF – Question to patient ACTG questionnaire for both TB medication and ART AUDIT score at 3 month

Page **14** of **67**

	6. Depression	Follow-up questions as per Russell's Standard and exhaled CO CES-D
6 months	1. TB treatment status (Primary outcome) 2. Sputum smear or culture result 3. ART information 4. TB and ART medication adherence 5. Alcohol history (repeat AUDIT) 6. Smoking history and exhaled CO 7. Depression	TB treatment outcome from TB Treatment Record combined with information from TB record on cultures and smear results. CRF- Question to patient Follow-up ACTG questionnaire at 6 months AUDIT at 6 months Questions as per Russell's Standard and exhaled CO CES-D

Page **15** of **67**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

7.2 Data management

Sefako Makgatho University (SMU) appointed a data manager who will utilise an electronic platform for data collection, ensuring data quality, and facilitating the SMS messages.

Fieldworkers collecting research data will be equipped with Android mobile phones, which will have a mobile application installed on them to allow for data collection in areas with poor internet connectivity. The electronic data captured will be stored on secure and password protected storage servers and mobile phones, which ensure data privacy through only allowing authorised research staff access to the data.

The electronic data collection system used for the study requires an SMS gateway to send and receive messages to the research participants. Consenting participants' phone numbers, participant IDs, and associated SMS messages will be stored on the SMS gateway's secured and password-protected server.

Data quality will be ensured by providing fieldworkers with standard operating procedures (SOPs), training, and ongoing support on the importance of data quality, data collection, and data collection problem-solving. The data manager will continuously monitor the captured data for missing variables and inconsistencies in order to resolve any data problems.

The data manager will export the data from the secured server, conceal the participants study arm allocation, and de-identify the data before sharing the data in STATA and R compatible formats. The exported de-identified data will be stored in Dropbox, a secure cloud storage platform, for sharing with the lead trial statistician at the University of York for analysis.

All research data and documents referring to the PROLIFE trial will be stored and maintained in a secured storage space at SMU for a minimum of 15 years from the end of the PROLIFE trial. Study materials will be destroyed 15 years after the study.

8.   Analysis

The computer packages STATA 16 (StataCorp. 2019) and R 3.5.3 (ref) will be used. Significance tests will be two-sided and the significance level is set at 0.05. The statistician will remain blind to allocation until results are finalised. We will follow the CONSORT statement guidelines in reporting.

Below, we detail the analyses that we will carry out for the data collected at baseline, the primary outcome, the secondary outcomes, and adverse events. We also list the sensitivity analyses that we might perform and subgroup analyses.

8.1 Participants Flow

Figure 1 CONSORT DIAGRAM SHOWING FLOW OF PARTICIPANTS

8.2 Baseline data

Baseline data Analysis Plan:

       Baseline data including demographic variables will be summarised descriptively by trial arm, but no formal statistical comparisons will be undertaken. Continuous measures will be reported as means and standard deviations (SD) while categorical data will be reported as counts and percentages, see Tables 1 to 4 in Appendix A. For skewed continuous measures, we will also provide medians and interquartile ranges.

Baseline data results:

Consent:

In the control arm (Arm1) 286 gave written consent and 5 verbal consent for participation in the study and for access to their medical records
In the intervention arm (Arm2) 279 gave written consent and 4 verbal consent for participation in the study and for access to their medical records

Baseline Imbalances

Education:

 It seems that for education there is imbalance between the two arms for Grades 8-11/Grade 12/Higher; the control arm (Arm1) had a higher educated group the difference in percentage points 8.2% as opposed to 2.8% in the intervention arm, see Table 2 for further details. There are 9 participants who are not literate in the study (7 in the control arm (Arm1) and 5 in the intervention arm (Arm2)).

Drinking

In the intervention arm, 223 (78.8%) had a drink in the past 12-months compared to 208 (71.5%) in the control arm, see Table 3.
In the control arm (Arm1), 110 (37.8%) were drinkers only, 83 (28.5%) were smokers only, and 98 (33.7%) were smokers and drinkers compared to 92 (32.5%), 60 (21.2%), and 131 (46.3%) in the intervention arm (Arm2), respectively.

Assets:

The vast majority had a radio (84%), a television (89%), a refrigerator (85%), an electric or gas stove (86%), and a microwave (67%), however, only 50% had a washing machine. Furthermore, a minority had a landline telephone (7.5%), a desktop or laptop computer (20%:), and a vacuum cleaner or floor polisher (15%). Figure 2 is a boxplot of the total number of assets by study arm. The spread in the control arm (Arm1) is greater than that in the intervention arm (Arm2). However, the mean number of assets is similar across the two groups of 5 (SD: 1.87).


Figure 2: A boxplot of the total number of assets by study arm

Medical History:

There were 305 (53.2%) **HIV positive** participants out of which   204 (65.38%) were using Cotrimoxazole and 257 (82.37%) were undergoing anti-retroviral therapy, see Table 2.

TB History: The vast majority of participants were New TB patients 513(91.3%), with Pulmonary only (ICD-10 A15) being the site of disease for the vast majority 553 (98.9%). Among those with results known, the majority had one pre-treatment smear result 366 (89.9%), one Gene XPert recorded 435 (97.5%), and one culture result recorded 96 (96%).

Among those with results available, 220 (58.51%) had at least **one positive smear result**,362 (87.23%) had at least **one positive Gene XPert result**, and 35 (47.95%) at least **one positive culture result**.

However, 85 (53.46%) in the control arm had at least one positive smear result within 60 days of the TB treatment start date compared to 96 (61.15%) in the intervention arm.

In addition, only 34 had their culture results within 60 days from the TB start dates of which 21 had positive results; 11 in the control arm compared to 10 in the intervention arm.

The vast majority of participants did not have any **co-morbidities** 525 (96.3%) and 18 (3.3%) had one.

Baseline Smoking Related variables:

Thirty five percent (202) did not smoke in the past month, whereas 52% smoked daily and the remaining 13% smoked in the past month but less frequently than on a daily basis, see Table 3.

In the past 30 days, the vast majority were exposed to smoke for seven days or less at: home 462 (80.5%); cafes/restaurants 464 (80.8%); Shebeens, bars or clubs 432 (75.3%); Bus/train/taxi/ vehicle 448 (78.0%); and Shops/shopping mall 461 (80.3%) and where applicable at the workplace 173 (66.8%).

Among those who smoked in the past month 372: 181 in the control arm (Arm1) vs 191 in the intervention arm (Arm2),

345 (92.7%) **smoked manufactured cigarettes** of which 225(65%) did so on a daily basis in the past seven days whereas 40 (11.6%) did not smoke in the past week. The mean number of days smoked was 5.42 days in the past week (SD: 2.49) with 6.34 cigarettes (SD: 7.39) smoked daily on average.

Hand-Rolled cigarettes were used by 35 participants of which 16 (45.7%) smoked daily in the past week. They smoked on average for 4.11 (SD:2.91) days in the past week and on average smoked 3.77 (SD: 3.27) hand-rolled cigarettes per day.

There was only one person who exclusively smoked waterpipe, two who exclusively smoked pipe, and seven who exclusively used other formats of tobacco other than the ones that are listed here.

For the vast majority the total number of cigarettes smoked is based on their answer to   manufactured cigarettes. In 27 cases, they supplemented this with other sources and 8 used only other forms to report the number smoked on average per day.

Over the past 3 months, they **spent** on average 174.58 (SD: 181.61) Rands per week on tobacco products.

Statistical Analysis Plan PROLIFE Trial Jan 2020

Smoking restrictions

No smoking was allowed **inside home** for 204(54.8%) participants, whereas 119(32.0%) had some rule where/when it is allowed and 49(13.2%) had no rules in place.

Quit Attempts:

Among smokers, 116 (31.2%) made an **attempt to quit**; the mean number of attempts to quit was 2.56 (SD: 2.32).

Furthermore, 213 (57.3%) said they will probably **try to quit** smoking completely and permanently in the next three months and 126 (33.9%) said that they definitely will.

Whereas, 207 (55.6%) said they will probably **quit** smoking completely and permanently in the next three months and 130 (34.9%) said that they definitely will.

Only 39 (10.5%) have ever used any methods in the past 3 months to help them stop smoking tobacco. These spent on average 136.64 (SD: 205.36) Rands on methods to help you stop smoking in the past 3 months.

Smokeless tobacco was used by only 24 participants (4.2%). They have been using ST for an average of 10.5 years (SD: 8.8) and have started using it at the age of 27 (SD: 11.33) years on average.

Heaviness of smoking:

In the control arm (Arm1), 67(37.0%) of smokers reported smoking within 5 minutes of waking up whereas 82(42.9%) did so in the intervention arm (Arm2).

Among those who smoked and who reported the number of cigarettes/pipes/cigars they used on average per day, 134(74.03%) in the control arm (Arm1) and 158(82.72%) in the intervention arm (Arm2) were considered as heavy smokers.

Page **23** of **67**

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

8.3 Primary analysis

8.3.1 Primary outcome definition:

As per section 6.1, we would define the primary outcome as those who had a successful treatment versus not. Where successful treatment is considered if the patient is considered to have been cured or treatment completed; all other categories will be deemed as not successful. The successful treatment[5] categories are defined as follows:

Cure	Patient in whom baseline smear or culture was positive at beginning of treatment AND is smear/culture negative in the last month of treatment and on at least one previous occasion at least 30 days prior. According to local protocol, a patient who is diagnosed using Gene Xpert and is sputum negative for TB at 11 and 23 weeks is considered 'Cured'.
Treatment completed	Patient whose baseline smear or culture was positive at the beginning and has completed treatment but does not have a negative smear/culture in the last month of treatment and on at least one previous occasion > 30 days prior. Patients diagnosed with PTB whose baseline smear (or culture) result was negative and who started treatment based on clinical and radiological findings who have shown clinical improvement and completed the prescribed course of treatment. *N.B. The smear examination may not have been done or the results may not be available at the end of treatment.*

8.3.2 Primary outcome Analysis

For the primary outcome, we will conduct analysis on an intention-to-treat basis. We will use binary logistic regression to compare the main outcome between the

---

[5] Following discussion with the team, we will take this at face value as it is not possible to query some of the anomalies found in the recording of dates of tests.

Page **24** of **67**

intervention and the usual care arm. We will also investigate any potential clustering at the centre level and account for it. We will present the results for this analysis in Table 6.

We will also adjust for HIV status, sex, alcohol versus tobacco versus both, and district; if these differ between trial arms at baseline.

8.3.3 Primary outcome Analysis Results

Table 4 gives the descriptive statistics for the initial outcome and the derived - dichotomised outcome; these indicate that overall, 69% were classified as successful treatment based on the medical professional assessment (cured/treatment completed). This percentage was similar for the two arms with the control arm (Arm1) having a slightly higher percentage of success of 70.1% compared to 67.8% in the intervention arm (Arm2)[6]. Table 9 gives the distribution per centre by study arm. Generally, these are fairly balanced any imbalance observed is most probably due to the early termination of the study.

For 203 participants, the TB treatment outcome date was not available, with those participants more likely to not have been cured (59% not cured), however, the percentage was similar across the two study arms for those with missing TB treatment outcome date.

The odds of successful treatment is 0.9 (95% CI: (0.64,1.27)) in the intervention arm (Arm2) compared to the control arm (Arm1). This estimate is very similar to the estimate adjusting for district and drinking/smoking status. This is also the case if you further adjust for sex and HIV status at baseline where the OR is 0.86 (95% CI: (0.60,1.24)); see Table 6 for further details.

---

[6] Primary outcome Control: 204/291, 95% CI proportion   0.70 (0.64,0.75)
Primary outcome Intervention:192/283, 95% CI proportion 0.68 (0.62,0.73)

8.4 Secondary analyses

Secondary analyses plan

In the group of participants who had bacteriology confirmed at baseline, we will use logistic regression to compare cured versus not cured, as indicated by the outcome at the end of treatment, between the two study arms. We will also control for baseline characteristics and other covariates such as sex, alcohol use, HIV-status, district, and account for any potential clustering by centre.

We will use a similar approach for the six-months continuous smoking abstinence outcome. This analysis will be performed on the group of participants who were current tobacco smokers at baseline. We will also control for baseline characteristics and other covariates such as age, duration of smoking, alcohol problem (hazardous, harmful, non-drinker/light drinker), heaviness of smoking index[7], depression, and potentially HIV-status.

For the reduction in harmful or hazardous drinking, we will use linear regression to measure difference in total AUDIT score between control and intervention groups accounting for the baseline AUDIT scores. Separate analyses for the AUDIT at 3 and 6 months will be performed.

The AUDIT is a 10-items questionnaire with a range between 0 and 40 where higher values indicate higher dependency.[8] It is worth mentioning that a score of 8 or more

---

[7] [Goedele's Comment on an earlier Version]Definitely a measure of severity of smoking and duration of smoking. For example Heaviness of Smoking Index which can be derived as follows:

HSI=Heaviness of smoking index ≥ 4, calculated based on sum of time to first cigarette (0: 61+min, 1:31-60 min, 2: 6-30 min, 3: ≤5 min) and number of cigarettes smoked per day (0: 0-10 cigarettes per day [CPD]

Also: age, duration of smoking, alcohol problem (hazardous, harmful, non-drinker/light drinker), maybe HIV-status, (adding this may reduce your sample size too much, because of missing HIV-status, unless you include HIVstatus unknown as a category of HIV-status). Depression

[8] Scoring the audit
Scores for each question range from 0 to 4, with the first response for each question (eg never) scoring 0, the second (eg less than monthly) scoring 1, the third (eg monthly) scoring 2, the fourth (eg weekly) scoring 3, and the last response (eg. daily or almost daily) scoring 4. For questions 9 and 10, which only have three responses, the scoring is 0, 2 and 4 (from left to right).
A score of 8 or more is associated with harmful or hazardous drinking, a score of 13 or more in women, and 15 or more in men, is likely to indicate alcohol dependence.

is associated with harmful or hazardous drinking, a score of 13 or more in women, and 15 or more in men, is likely to indicate alcohol dependence. Eligibility criteria for our study is an AUDIT score ≥ 8 for men or ≥ 7 for women but <20. However, if assumptions of linear regression are not met we will either transform the data or use alternative regression analyses such as ordinal logistic regression.

Adherence to TB and ART medication will be measured using an adherence index based on a modified version of the AIDS Clinical Trials Group (ACTG) Adherence Questionnaire; where patients with at least 95% of adherence will be considered as having optimal adherence otherwise will be considered as having low (or suboptimal) adherence. We will use logistic regression to model patient's characteristics (age, sex, alcohol, smoking status, depression) that might influence adherence at 6-month; we will also compare adherence between study arms. Similar to the previous outcomes, we will account for any potential clustering by centre.

We will also report the proportion of HIV-positive participants on ART at six months and compare these to the baseline using standardised questions on the CRF.

8.4.1 Secondary outcome definitions that involve defining a positive baseline test:

To operationalise the above we need to define how we determine if someone has a positive baseline smear or culture. Each participant might have up to two tests of the following: smear test, GeneExpert test, and culture test.

If a test was administered two times then to be considered negative both tests should be negative, otherwise it is considered positive. If a test was administered only once, then the result of that instance is taken as is.

1Saunders JB, Aasland OG, Babor TF et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption — II. Addiction 1993, 88: 791–803

If for a patient more than one test was administered, then to be considered negative the result should be negative under both tests.

This is illustrated in the following table.

Baseline	P=+, N = -		
		XXXX Test at run 2 (Result 2)	
XXXX Test run 1 (Result 1)		N	P
	N	NN	NP
	P	PN	PP
XXXX=Smear or Culture or GeneXpert			
Smear test at baseline	N1	NN	
	P1	NP, PN, PP	
Genexpert	N2	NN	
	P2	NP, PN, PP	
culture	N3	NN	
	P3	NP, PN, PP	
Positive at baseline	PB	P1 or P2 or P3	
Negative at baseline	NB	N1 and N2 and N3	

To define a conversion among those who were positive at baseline, we used the primary outcome response category cured to indicate a negative result at month 6 per the nurse's assessment.

Among the 403 participants who were positive at baseline 168(41.69%) were recorded as cured by 6-month of these 83 (39.9%) in the control arm compared to 85 (43.59%) see Table 4. The odds ratio of conversion is 1.16 (95% CI: (0.83,1.63)) comparing the intervention arm to the control arm.   When adjusting for district, sex, and smoking/drinking status and HIV status at baseline, the OR reduces to 1.07 (95% CI: (0.76,1.51))

8.4.2 6-months Continuous Abstinence

For this outcome, those who smoked cigarettes at baseline were considered as the analytic sample. In addition, those where the following could not be ascertained: self-report of not smoking > 5 cigarettes six months from the start of the abstinence period and supported by a negative biochemical test CO < 7 ppm were considered as smokers for the analysis of this variable. The number of participants who identified as cigarette smokers at baseline were 345 (60.1%)[9].

23 (85.19%) out of 27 with three measurements available[10] managed to abstain continuously for six months. These were similarly distributed across the two study arms, see Table 4. Among those who identified as cigarette smokers, 10 (5.59%) participants in the intervention arm continuously abstained. In the control arm there were 12 (7.23%) who continuously abstained for 6-months.

The crude odds of 6-months continuous abstinence is 0.76 (95% CI: (0.35,1.63)) in the intervention arm compared to the control arm among baseline cigarette smokers. Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline, the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm did not differ much from the crude estimate of 0.76. The adjusted estimate for the various models ranged between 0.73 and 0.76 with similar confidence limits as for the crude estimate. Furthermore, we did not have evidence that any of the adjusting variables were statistically significantly correlated to continuous abstinence in these models.

We carried an additional analysis where those who died and were smokers at baseline, 22 in total, 20 were cigarette smokers and were removed from the analytical sample for the continuous abstinence outcome. This resulted in a crude

---

[9] Any type of tobacco smoking at baseline 372 (64.8%). The numbers reflect those who used manufactured cigarettes which were the vast majority.

[10] We had only 27 participants who had self-report of not smoking at 3 months, 6 months and a carbon monoxide reading at 6 months. Continuous abstinence was defined as a self-report of not smoking > 5 cigarettes six months from the start of the abstinence period and supported by a negative biochemical test CO < 7 ppm

Page **29** of **67**

OR of 0.78 which is similar to the OR when the larger analytic sample was considered; this was also the case for the associated 95% CI. Similar estimates were observed when adjusting for the aforementioned variables.

We carried an additional analysis where the analytic sample was all those who were smokers regardless of the type used. There were a total of 372 that identified as smokers. The crude odds ratio in this case changes to 0.86 (95% CI: (0.38,1.95)). The 95% CI is similar to that of the smaller analytic sample. When adjusting for the heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline, the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm did not differ much from the crude estimate.

3-months Continuous Abstinence

Among those who identified as cigarette smokers, 20 (11.17%) participants in the intervention arm continuously abstained for 3-months while in the control arm there were 27 (16.27%) who continuously abstained for 3-months.

The crude odds of 3-months continuous abstinence is 0.65 (95% CI: (0.37,1.14)) in the intervention arm compared to the control arm among baseline cigarette smokers. Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline, the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm did not differ much from the crude estimate of 0.65. The adjusted estimate for the various models ranged between 0.63 and 0.66 with similar confidence limits as for the crude estimate.

Point Abstinence

There were 57 participants who indicated that they stopped smoking tobacco completely at the 3-month follow-up, of which one had more than 5 cigarettes in the past 3 months. There were 81 participants who indicated that they stopped smoking tobacco completely at the 6-month follow-up, of which three had more than 5 cigarettes in the past 3 months. Only 30 participants had information for the entirety of the 6-month period, of which none consumed more than 5 cigarettes over the past 6-month period. Of these, 23 had a confirmed CO < 7 ppm, 4 had these levels >= 7, and 3 were missing.

182 responded that they continued smoking either as usual or at a reduced rate but regularly at month 3; whereas 133 done so at month 6 of these we had 97 that had measurements at both time points thus resulting in a total of 218 where they have smoked on a regular basis over the past 6 month period. 11 had responded as not smoking in the past three months at month 6 but had missing information for the first three months; 9 of these had carbon monoxide readings available at month 6. Of these nine, two had their CO >= 7 (in fact these were 10 & 10.1).

8.4.4 Change in harmful or hazardous drinking at month 3 and 6 follow-ups

Alcohol use was measured using the AUDIT questionnaire. We will assess whether there has been a reduction in alcohol consumption three months and six months following recruitment. This analysis will be performed on the group of participants who were harmful or hazardous drinkers at baseline. Figure YYY provides histograms of the AUDIT score at baseline, 3-months and 6-months, respectively, among those who were considered as hazardous or harmful drinkers. It also presents scatterplots of the 3-months and 6-months scores versus the baseline scores for this group by trial arm, respectively.

Among those who were harmful or hazardous drinkers at baseline those in the intervention arm had on average a reduction of 0.04 points (95% CI: (-2,1.91)) on the AUDIT score at 6-months compared to those in the control arm controlling for their baseline score, see Table 6. However, when additionally adjusting for district, sex, and smoking/drinking status (which effectively flags smokers/non-smokers who are also drinkers) and HIV status at baseline; the intervention arm had an average increase of 0.02 points on the AUDIT score (95% CI: (-1.55,1.6)) compared to the control arm. It is worth noting that of the variables in the adjusted model; the only statistically significant result is for the district variable. It seems that those in district "S" score on average 5.8 points less than those in "B" (95% CI: (-11.26,-0.35)); similarly those in "L" score 5 points less than those in "B" on AUDIT but we do not have evidence that this difference is statistically significant (95% CI: (-10.35,0.26)), see Table 6 for further details.

At 3-month, the estimates were an average increase of 0.55 (95% CI: (-1.01,2.11)) on the AUDIT score in the intervention arm compared to the control arm when only accounting for the baseline scores; whereas it increased to 0.74 (95% CI: (0.62,2.1)) when adjusting for other covariates in the model, for further details see Table 7.

Figure YYY: Graphs (a), (b), and (c) are histograms of the AUDIT score at baseline, 3-months and 6-months, respectively, among those who were considered as hazardous or harmful drinkers. (d) and (e) are scatterplots of the 3-months and 6-months scores versus the baseline scores for this group, respectively.

8.4.5 **Proportion of ART uptake of HIV-positive participants at month 3 and 6 follow-ups**

We will assess whether there has been an increase in proportion of HIV-positive participants on ART at three and six months from baseline using standardised questions on the CRF.

There were 171 HIV-positive participants whose baseline ART medication status was known and whose ART medication status was known as well at 6-months. Of these, 123 remained on their medication, 19 took up medication at 6-months compared to not taking medication at baseline, whereas 29 stopped taking their medication at 6-months but were on medication at baseline, see Table 6 for further details.

There were 10 who had an unknown status in terms of medication at baseline and no information was available about them at 6-months, 12 who were initially of unknown medication status who took up medication at 6-months (these were equally distributed between the two arms). Furthermore, there were 10 who were not taking medication at baseline and 102 who were taking medication at baseline whose 6-months medication status was not recorded.

At 6-months, the odds ratio of taking medication at 6-months was 2.05 (95% CI: (0.80,5.27)) in the intervention arm compared to the control arm, controlling for ART baseline medication status.

There were 188 HIV-positive participants whose baseline ART medication status was known and whose ART medication status was known as well at 3-months. Of these, 122 remained on their medication, 16 took up medication at 3-months compared to not taking medication at baseline, whereas 50 stopped taking their medication at 3-months but were on medication at baseline, see Table 7 for further details.

There were 9 who had an unknown status in terms of medication at baseline and no information was available about them at 3-months, 11 who were initially of unknown

medication status who took up medication at 3-months, and two who were initially of unknown medication status who were not taking medication at 3-months. Furthermore, there were 9 who were not taking medication at baseline and 82 who were taking medication at baseline whose 3-months medication status was not recorded. Furthermore, there were 4 who carried on not taking medication at 3-months.

At 3-months, the odds ratio of taking medication at 6-months was 0.79 (95% CI: (0.38,1.65)) in the intervention arm compared to the control arm, controlling for ART baseline medication status.

Medicine Adherence:

At 3-months 165 (98.8%) of 167 participants had optimal ART medication adherence, whereas 139(97.2%) of 143 had optimal ART medication adherence. These were similar across the two arms.

Similarly, at 3-months 319(91.67%) of 348 participants had optimal TB medication adherence, whereas 120(90.23%) of 133 had optimal TB medication adherence. These were similar across the two arms.

8.5 Subgroup analyses (See above analyses)

We will conduct subgroup analyses to determine whether TB treatment outcomes differ between subgroups, as follows: HIV-positive versus HIV-negative participants; participants with an alcohol problem only versus smokers only versus participants who are conjoint smokers and drinkers; and participants who were GeneXpert positive versus participants who were GeneXpert negative at baseline.

8.5 Sensitivity analyses

In case of missing data, multiple imputations and appropriate sensitivity analyses will be conducted. As it is likely that more than one variable will have missing data we will use multiple imputations using chained equations (**MICE**). A minimum of 10 imputations will be performed; however, the final number of imputations will depend on the missing in the data. We will report the decisions that we make with regard to the number of imputations and the

variables we use in the imputations. We will also conduct a sensitivity analysis to explore the implications of the missing at random assumption [21p,22p].

8.6 Adverse events

Analysis of adverse events and serious AE will explore whether these differ by treatment arm using Chi-square tests.

8.7 Planned interim review and analyses

No interim analysis is planned. The main analyses will be completed after three months of the data closing.

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

8.8 List of Tables and Graphs

Measures of central tendency and percentages will be reported to two decimal places whereas measures of variability and p-values will be reported to three decimal places.

The following is a list of suggested tables and graphs; the templates are included in Appendix A.

TABLE 1: Numbers in the study at Baseline and follow-ups at month 3, and 6 by centre and study arm.

TABLE 2: Descriptive statistics for socio-demographic and socio-economic characteristics at baseline and as analysed by study arm. Frequencies and (percentages) are presented unless otherwise stated

TABLE 3: Descriptive statistics for smoking history, alcohol history, clinical characteristics and depression score at baseline and as analysed by study arm. Frequencies and (percentages) are presented unless otherwise stated.

TABLE 4: Descriptive statistics for primary and secondary outcomes by study arm at baseline (where available), 3 month (where available) and 6 month. Frequencies and (percentages) are presented unless otherwise stated.

TABLE 5: Number and type of adverse events at month 2, 3, and 6 by centre and study arm.

TABLE 6: Regression analysis results for the primary and secondary outcomes at 6 month. Estimates presented with corresponding 95% CI. Crude and adjusted estimates are provided.

TABLE 7: Regression analysis results for the secondary outcomes that are measured at 3 month. Estimates presented with corresponding 95% CI. Crude and adjusted estimates are provided.

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

9.   SAP amendment log

Amendment/addition to SAP and reason for change	New version number, name and date
SAP completed and signed-off	*V1.0,*
Updated verion	*V1.1, May 2020*

10.   Signatures of approval

Sign-off of the final approved version of the Statistical Analysis Plan by the principle
investigator and trial statistician(s) (can also include Trial Manager/Co-ordinator)

Name	**Trial Role**	**Signature**	**Date**

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

11.   References

Moriarty, A.S., Louwagie, G.M., Mdege, N.D. *et al*. ImPROving TB outcomes by modifying LIFE-style behaviours through a brief motivational intervention followed by short text messages (ProLife): study protocol for a randomised controlled trial. *Trials* **20,** 457 (2019) doi:10.1186/s13063-019-3551-9

Department of Health, Republic of South Africa. National Tuberculosis Management Guidelines. 2014. http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-27.5.2014.pdf. Accessed 8 Jan 2018

21p.   James R Carpenter and Michael G Kenward. Missing data in clinical trials — a practical guide. Birmingham: National Health Service Co-ordinating Centre for Research Methodology, 2008.
22p.   James R Carpenter, Michael G Kenward, and Ian R White. Sensitivity analysis after multiple imputation under missing at random — a weighting approach. Statistical Methods in Medical Research, 16:259–275, 2007.

StataCorp. 2019. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC.

R Core Team (201?). R: A language and environment for statistical
 computing. R Foundation for Statistical Computing, Vienna, Austria.
 URL http://www.R-project.org/.

12. Appendix A (Results tables)

Table 1: Numbers in the study at Baseline and follow-ups at month 3 and 6 by centre and study arm. (SEE FLOWCHART)

TABLE 1: NUMBERS IN THE STUDY AT BASELINE AND FOLLOW-UPS AT MONTH 3 AND 6 BY CENTRE AND STUDY ARM.								
Centre	Baseline			Month 3		Month 6		
	Intervention	Control	Intervention	Control	Intervention	Control		
Total								

TABLE 2: Descriptive statistics for socio-demographic, socio-economic, and clinical characteristics at baseline by study arm. Frequencies and (percentages) are presented unless otherwise stated

TABLE 2: DESCRIPTIVE STATISTICS FOR SOCIO-DEMOGRAPHIC, SOCIO-ECONOMIC, AND CLINICAL CHARACTERISTICS AT BASELINE AND AS ANALYSED BY STUDY ARM. FREQUENCIES AND (PERCENTAGES) ARE PRESENTED UNLESS OTHERWISE STATED				
			Baseline	
	N1/N2	Control	Intervention	Total
		Arm 1	Arm 2	
Age in years: mean (SD)	291/283	39.37 (12.60)	38.56 (11.15)	
Age in years: median (IQR)				
Gender				
Female		69 (23.7)	60 (21.2)	129 (22.5)
Male		222 (76.3)	223 (78.8)	445 (77.5)
Do not want to disclose				
Marital status				
Married or living together		102 (35.1)	95 (33.6)	197 (34.3)
Divorced/separated		20 (6.9)	18 (6.4)	38 (6.6)
Widowed		10 (3.4)	7 (2.5)	17 (3.0)
Never married and never lived together		144 (49.5)	150 (53.0)	294 (51.2)
Declined to answer		15 (5.2)	13 (4.6)	28 (4.9)
Education				
No education		7 (2.4)	5 (1.8)	12 (2.1)
Grades 1-5		23 (7.9)	20 (7.1)	43 (7.5)
Grades 6-7		32 (11.0)	35 (12.4)	67 (11.7)

Grades 8-11		96 (33.0)	128 (45.2)	224 (39.0)
Grade 12		87 (29.9)	70 (24.7)	157 (27.4)
Higher		24 (8.2)	8 (2.8)	32 (5.6)
Declined to answer		22 (7.6)	17 (6.0)	39 (6.8)
Employment				
Self-employed (full-time)		30 (10.3)	36 (12.7)	66 (11.5)
Employed full-time (30 hrs a week or more)		62 (21.3)	54 (19.1)	116 (20.2)
Employed part-time (less than 30 hrs a week)		19 (6.5)	29 (10.2)	48 (8.4)
Retired		17 (5.8)	16 (5.7)	33 (5.7)
Unemployed (but able to work)		125 (43.0)	120 (42.4)	245 (42.7)
Unable to work because of long-term disability or ill health		9 (3.1)	8 (2.8)	17 (3.0)
Full-time student		12 (4.1)	4 (1.4)	16 (2.8)
Caring from my home and family/doing household work/housewife		0 (0.0)	2 (0.7)	2 (0.3)
Occasional work ("piece job")		17 (5.8)	12 (4.2)	29 (5.1)
Declined to answer		0 (0.0)	2 (0.7)	2 (0.3)
Ever worked or spent time in mines				
No		244 (83.8)	237 (83.7)	481 (83.8)
Yes		46 (15.8)	45 (15.9)	91 (15.9)
Socioeconomic status				

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

Household items (Yes is displayed)			
A radio	249 (85.6)	234 (82.7)	483 (84.1)
A television	255 (87.6)	255 (90.1)	510 (88.9)
A landline telephone	21 (7.2)	22 (7.8)	43 (7.5)
A desktop or laptop computer	67 (23.0)	48 (17.0)	115 (20.0)
A refrigerator	248 (85.2)	240 (84.8)	488 (85.0)
A vacuum cleaner or floor pol	49 (16.8)	35 (12.4)	84 (14.6)
A microwave oven	198 (68.0)	189 (66.8)	387 (67.4)
An electric or gas stove	254 (87.3)	238 (84.1)	492 (85.7)
A washing machine	153 (52.6)	136 (48.1)	289 (50.3)
Total number of assets: mean (SD)	5.14 (1.96)	4.94 (1.77)	5.04 (1.87)
In the past month, number of days you or people in the household went to bed hungry because there was no food to eat			
0 days	244 (83.8)	238 (84.1)	482 (84.0)
1-7 days	45 (15.5)	34 (12.0)	79 (13.8)
More than 7 days	2 (0.7)	9 (3.2)	11 (1.9)
Declined to answer	0 (0.0)	2 (0.7)	2 (0.3)
TB and medical history			
TB history			
Patient category			
New patient	264 (92.3)	249 (90.2)	513 (91.3)
Relapse	10 (3.5)	9 (3.3)	19 (3.4)
Re-treatment after default	9 (3.1)	14 (5.1)	23 (4.1)
Re-treatment after failure	1 (0.3)	2 (0.7)	3 (0.5)
Other	2 (0.7)	2 (0.7)	4 (0.7)
Site of disease			
Pulmonary and Extra Pulmonary (ICD-10 A17-A19)	3 (1.1)	3 (1.1)	6 (1.1)

Pulmonary only (ICD-10 A15)		281 (98.9)	272 (98.9)	553 (98.9)
Number of pre-treatment smear results				
One		197 (92.1)	169 (87.6)	366 (89.9)
Two		17 (7.9)	24 (12.4)	41 (10.1)
Smear result	N =	196	180	376
At least one positive smear result		111 (56.63)	109 (60.56)	220 (58.51)
Number of Gene XPert results recorded				
One		225 (97.8)	210 (97.2)	435 (97.5)
Two		5 (2.2)	6 (2.8)	11 (2.5)
Gene XPert result	N =	211	204	415
At least one positive Gene XPert result		184 (87.2)	178 (87.25)	362 (87.23)
Number of culture results recorded on the TB Treatment record				
One		54 (94.7)	42 (97.7)	96 (96.0)
Two		3 (5.3)	1 (2.3)	4 (4.0)
Culture result	N =	41	32	73
At least one positive culture result		20 (48.78)	15 (46.88)	35 (47.95)
Co-morbidities				
Hypertension		19 (6.93)	11 (4.1)	30 (5.54)
Diabetes		5 (1.84)	4 (1.49)	9 (1.66)
Epilepsy		3 (1.09)	4 (1.49)	7 (1.29)
Mental illness		3 (1.09)	0 (0)	3 (0.55)
Liver disease		1 (0.36)	1 (0.38)	2 (0.37)
Renal insufficiency		1 (0.36)	1 (0.38)	2 (0.37)
Allergies		2 (0.76)	0 (0)	2 (0.38)

Other		1 (0.36)	1 (0.38)	2 (0.37)
Total Number of comorbidities				
0		265 (96.0)	260 (96.7)	525 (96.3)
1		10 (3.6)	8 (3.0)	18 (3.3)
2		0 (0.0)	1 (0.4)	1 (0.2)
5		1 (0.4)	0 (0.0)	1 (0.2)
HIV status				
Negative		118 (40.7)	125 (44.2)	243 (42.4)
Positive		163 (56.2)	142 (50.2)	305 (53.2)
Unknown		9 (3.1)	16 (5.7)	25 (4.4)
HIV positive patients				
CD4 Count: mean(SD)				
Using Cotrimoxazole		104 (63.8)	100(67.11)	204 (65.38)
Using anti-retroviral		139 (85.28)	118 (79.19)	257 (82.37)

PROLIFE Trial

TABLE 3: Descriptive statistics for smoking history, alcohol history and depression score at baseline by study arm. Frequencies and (percentages) are presented unless otherwise stated.

TABLE 3: Descriptive statistics for smoking history, alcohol history and depression score at baseline and as analysed by study arm. Frequencies and (percentages) are presented unless otherwise stated.			
	Baseline		
	Control	Intervention	Total
	Arm 1	Arm 2	Total
In the past month, smoked tobacco			
Not at all	110 (37.8)	92 (32.5)	202 (35.2)
Daily	149 (51.2)	149 (52.7)	298 (51.9)
Less than Daily	32 (11.0)	42 (14.8)	74 (12.9)
Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)
AUDIT Score (males): mean (SD) [max :19] [min = 8 if drinkers only]	12.27 (3.98)	13.02 (3.78)	12.66 (3.89)
AUDIT Score (females): mean (SD) [max :19] [min = 7 if drinkers only]	11.32 (4.02)	10.98 (4.02)	11.15 (4)
Drinking and Smoking Combined (Constructed)			
Drinkers Only	110 (37.8)	92 (32.5)	202 (35.2)
Smokers Only	83 (28.5)	60 (21.2)	143 (24.9)
Smokers and Drinkers	98 (33.7)	131 (46.3)	229 (39.9)

Page **46** of **67**

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

	Arm 1	Arm 2	Total
Smoking History (current smokers only)	181	191	372
On the days that you smoke, how soon after you wake up do you have your first cigarette?			
After 60 minutes	30 (16.6)	28 (14.7)	58 (15.6)
31-60 minutes	24 (13.3)	16 (8.4)	40 (10.8)
6- 30 minutes	60 (33.1)	65 (34.0)	125 (33.6)
Within 5 minutes	67 (37.0)	82 (42.9)	149 (40.1)
Duration of smoking in **months**: mean (SD)	212.09 (134.03)	224.93 (127.82)	218.68 (130.86)
Duration of smoking in **months**: median (IQR)	186 (110, 282)	206 (135, 294)	200.5 (123, 287)
Age started smoking in **years**: mean (SD)	19.2 (6.3)	19.3 (6.3)	19.3 (6.3)
Age started smoking in **years**: median (IQR)	18 (15-20)	18 (16-21)	18 (15.5-20.5)
Form of tobacco used			
Manufactured cigarettes (Yes)	**166 (91.7)**	**179 (93.7)**	**345 (92.7)**
Number of days in the past 7days you smoked: mean (SD)	5.3 (2.65)	5.53 (2.33)	5.42 (2.49)
Average number of cigarettes smoked daily: mean (SD)	6.18 (6.43)	6.48 (8.21)	6.34 (7.39)
Hand-rolled cigarettes (Yes)	**14 (7.7)**	**21 (11.0)**	**35 (9.4)**
Number of days in the past 7days you smoked: mean (SD)	4.71 (2.84)	3.71 (2.95)	4.11 (2.91)
Average number of handrolled cigarettes smoked daily: mean (SD)	3.71 (3.97)	3.81 (2.82)	3.77 (3.27)
Pipe (Yes)	**4 (2.2)**	**2 (1.0)**	**6 (1.6)**
Number of days in the past 7days you smoked: median (IQR)	1 (0, 2.5)	4.5 (2, 7)	2 (0, 3)
Average number of daily sessions: median (IQR)	1 (0, 3.5)	3 (1, 5)	1.5 (0, 5)
Length of one session (on average) in **minutes**: median (IQR)	90 (60, 107.5)	60 (30, 90)	90 (30, 90)
Cigars, cheroots or cigarillos (Yes)	1 (0.55)	0 (0)	1(0.27)

Page **47** of **67**

	Control	Intervention	
Water pipe (Yes)	3 (1.7)	2 (1.0)	5 (1.3)
Other	10 (5.5)	4 (2.1)	14 (3.8)
Heaviness of smoking index >= 4	134(74.03)	158(82.72)	292(78.49)
Smoking inside your home restrictions			
Total: Not allowed	96 (53.0)	108 (56.5)	204 (54.8)
Some rules: where/when it is allowed	61 (33.7)	58 (30.4)	119 (32.0)
No rules	24 (13.3)	25 (13.1)	49 (13.2)
Attempts to quit smoking (current smokers only) (Yes)			
Ever attempted to quit in the past			
Yes	52 (28.7)	64 (33.5)	116 (31.2)
No	129 (71.3)	127 (66.5)	256 (68.8)
Number of attempts to quit: mean (SD)	2.46 (2.98)	2.64 (1.62)	2.56 (2.32)
Time elapsed since attempt to quit last time in months: mean (SD)	36.65 (94.62)	25.13 (37.91)	30.29 (69.22)
Longest duration abstinent in previous quit attempts: mean (SD)	6.15 (13.48)	4.22 (8.9)	5.09 (11.18)
Likelihood to TRY TO QUIT smoking completely and permanently in the next three months			
definitely will not	6 (3.3)	5 (2.6)	11 (3.0)
probably will not	10 (5.5)	12 (6.3)	22 (5.9)
probably will	104 (57.5)	109 (57.1)	213 (57.3)
definitely will	61 (33.7)	65 (34.0)	126 (33.9)
	Control	Intervention	

	Arm 1	Arm 2	Total
Likelihood that I WILL QUIT smoking completely and permanently in the next three months			
definitely will not	6 (3.3)	5 (2.6)	11 (3.0)
probably will not	11 (6.1)	13 (6.8)	24 (6.5)
probably will	103 (56.9)	104 (54.5)	207 (55.6)
definitely will	61 (33.7)	69 (36.1)	130 (34.9)
Ever used any methods to help you stop smoking tobacco in the past 3 months? (Yes)	23 (12.7)	16 (8.4)	39 (10.5)
Out of your pocket spend (in Rands) on methods to help you stop smoking in the past 3 months: mean (SD)	134.87 (237.58)	139.19 (155.07)	136.64 (205.36)
Average spend per week on cigarettes over the past 3 months: mean (SD)	168.77 (178.15)	180.29 (185.27)	174.58 (181.61)
Smokeless tobacco use (all participants)			
In the past month, have you used smokeless tobacco (Snuff) on a daily basis			
Not at all	275 (94.5)	275 (97.2)	550 (95.8)
Daily	12 (4.1)	6 (2.1)	18 (3.1)
Less than Daily	4 (1.4)	2 (0.7)	6 (1.0)
Duration of using ST in months: mean(SD)	113.69 (112.7)	152 (91.16)	126.46 (105.61)
Age started using ST in **years**: mean (SD)	27.56 (10.57)	25.88 (13.43)	27 (11.33)
Form of ST used (for SLT users)			
Snuff (by mouth)	2 (12.5)	0 (0.0)	2 (8.3)
Snuff (by nose)	11 (68.8)	5 (62.5)	16 (66.7)
Chewing tobacco leaves	0(0)	0(0)	0(0)
Other	1 (6.3)	0 (0.0)	1 (4.2)
	Arm 1	Arm 2	Total

PROLIFE Trial   Jan 2020

	Control	Intervention	
Tobacco smoke exposure: number of days in the past 30 days, you were in a place where someone smoked close to you (all participants?)			
Home			
7 days or less	233 (80.1)	229 (80.9)	462 (80.5)
More than 7 days	58 (19.9)	54 (19.1)	112 (19.5)
Workplace (Missing 315; probably Not Applicable)			
7 days or less	84 (65.6)	89 (67.9)	173 (66.8)
More than 7 days	44 (34.4)	42 (32.1)	86 (33.2)
Cafes/restaurants			
7 days or less	230 (79.0)	234 (82.7)	464 (80.8)
More than 7 days	61 (21.0)	49 (17.3)	110 (19.2)
Shebeens, bars or clubs			
7 days or less	219 (75.3)	213 (75.3)	432 (75.3)
More than 7 days	72 (24.7)	70 (24.7)	142 (24.7)
Bus/train/taxi/ vehicle			
7 days or less	229 (78.7)	219 (77.4)	448 (78.0)
More than 7 days	62 (21.3)	64 (22.6)	126 (22.0)
Shops/shopping mall			
7 days or less	235 (80.8)	226 (79.9)	461 (80.3)
More than 7 days	56 (19.2)	57 (20.1)	113 (19.7)
	Arm 1	Arm 2	Total

Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)
Help to stop drinking (drinkers only)			
Ever used any methods to stop drinking alcohol in the past 3 months	21 (11.2)	22 (10.7)	43 (10.9)
Average spend in Rands per week on alcohol over the past 3 months: mean (SD)	363.76 (531.56)	337.03 (387.94)	349.79 (461.66)
Depression: CESD 10 how often you felt or behaved this way during the past week			
I was bothered by things that usually don't bother me.			
Rarely or None of the Time (Less than 1 day)	180 (61.9)	159 (56.2)	339 (59.1)
Some or a Little of the Time (1-2 days)	71 (24.4)	78 (27.6)	149 (26.0)
Occasionally or a Moderate Amount of the Time (3-4 days)	24 (8.2)	31 (11.0)	55 (9.6)
Most or All of the Time (5-7 days)	16 (5.5)	15 (5.3)	31 (5.4)
I had trouble keeping my mind on what I was doing.			
Rarely or None of the Time (Less than 1 day)	150 (51.5)	136 (48.1)	286 (49.8)
Some or a Little of the Time (1-2 days)	93 (32.0)	85 (30.0)	178 (31.0)
Occasionally or a Moderate Amount of the Time (3-4 days)	31 (10.7)	38 (13.4)	69 (12.0)
Most or All of the Time (5-7 days)	17 (5.8)	24 (8.5)	41 (7.1)
I felt depressed.			
Rarely or None of the Time (Less than 1 day)	152 (52.2)	171 (60.4)	323 (56.3)
Some or a Little of the Time (1-2 days)	94 (32.3)	70 (24.7)	164 (28.6)
Occasionally or a Moderate Amount of the Time (3-4 days)	37 (12.7)	30 (10.6)	67 (11.7)
Most or All of the Time (5-7 days)	8 (2.7)	12 (4.2)	20 (3.5)
I felt that everything I did was an effort.			

PROLIFE Trial

Rarely or None of the Time (Less than 1 day)	140 (48.1)	117 (41.3)	257 (44.8)
Some or a Little of the Time (1-2 days)	77 (26.5)	87 (30.7)	164 (28.6)
Occasionally or a Moderate Amount of the Time (3-4 days)	38 (13.1)	43 (15.2)	81 (14.1)
Most or All of the Time (5-7 days)	36 (12.4)	36 (12.7)	72 (12.5)
I felt hopeful about the future.			
Rarely or None of the Time (Less than 1 day)	85 (29.2)	84 (29.7)	169 (29.4)
Some or a Little of the Time (1-2 days)	78 (26.8)	70 (24.7)	148 (25.8)
Occasionally or a Moderate Amount of the Time (3-4 days)	53 (18.2)	56 (19.8)	109 (19.0)
Most or All of the Time (5-7 days)	75 (25.8)	73 (25.8)	148 (25.8)
I felt fearful.			
Rarely or None of the Time (Less than 1 day)	175 (60.1)	159 (56.2)	334 (58.2)
Some or a Little of the Time (1-2 days)	82 (28.2)	79 (27.9)	161 (28.0)
Occasionally or a Moderate Amount of the Time (3-4 days)	25 (8.6)	32 (11.3)	57 (9.9)
Most or All of the Time (5-7 days)	9 (3.1)	13 (4.6)	22 (3.8)
My sleep was restless.			
Rarely or None of the Time (Less than 1 day)	142 (48.8)	135 (47.7)	277 (48.3)
Some or a Little of the Time (1-2 days)	95 (32.6)	89 (31.4)	184 (32.1)
Occasionally or a Moderate Amount of the Time (3-4 days)	31 (10.7)	33 (11.7)	64 (11.1)
Most or All of the Time (5-7 days)	23 (7.9)	26 (9.2)	49 (8.5)
I was happy.			
Rarely or None of the Time (Less than 1 day)	85 (29.2)	74 (26.1)	159 (27.7)
Some or a Little of the Time (1-2 days)	70 (24.1)	65 (23.0)	135 (23.5)
Occasionally or a Moderate Amount of the Time (3-4 days)	73 (25.1)	86 (30.4)	159 (27.7)
Most or All of the Time (5-7 days)	63 (21.6)	58 (20.5)	121 (21.1)
I felt lonely.			

Rarely or None of the Time (Less than 1 day)	158 (54.3)	161 (56.9)	319 (55.6)
Some or a Little of the Time (1-2 days)	89 (30.6)	83 (29.3)	172 (30.0)
Occasionally or a Moderate Amount of the Time (3-4 days)	23 (7.9)	26 (9.2)	49 (8.5)
Most or All of the Time (5-7 days)	21 (7.2)	13 (4.6)	34 (5.9)
I could not get "going".			
Rarely or None of the Time (Less than 1 day)	168 (57.7)	174 (61.5)	342 (59.6)
Some or a Little of the Time (1-2 days)	78 (26.8)	69 (24.4)	147 (25.6)
Occasionally or a Moderate Amount of the Time (3-4 days)	35 (12.0)	29 (10.2)	64 (11.1)
Most or All of the Time (5-7 days)	10 (3.4)	11 (3.9)	21 (3.7)
Total CESD 10: mean (SD)	8.44 (4.38)	8.74 (4.8)	8.59 (4.59)

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

Table 4: Descriptive statistics for primary and secondary outcomes by study arm at baseline (where available), 3 month (where available) and 6 month. Frequencies and (percentages) are presented unless otherwise stated

TABLE 4: DESCRIPTIVE STATISTICS FOR PRIMARY AND SECONDARY OUTCOMES BY STUDY ARM AT BASELINE (WHERE AVAILABLE), 3 MONTH (WHERE AVAILABLE) AND 6 MONTH. FREQUENCIES AND (PERCENTAGES) ARE PRESENTED UNLESS OTHERWISE STATED.

	Baseline			Follow-up 3-month			Follow-up 6-month		
	Control	Intervention	Total	Control	Intervention	Total	Control	Intervention	Total
	Arm1	Arm2	Total	Arm1	Arm2	Total	Arm1	Arm2	Total
TB treatment status detailed									
Cured							108 (37.11)	105 (37.1)	213 (37.11)
Treatment completed							96 (33.0)	87 (30.74)	183 (31.88)
Treatment default							15 (5.2)	29 (10.25)	44 (7.67)
Treatment failure							5 (1.7)	2 (0.7)	7 (1.2)
Acquired drug resistance							1 (0.34)	4 (1.41)	5 (0.87)
Died							11 (3.78)	15 (5.30)	26 (4.53)
Transfer out							8 (2.75)	11 (3.89)	19 (3.31)
Unknown							42 (14.43)	25 (8.83)	67 (11.67)
Missing							5 (1.72)	5 (1.77)	10 (1.74)
TB treatment status binary (Primary outcome**)									
Not Successful							87 (29.9)	91 (32.16)	178 (31.01)
Successful							204 (70.10)	192 (67.84)	396 (68.99)
At least one positive smear result	85 (53.46)	96 (61.15)	181 (57.28)						
At least one positive Gene XPert result	184 (87.20)	178 (87.25)	362 (87.23)						
At least one positive culture result	11 (57.89)	10 (66.67)	21 (61.76)						

Sputum smear, Gene XPert, or culture result									
Negative	29 (12.45)	32 (14.16)	61 (13.29)						
Positive	204 (87.55)	194 (85.84)	398 (86.71)						
Conversion from positive to negative*									
Yes							83(39.9)	85(43.59)	168(41.69)
No							125(60.1)	110(56.41)	235(58.31)
Continuous smoking abstinence among cigarette smokers at baseline									
Yes				27(16.27)	20(11.17)	47(13.62)	12(7.23)	10(5.59)	22(6.38)
No				139(83.73)	159(88.83)	298(86.38)	154(92.77)	169(94.41)	323(93.62)
Harmful or hazardous drinking[1]									
Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)						
AUDIT score: mean (SD)	12.03 (4)	12.53 (3.93)	12.29 (3.96)						
Harmful or hazardous drinkers out of those who had a drink in the past 12-months at baseline (%)	188(90.38)	206(92.38)	394(91.42)	141	130	271	112	127	239
AUDIT Score (males): mean (SD) [max :19; min = 8]*!	13.14 (3.31)	13.61 (3.29)	13.39 (3.31)	8.20(6.08)	9.08(4.97)	8.63(5.58)	9.21(6.58)	8.24(5.41)	8.69(5.99)
AUDIT Score (females): mean (SD) [max :19; min = 7]*!	11.73 (3.52)	11.55 (3.6)	11.64 (3.54)	8.5(6.52)	8.15(6.44)	8.33(6.44)	7.67(6.84)	9.97(6.79)	8.89(6.86)
AUDIT score: mean (SD)	12.76 (3.42)	13.12 (3.47)	12.94 (3.45)	8.28(6.18)	8.84(5.38)	8.55(5.81)	8.79(6.66)	8.70(5.83)	8.74(6.22)
Difference from baseline				-4.61 (6.26)	-4.07(5.33)	-4.35(5.83)	-4.25(6.56)	-4.17(6.61)	-4.21(6.57)

Taking ART medication among HIV Positive patients	[163 (56.2)]	[142 (50.2)]	[305 (53.2)]	[122]	[83]	[205]	[100]	[83]	[183]
Yes	139 (85.28)	115 (80.99)	254 (83.28)	91 (74.6)	58 (69.9)	149 (72.7)	80 (80.0)	74 (89.2)	154 (84.2)
ART medication adherence									
Optimal adherence				101(99.02)	64(98.46)	165(98.8)	75(97.4)	64(96.97)	139(97.2)
Suboptimal adherence				1(0.98)	1(1.54)	2(1.2)	2(2.6)	2(3.03)	4(2.8)
TB medication adherence									
Optimal adherence				181(92.35)	138(90.79)	319(91.67)	61(89.71)	59(90.77)	120(90.23)
Suboptimal adherence				15(7.65)	14(9.21)	29(8.33)	7(10.29)	6(9.23)	13(9.77)

[1] hazardous/harmful drinkers who are not alcohol dependent= AUDIT score ≥ 8 for men or ≥ 7 for women but < 20

Primary Outcome: in the published protocol paper "This is a binary variable defined as either successful treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss to follow-up or 'default', or not outcome evaluated.

*** Conversion from positive to negative: this was based on having a cured treatment outcome among those who were positive at baseline.

*! Important distinction at baseline for eligibility purposes.

Statistical Analysis Plan   PROLIFE Trial   Jan 2020

TABLE 5: Number and type of adverse events at month 2, 3, and 6 by centre and study arm (see other document)

TABLE 5: Number and type of adverse events at month 2, 3, and 6 by centre and study arm							
Centre		Month 2		Month 3		Month 6	
	TYPE	Intervention	Control	Intervention	Control	Intervention	Control

TABLE 6:   Regression analysis results for the primary and secondary outcomes at 6 months. Estimates presented with corresponding 95% CI. Crude and adjusted estimates are provided.

TABLE 6: Regression analysis results for the primary and secondary outcomes at 6 months. Estimates presented with corresponding 95% CI. Crude and adjusted estimates are provided.					
	Crude Odds Ratio (95% CI)*	P Value*	Adjusted Odds Ratio (95% CI)*	P Value*	
Primary outcome					
TB treatment status: Successful (**Ref: Not successful**)	0.9 (0.64,1.27)	0.548	0.86 (0.60,1.24)	0.421	
Secondary outcomes					
Sputum smear or culture result: converted from positive to negative (Ref: Not converted)	1.16 (0.83,1.63)	0.374	1.07‡ (0.76,1.51)	0.684	
Six-month continuous smoking abstinence among cigarette smokers at baseline (Ref: No)	0.76 (0.35,1.64)	0.482			
Taking ART medication among HIV positive patients[‖]	2.05 (0.80,5.27)	0.136			
TB medication adherence (Reference: Optimal)	0.89 (0.26,3.07)	0.849			
ART medication adherence (Reference: Optimal)	1.17 (0.14,9.94)	0.884			

	Study arm regression coefficient		Study arm regression coefficient		
AUDIT for those who were harmful or hazardous drinkers at baseline**:	-0.04 (-2,1.91)	0.966	0.02[!] (-1.55,1.6)	0.976	

* analyses accounted for potential clustering by centre.
† Number of participants whose outcome was treatment successful among the total number in the group.
‡ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline
**Controlling for the AUDIT baseline values.
! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline
!! Adjusting for art status at baseline

Page **60** of **67**

TABLE 7:   Regression analysis results for secondary outcomes measured at 3-months. Estimates presented with corresponding 95% CI. Crude and adjusted estimates are provided.

	Crude Odds Ratio (95% CI)	P Value	Adjusted Odds Ratio (95% CI)	P Value	
TABLE 7: Regression analysis results for secondary outcomes measured at 3-months. Estimates presented with corresponding 95% CI. Crude and adjusted estimates are provided.					
Secondary outcome					
3-months continuous smoking abstinence among cigarette smokers at baseline	0.65 (0.37,1.14)	0.135			
Taking ART medication among HIV positive patients[!!]	0.79 (0.38,1.65)	0.53	0.74‡ (0.35,1.58)	0.443	
TB medication adherence (Reference: Optimal)	1.22 (0.52,2.87)	0.641	████████		
ART medication adherence (Reference: Optimal)	1.58 (0.10,26.12)	0.750	████████		
	Study arm regression coefficient		Adjusted estimates		
AUDIT for those who were harmful or hazardous drinkers at baseline**:	0.55 (-1.01,2.11)	0.474	0.74 (-0.62,2.1)	0.273	

*   analyses accounted for clustering.
‡ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline
**Controlling for the AUDIT baseline values.
! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline
!! Adjusting for art status at baseline

Statistical Analysis Plan

PROLIFE Trial

Jan 2020

Additional tables
SMS-fidelity

Variable	Intervention (N= ....) (=no. of participants allocated to intervention group, for example 245)	Control (N=...) (=no. participants allocated to control group, for example 248)
No. of participants who received ALL due IMB messages INDEPENDENT OF WHETHER they completed MI 1 (i.o.w this is ITT analysis)	For example 120/245 (49 %)	For example 2/248 (...%)
Completion of first MI and initiation of SMS-sequence		
Completed first MI	n/N (%) (=No. who completed first MI in intervention arm/ no. participants allocated to intervention arm [%] For example 170/245 [69%])	n/N (%) (=No. who completed first MI in control/ no. participants allocated to control [%] For example 2/248)
No. of participants who received ALL due messages after receipt of MI1 and SMS sequence was generated (this is a type of Per Protocol analysis:	For example 120/170 (71%)	2/2

Page **62** of **67**

	Mean (SD)	Median (IQR) Range	Mean (SD)	Median (IQR)
denominator limited to those who had MI1)				
SMS delivery for participants for whom the SMS-sequence was initiated (after receipt of first MI)				
Average no. adherence messages received per participant (n=...) (n = the no. of participants who completed first MI, in this example 170)	For example 8 (3.4)	9 (7-10) Range 0-10	Expected to be 0 or close to it	Expected to be 0 or close to it
Average no. tobacco-related messages received (n=...) (n=no of participants who completed first MI AND were current tobacco users at baseline, for example 90)	For example 7 (3.4)	7 (6-7) Range 0-7	Expected to be 0 or close to it	Expected to be 0 or close to it
Average no. alcohol related messages received (n=...) (n=no. participants who completed first MI	For example 7 (3.4)	7 (6-7) Range 0-7	Expected to be 0 or close to it	Expected to be 0 or close to it

Page **63** of **67**

AND were drinkers at baseline=….for example 100)				
Average no. IMB messages received (n= total no who completed first MI)	For example 16 (4.5)	15 (10-20) Range 0-24	Expected to be 0 or close to it	Expected to be 0 or close to it

Other variables not yet analysed:

CESD at 3 and 6-month FU
Other smoking related questions at 3 and 6 month (quit intentions etc) but also SLT use at 3 and 6 month. (important because participants may have switched from tobacco smoking to SLT)
Other non-HE questions not yet analysed

13.   Additional descriptive Statistics

TABLE 8:   Additional Descriptive statistics for   characteristics at baseline by study arm. Frequencies and (percentages) are presented unless otherwise stated

		Baseline		
	N1/N2	Intervention	Control	Total
		Arm 1	Arm 2	
TYPE OF MINE WORK	46/45			91
Coal		7 (15.2)	3 (6.7)	10 (11.0)
Diamond		3 (6.5)	1 (2.2)	4 (4.4)
Gold		13 (28.3)	17 (37.8)	30 (33.0)
Platinum and palladium		24 (52.2)	17 (37.8)	41 (45.1)
Chromium		11 (23.9)	12 (26.7)	23 (25.3)
Uranium		1 (2.2)	1 (2.2)	2 (2.2)
Manganese		0(0)	0(0)	0(0)
Other		0(0)	0(0)	0(0)
Total Types of Mines worked in				
1	73			
2	12			
3	3			
4	1			

Exact Distribution for number smoked in the past seven days				
0		24 (14.5)	16 (8.9)	40 (11.6)
1		4 (2.4)	4 (2.2)	8 (2.3)
2		4 (2.4)	3 (1.7)	7 (2.0)
3		5 (3.0)	13 (7.3)	18 (5.2)
4		13 (7.8)	8 (4.5)	21 (6.1)
5		5 (3.0)	17 (9.5)	22 (6.4)
6		1 (0.6)	3 (1.7)	4 (1.2)
7		110 (66.3)	115 (64.2)	225 (65.2)
new_a_positive_TB				
0		29 (11.98)	33 (14.35)	62 (13.14)
1		122 (50.41)	104 (45.22)	226 (47.88)
2		80 (33.06)	81 (35.22)	161 (34.11)
3		11 (4.55)	12 (5.22)	23 (4.87)

Age started smoking

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
Introduction			
Background and	2a	Scientific background and explanation of rationale	4-5
objectives	2b	Specific objectives or hypotheses	5-7
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5-6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	5
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	7-8
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	8
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	6
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	6
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	6
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	6
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	6

		assessing outcomes) and how		
	11b	If relevant, description of the similarity of interventions		NA
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes		9
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses		9
Results				
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome		10, Figure 1
	13b	For each group, losses and exclusions after randomisation, together with reasons		10, Fig 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up		5-6
	14b	Why the trial ended or was stopped		10,21
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group		Table 1 and 2, Supp Table 1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups		Fig 1, Table 3
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)		Table 3,4,5
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended		Only relative effect
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory		Table 4, 5
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)		No harms reported
Discussion				
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses		21-22
Generalisability	21	Generalisability (external validity, applicability) of the trial findings		NA, no effect
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence		21
Other information				
Registration	23	Registration number and name of trial registry		2
Protocol	24	Where the full trial protocol can be accessed, if available		Published paper referenced

CONSORT 2010 checklist

Page 2

| Funding | 25 | Sources of funding and other support (such as supply of drugs), role of funders | 23 |

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Effect of a brief motivational interview and text message intervention targeting tobacco smoking,**

2 **alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult**

3 **patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in**

4 **South Africa**

5 Goedele Maria Louwagie[1, 2], Mona Kanaan[3], Neo Keitumetse Morojele[4, 5], André van Zyl[1], Andrew

6 Stephen Moriarty[3], Jinshuo Li[3], Kamran Siddiqi[3], Astrid Turner[2], Noreen Dadirai Mdege[3], Olufemi

7 Babatunde Omole[6], John Tumbo[1], Max Oscar Bachmann[7], Steve Parrott[3], Olalekan Ayo-Yusuf[1, 2]

8 Correspondence to Goedele Maria Louwagie; goedele.louwagie@up.ac.za

9

10 [1]Goedele Maria Louwagie, Sefako Makgatho Health Sciences University and [2]School of Health

11 Systems and Public Health, University of Pretoria , RSA; goedele.louwagie@up.ac.za

12

13 [3]Mona Kanaan, Department of Health Sciences, University of York, UK; mona.kanaan@york.ac.uk

14

15 [4]Neo Keitumetse Morojele, Department of Psychology, University of Johannesburg and [5]Alcohol,

16 Tobacco and Other Drug Research Unit, South African Medical Research Council, RSA;

17 nmorojele@uj.ac.za

18

19 [1]André van Zyl, Sefako Makgatho Health Sciences University, RSA; drevanzyl@gmail.com

20

21 [3]Andrew Stephen Moriarty, Department of Health Sciences and the Hull York Medical School,

22 University of York, UK; andrew.moriarty@york.ac.uk

23

24 [3]Jinshuo Li, Department of Health Sciences, University of York, UK; jinshuo.li@york.ac.uk

25

26 [3]Kamran Siddiqi, Department of Health Sciences and the Hull York Medical School, University of York,

27 UK; kamran.siddiqi@york.ac.uk

28

29 [2]Astrid Turner, School of Health Systems and Public Health, University of Pretoria, RSA;

30 astrid.turner@up.ac.za

31

32 [3]Noreen Dadirai Mdege, Department of Health Sciences, University of York, UK;

33 noreen.mdege@york.ac.uk

34

35 [6]Olufemi Babatunde Omole, Department of Family Medicine, University of Witwatersrand, RSA;

36 Olufemi.Omole@wits.ac.za

37

38 [1]John Tumbo, Department of Family Medicine, Sefako Makgatho Health Sciences University, RSA;

39 tumbo@lantic.net

40

41 [7]Max Oscar Bachmann, Norwich Medical School, University of East Anglia, UK;

42 m.bachmann@uea.ac.uk

43

1

44   ³Steve Parrott, Department of Health Sciences, University of York, UK; steve.parrott@york.ac.uk

45

46   ¹Olalekan Ayo-Yusuf, Africa Centre for Tobacco Industry Monitoring & Policy Research, Sefako

47   Makgatho Health Sciences University, and ²School of Health Systems and Public Health, University of

48   Pretoria, RSA; lekan.ayo-yusuf@smu.ac.za

49

50   **ABSTRACT**

51   **Objectives:** t̶to investigate the effectiveness of a complex behavioural intervention, ProLife, on

52   tuberculosis (TB) treatment success, medication adherence, alcohol use and tobacco smoking.

53   **Design:** m̶multi-centre, individual, randomised controlled trial where participants were assigned

54   (1:1) to the ProLife intervention or usual care.

55   **Setting:** 27 primary care clinics in South Africa.

56   **Participants:** 574 adults starting treatment for drug-sensitive pulmonary TB who smoked tobacco or

57   reported harmful/hazardous alcohol use.

58   **Interventions:** The intervention, delivered by lay health workers (LHWs), consisted of 3 brief

59   motivational interviewing (MI) sessions , augmented with Short Message Service (SMS) messages,

60   targeting medication adherence, alcohol use and tobacco smoking.

61   **Outcome measures:** the primary outcome was successful versus unsuccessful TB treatment at 6 to 9

62   months, from TB records; secondary outcomes: biochemically confirmed sustained smoking

63   cessation, reduction in the Alcohol Use Disorder Identification Test (AUDIT) score, improved TB and

64   antiretroviral treatment (ART) adherence and ART initiation, each measured at 3 and 6 months by

65   questionnaires; cure rates in patients who had bacteriology-confirmed TB at baseline, from TB

66   records.

67   **Results:** Between 15 November 2018 and 31 August 2019, 574 participants were randomised to

68   receive either the intervention (n=283) or usual care (n=291). TB treatment success rates did not

69   differ significantly between intervention (67.8%) and control (70.1%) (OR=0.9 (95% CI: 0.64,1.27)).

70   There was no evidence of an effect at 3- and 6-months respectively on continuous smoking

71   abstinence (OR=0.65 (95% CI: 0.37,1.14); OR=0.76 (95% CI: 0.35,1.63)), TB medication adherence

72   (OR=1.22 (95%CI: 0.52,2.87); OR=0.89 (95%CI: 0.26,3.07)), taking ART (OR=0.79 (0.38,1.65), OR=2.05

73   (0.80,5.27)) or AUDIT scores (mean score difference 0.55 (95% CI: -1.01,2.11); -0.04 (95% CI: -2,1.91);

74   and adjusting for baseline values. Cure rates were not significantly higher (OR=1.16 (0.83,1.63)).

75   **Conclusions:** Simultaneous targeting of multiple health risk behaviours with MI and SMS using LHWs

76   may not be an effective approach to improve TB outcomes.

77

2

78   **Trial registration:** ISRCTN62728852, Registered on 13th April 2018.

79   **Key words:** Tuberculosis, smoking, alcohol, motivational interviewing, mHealth, anti-retroviral

80   therapy, adherence

81

82   **STRENGTHS AND LIMITATIONS OF THIS STUDY**

83   • The use of motivational interviewing combined with Short Text Messaging to address the

84   effect of multiple risk behaviours (smoking, drinking and poor adherence) on tuberculosis TB

85   treatment outcomes is a novel and much needed intervention.

86   • Our study design was strong: this was a multi-site individually randomised controlled trial

87   with a large sample size and a high follow up rate for the primary outcome.

88   • We used validated measurement tools; furthermore data analysis and primary outcome

89   assessment were blinded, thereby limiting measurement bias.

90   • The study was underpowered for secondary outcomes. TLowhe intervention uptake may

91   have diluted any potential intervention effects.

92

3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

93

94   Tuberculosis (TB) is among the most common chronic infectious diseases in the world today. In 2019,

95   1.4 million deaths worldwide were attributed to TB, and the majority of these occurred in low-

96   income and middle-income countries (LMICs).(1) South Africa not only has one of the highest TB

97   burdens in the world; it is faced with high TB treatment interruption and loss to follow-up rates. of

98   the 30 high TB burden countries. It also has a high prevalence of human immunodeficiency virus

99   (HIV) co-infection in patients with TB and a relatively high mortality in these co-infected patients.(1)

100   Studies of interventions to advance the goal of ending the TB epidemic and improving treatment

101   outcomes are therefore research priorities in South Africa and other LMICs.(2)

102   Mortality and morbidity from TB is strongly associated with health risk behaviours, particularly

103   smoking and hazardous or harmful alcohol use, both of which are prevalent and often co-occur in TB

104   patients with TB.(3–10) Strategies are also required to improve TB medication adherence in patients

105   with TB and adherence to TB medication and anti-retroviral therapy (ART) in TB-HIV co-infected

106   patients co-infected with TB and HIV, both of which may be negatively influenced by excessive

107   alcohol use.(1) There is very limited research on how to concurrently tackle these three risk

108   behaviours - namely smoking, harmful alcohol use and poor medication adherence - in patients with

109   TB, particularly in LMICs.

110   Motivational Interviewing (MI) is a counselling technique known to facilitate behaviour change,(11)

111   and has been shown to effectively support reduced drinking, smoking cessation in TB patients and TB

112   treatment and/or antiretroviral therapy (ART) medication adherence.(11–13) MI interventions can

113   be effectively delivered by lay health workers (LHWs).(14) The more widespread use of LHWs and

114   the increased use of mobile health (mHealth) digital technologies represent promising ways to

115   increase the scalability of MI interventions. Indeed, the World Health Organisation (WHO) has called

116   for researchers to capitalise on advances in mobile phone technology, network coverage and the

117   increased use of common and widely available digital technologies (including the mobile phone short

118   message service (SMS)) to improve TB care.(15) There is robust evidence that mHealth technologies

119   can have modest beneficial effects on a range of health outcomes, including medication

120   adherence..(16)(16,17) Mobile phone messaging also shows a modest effect in improving TB

121   treatment success rates.(18,19) The evidence is however stronger for two-way messaging and

122   interactive systems for which smart phones are required.(18) These are often not available to

123   patients with TB in Africa.(20) An SMS intervention in co-infected TB/HIV patients demonstrated

124   effectiveness in increasing adherence to ART,(17) although the existing evidence is not of sufficient

125   quality to know if this consistently applies to medication adherence in TB patients.(18)

4

126

127 A limitation of existing MI and mHealth interventions is that they have been studied in the context of

128 modifying a single lifestyle factor. Integrated interventions are likely to be better accepted and more

129 effective than multiple interventions targeting different health risk factors.(21,22) In the case of TB,

130 there is a need for an intervention that has the flexibility to target multiple lifestyle factors as

131 appropriate and in line with patient preferences. This could be achieved through increased

132 integration of TB and non-communicable disease services.(23)

133

134 Recent re-engineering of primary health care in South Africa has seen the introduction of municipal

135 ward-based primary healthcare outreach teams of community health workers (CHWS). CHWs work

136 in an integrated, team-based manner, supported by nurses, and take responsibility for health

137 education and promotion, counselling and support for a range of health conditions.(24,25) Task

138 shifting in this context has been shown to improve population health in LMICs (26) and these teams

139 can be trained and supported to take responsibility for TB/HIV care.(27) Integrated interventions

140 could be implemented within this framework in a feasible and scalable way to improve outcomes for

141 patients with TB across South Africa and beyond.

142

143 Building on previous successes with MI and mHealth interventions, we developed a complex

144 behavioural intervention (ProLife) comprising MI-based counselling and SMS, targeting three

145 lifestyle risk behaviours for poor TB outcomes (smoking, hazardous/harmful alcohol consumption

146 and poor medication adherence), and delivered by LHWs. We then conducted a randomised

147 controlled trial (RCT) to assess the effectiveness of the ProLife intervention on improving TB

148 treatment outcomes, smoking abstinence, reducing alcohol consumption and improving adherence

149 to TB and ART medication compared to usual care. The cost-effectiveness of the intervention was

150 also assessed but only the costing results will be presented in this paper.

151

152 **METHODS**

153

154 **Study design and participants**

155 This was a prospective, two-arm, multi-centre, individually ~~randomised controlled trial~~RCT, which

156 took place across 27 primary care clinics in 3 districts in South Africa (Lejweleputswa in the Free

157 State province; Bojanala in the North West province; and Sedibeng in Gauteng province). Adult

158 patients (18 years or older) were eligible for the study if they had drug-sensitive Pulmonary TB (PTB),

159 and were initiating TB treatment or had been on TB treatment for less than a month for this

5

1
2
3   160   treatment episode (both "new" and "retreatment patients"). They had to be tobacco smokers
4
5   161   (defined as smoking daily or non-daily in the last four weeks on the Global Adult Tobacco Survey
6
7   162   questionnaire)(28) and/or hazardous/harmful drinkers who were not alcohol dependent (Alcohol
8
9   163   Use Disorders Identification Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20).(29) They also
10
11   164   had to have access to a mobile phone and understand one of the 4 languages used for the trial
12   165   (English, IisiZulu, SeSotho and Setswana). Potential participants were recruited consecutively at the
13
14   166   participating clinics between 15 November 2018 and 31 August 2019. Trained field workers
15   167   identified those interested in the study and screened them for eligibility. If eligible and willing to be
16
17   168   enrolled into the trial, written informed consent was obtained. The RCT received ethics approval
18
19   169   from the Research Ethics Committees of the five participating research institutions.(30)
20
21   170
22   171   **Randomisation and blinding**
23
24   172   Patients were centrally randomised (1:1) to the ProLife intervention or control group using a
25   173   randomised sequence generator by the trial statistician (MK) who was blind to the arm allocation.
26
27   174   We used block randomisation with varying block sizes stratified by clinic so as to achieve equal
28
29   175   numbers in intervention and control groups within each clinic. Fieldworkers used sequentially
30   176   numbered, sealed, opaque envelopes to allocate participants to intervention or control. ProLife
31
32   177   involved a complex behavioural intervention therefore LHWs and participants could not be blinded
33
34   178   to the intervention. However, the determination of the primary outcome was done by the TB nurses
35   179   who were blinded to the intervention status of the participants, based on routinely collected data.
36
37   180   The statistician (MK) was blinded to the intervention or control arm allocation of participants during
38
39   181   the analysis.
40
41   182
42   183   **Intervention and procedures**
43
44   184   The ProLife intervention was developed based on a conceptual framework, following a review of
45   185   pre-existing evidence.(31) This framework assumed that smoking cessation, reducing harmful
46   186   alcohol use and improved adherence to TB and HIV treatment would result in improved TB
47   187   treatment outcomes.(30) The intervention consisted of 3 brief MI counselling sessions, lasting 15-20
48   188   minutes, one month apart, delivered by trained LHWs at their TB clinic. The first MI session took
49   189   place immediately or shortly after the randomisation and involved prioritisation and agenda setting,
50   190   wherein the participant determined which factor should be prioritised (either a plan to quit tobacco
51   191   smoking, or reduce or quit drinking, or deal with barriers relating to ART or TB medication
52   192   adherence). The second and third sessions built on the previous one until all relevant behavioural
53   193   problems had been addressed. These sessions were reinforced with follow-up SMS text messages,
54   194   twice a week over 12 weeks.(30) Study patients received 10 TB-related messages followed by seven
55   195   alcohol reduction- and/or seven smoking cessation-related messages, as appropriate. Messages
56   196   were aimed at giving information, and augmenting motivation or behavioural skills (we refer to the
57   197   feasibility paper for more details).(31) Applicable SMS-messages were automatically activated after
58
59
60
                                                                                                        6

198 the first MI had taken place. Thereafter the remaining messages were delivered even if the
199 participant did not attend the second or third MI session.
200

201

202

203 Participants randomised to the ProLife intervention also received the same "usual care" as those in

204 the control group. The control group received the usual care and routine treatment and support

205 offered to ~~TB~~ patients with TB in South Africa, which varies by district but includes: health education;

206 dietetic input; social support; point of care biochemical testing; and HIV testing with pre- and post-

207 test HIV test counselling.

208

209 Data were collected at baseline, 3- and 6-months and recorded by fieldworkers equipped with

210 mobile phones with the ProLife mobile data collection application (built with CommCare)(32)

211 installed. They used a standardised electronic case report form (CRF) and followed standard

212 operating procedures (SOPs) to ensure quality. Details of data collection, protection and storage

213 procedures have been reported elsewhere.(30)

214

215 **Patient and public involvement**

216 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination

217 plans of our research.

218

219 **Outcomes**

220 Primary Outcome

221 The primary outcome of TB treatment success at 6 to 9 months follow-up (depending on when it was

222 recorded) was as per the WHO definitions adopted in South Africa,(10) that is, either successful

223 treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss

224 to follow-up (defined as treatment interruption of more than 2 months), or outcome not evaluated.

225 It was measured using the routinely collected TB treatment outcomes in patients' individual files.

226

227 Secondary Outcomes

228 For those participants with bacteriologically confirmed PTB at baseline (either sputum acid fast

229 bacilli (AFB) positive, culture positive or GeneXpert positive PTB), sputum conversion at the end of

230 treatment ("cure rate") was measured as a secondary outcome.(10) Continuous smoking abstinence

231 was assessed at 3- and 6-months follow-up in those participants who were current cigarette smokers

232 at baseline. It was defined as having quit smoking completely and a self-report of not smoking more

7

233 than 5 cigarettes from the start of the study, in addition to a negative biochemical test (exhaled

234 Carbon Monoxide (CO) < 7 ppm).(33,34) Changes in alcohol consumption were computed using the

235 AUDIT questionnaire scores measured at 3- and 6-months follow-up in those participants who were

236 hazardous/harmful drinkers at baseline.

237 HIV positive participants were asked about ART status at baseline, 3- and 6-months using

238 standardised questions on the CRF and change in ART status as measured at the 2 follow-up times.

239 TB and ART medication adherence was measured using modified versions of the AIDS Clinical Trials

240 Group Adherence Questionnaire, a validated tool for measuring adherence specifically to ART.(35)

241 Adherence was measured using an adherence index calculated by the formula (using the 4-day

242 recall): [Total number of doses taken/Total number of doses prescribed] x 100. Patients with at least

243 95% adherence were classed as having optimal adherence and those with less than 95% were

244 classed as having low (or suboptimal) adherence. This was assessed at 3- and 6-months.

245 During COVID-19 lockdown (in the second term of 2020) we switched to telephonic follow-up of

246 participants using a shortened questionnaire whereby only strictly needed information for the

247 measurement of outcomes was inquired about.

248 Training and Intervention Fidelity Monitoring

249 The training and intervention fidelity monitoring is described in more detail in previous

250 papers.(30,31) In brief, 18 LHWs, 3 district coordinators and 1 research assistant who focused on

251 counselling supervision underwent MI training over 5 days. LHWs completed a post-session semi-

252 structured form onto which they indicated the extent to which they implemented each element of

253 MI, as well as their general qualitative impressions of that particular session. In addition, we

254 assessed MI intervention fidelity based on ratings of the counsellors' recorded MI sessions, as

255 described below and in footnotes to the relevantSupplementary table 4. SMS-message delivery was

256 also assessed.

257

258 Economic evaluation

259 The ProLife intervention costs consisted of the costs of training and the delivery of the ProLife

260 intervention, including relevant personnel involvement (trainers and LHWs), materials used, travel,

261 accommodation and refreshments, and digital infrastructure for the intervention. These were

262 estimated based on research team records. Usual care costs consisted of TB medication costs,

263 biochemical investigations, and ART costs if applicable. These were estimated based on information

264 obtained through routine records. The country specific version of Euroqol with 5 dimensions and

8

265 ~~with~~ 3 levels of response categories (EQ-5D-3L) for South Africa was administered to participants at

266 baseline, 3- and 6-months follow-up to measure health-related quality of life.(36,37)

267

Statistical analysis

269 The sample size was estimated at 696 in total (348 participants per arm), to detect a 10% difference

270 in TB treatment success rates (0.86 vs. 0.76) in the ProLife arm (intervention) vs. the control arm

271 with 80% power, a significance level of 0.05 and 25% attrition rate. The assumed success rates in the

272 control group were based on actual success rates in ~~TB~~ patients with TB in the studied provinces

273 obtained from TB managers at the time of the grant application for this study.

274 We summarised baseline data descriptively by trial arm. For the primary outcome, we conducted

275 statistical analysis on an intention-to-treat basis. We used binary logistic regression to compare the

276 main outcome (TB treatment success rate) between the intervention and the usual care arm. Where

277 treatment outcome data were missing, the outcome was coded as unsuccessful. TB treatment

278 outcomes recorded by the TB nurse were taken on face value as inconsistencies in the dates of

279 bacteriological results did not permit us to verify the correctness of the nurse assessment. We

280 carried out similar statistical analyses for the secondary outcomes with appropriate regression

281 techniques. For the reduction in harmful or hazardous drinking, we used linear regression to

282 estimate the difference in total AUDIT score between control and intervention groups accounting for

283 the baseline AUDIT score as covariate. Separate analyses at 3- and 6-months were performed.

284 For our main analyses we adjusted for baseline characteristics if these differed between trial arms at

285 baseline. The covariates that we controlled for in each model are specified when a model is

286 presented. The statistical packages STATA (38) and R (39) were used to carry out the analyses, with a

287 P-value < 0.05 considered statistically significant.

288 The validated Motivational Interviewing Treatment Integrity (MITI) coding tool (version 4.2.1) was

289 used to assess MI intervention fidelity.(40) The coding entailed making 'Global Ratings' (on 4

290 dimensions: Cultivating change talk, Softening sustain talk, Partnership and Empathy) and

291 'Behaviour' counts (with respect to the items: giving information, persuade, persuade with

292 permission, question, simple reflection, complex reflection, affirm, seeking collaboration,

293 emphasising autonomy and confront). A score was assigned to each of these items and the scores

294 compared against the competency and proficiency thresholds that are specified in the MITI manual.

295

9

296   For the analysis of the costs, all costs were collected in South Africa Rand (ZAR) except for the data

297   management system subscription. Results are presented in both ZAR and US dollar ($) using the

298   2019 OECD exchange rate (1 USD = 14.448 Rand).(36) No South African specific valuation set was

299   available for EQ-5D-3L. The valuation set of Argentina, based on a Visual Analogue Scale for EQ-5D-

300   3L, was used to derive utility values, because the GDP per capita in international dollars was the

301   closest between the two countries at the time of analysis.(37,41) Quality-adjusted life years (QALYs)

302   were derived from the utility values at the time points by calculating the area under the curve.(42)

303   No missing data imputation was performed.

304

305

306   **RESULTS**

307

308   **Participant enrolment and follow-up**

309   A total of 2099 TB patients with TB were screened for eligibility out of which 574 consenting and

310   eligible participants were randomised: 291 to control and 283 to intervention. Trial recruitment was

311   terminated on 31 August 2019 before the planned sample size was reached because of budget and

312   time constraints. In the intervention arm, 227 (80.2%) participants completed the first MI (MI 1)

313   session, 199 (70.3%) MI 2 and 150 (53.0%) MI 3. In the intervention arm, at least one message was

314   delivered to 208 (73.5%) participants, while 99 (35.0%) received all messages. Of those randomised

315   to the control and intervention groups, the primary outcome was recorded in 244 (83.8%) and 253

316   (89.4%) participants, respectively. (Figure 1)

317

318   **Figure 1 Consort flow diagram**

319

320   **Baseline participant characteristics of the intervention and control arm**

321   Socio-demographic; socio-economic and clinical characteristics

322   Baseline characteristics were distributed similarly in the intervention and control arms for most

323   variables but with some imbalances in educational level. A total of 513 (91.3%) participants were

324   new TB patients with TB, 129 (22.5%) women, and nearly all had PTB (International Classification of

325   Diseases-10 A15) without extrapulmonary TB manifestations (553 (98.9%)). About half of the

326   participants were HIV positive (305 (53.2%)), of whom 204 (65.4%) were on cotrimoxazole and 257

327   (82.4%) were on ART. (Table 1) Details of marital status, employment, wealth, depression status and

328   co-morbidities are presented in Supplementary table 1.

329

10

	Control (N = 291) n (%)*	Intervention (N = 283) n (%)*	Total (N=574) n (%)*
Table 1 Baseline descriptive socio-economic statistics and clinical characteristics by study arm			
Age in years: mean (SD)	39.37 (12.60)	38.56 (11.15)	
Female Sex	69 (23.7)	60 (21.2)	129 (22.5)
Education			
No education	7 (2.4)	5 (1.8)	12 (2.1)
Grades 1-5	23 (7.9)	20 (7.1)	43 (7.5)
Grades 6-7	32 (11.0)	35 (12.4)	67 (11.7)
Grades 8-11	96 (33.0)	128 (45.2)	224 (39.0)
Grade 12	87 (29.9)	70 (24.7)	157 (27.4)
Higher	24 (8.2)	8 (2.8)	32 (5.6)
Declined to answer**	22 (7.6)	17 (6.0)	39 (6.8)
TB Patient category			
New patient	264 (92.3)	249 (90.2)	513 (91.3)
Relapse	10 (3.5)	9 (3.3)	19 (3.4)
Re-treatment after default	9 (3.1)	14 (5.1)	23 (4.1)
Re-treatment after failure	1 (0.3)	2 (0.7)	3 (0.5)
Other	2 (0.7)	2 (0.7)	4 (0.7)
TB Site of disease Pulmonary only (ICD-10 A15)	281 (98.9)	272 (98.9)	553 (98.9)
TB Sputum smear, Gene XPert, or culture result available N=	236	227	463
At least one Sputum smear, Gene XPert, or culture result positive	208 (88.1)	195 (85.9)	403 (87.0)
HIV status			
Negative	118 (40.7)	125 (44.2)	243 (42.4)
Positive	163 (56.2)	142 (50.2)	305 (53.2)
Unknown	9 (3.1)	16 (5.7)	25 (4.4)
HIV positive patients			
Using Cotrimoxazole	104 (63.8)	100 (67.1)	204 (65.4)
Using anti-retroviral	139 (85.3)	118 (79.2)	257 (82.4)

11

330 * Frequencies and (percentages) are presented unless otherwise stated
331 **More variables with the option "declined to answer" are listed in the Supplementary table 1
332

Table 2 Baseline descriptive alcohol and smoking characteristics by study arm			
	Control (N=291)	Intervention (N=283)	Total (N=574)
	n (%)*	n (%)*	n (%)*
In the past month, smoked tobacco			
Not at all**	110 (37.8)	92 (32.5)	202 (35.2)
Daily	149 (51.2)	149 (52.7)	298 (51.9)
Less than Daily	32 (11.0)	42 (14.8)	74 (12.9)
Had a drink in the past 12-months	208 (71.5)	223 (78.8)	431 (75.1)
AUDIT Score (males) : mean (SD) [max: 19]†	12.27 (3.98)	13.02 (3.78)	12.66 (3.89)
AUDIT Score (females): mean (SD) [max: 19]†	11.32 (4.02)	10.98 (4.02)	11.15 (4.0)
Hazardous/harmful drinking and Smoking Combined (Constructed)			
Hazardous/harmful drinking Only‡	110 (37.8)	92 (32.5)	202 (35.2)
Smoking Only	103 (35.4)	77 (27.2)	180 (31.4)
Smoking and hazardous/harmful drinking‡	78 (26.8)	114 (40.3)	192 (33.4)

333 * Frequencies and (percentages) are presented unless otherwise stated
334 **Non-smokers were only included if they were harmful or hazardous drinkers
335 †Only hazardous/harmful drinkers and/or current smokers were included in the study. Therefore ~~TB~~ patients with TB were excluded if they were non-current smokers and had an AUDIT
336 score <7 (females) or <8 (males) or >19; however, they were included if they were smokers independent of whether they had a drink in the past year and therefore independent of the
337 AUDIT score. These AUDIT scores are thus representative of the mean AUDIT scores in the entire study sample and differ from the AUDIT score in the harmful/hazardous drinkers whose
338 change in AUDIT score was measured at 3 and 6-months follow-up ~~(see Table 3)~~
339 ‡Harmful/hazardous drinking is defined as Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20
340

12

341 There were 372 current smokers (298 daily, 74 less than daily). Seventy eight participants (26.8 %)

342 in the control arm were dual smokers *and* drinkers compared to 114 (40.3 %) in the intervention

343 arm. In the control arm, 110 (37.8%) were hazardous/harmful drinkers only and 103 (35.4%) were

344 smokers only, compared to 92 (32.5%) and 77 (27.2) respectively, in the intervention arm. (Table 2)

345 More details of smoking and drinking history, forms of tobacco use, addiction and quit attempts are

346 presented in Supplementary Table 2.

347

348 **Primary outcome**

349 Overall, 396 (70%) of participants were classified as treated successfully (treatment completed or

350 cured). The remainder either interrupted treatment, failed treatment, developed drug resistance,

351 wereas transferred out or had an unknown the treatment outcome.(Supplementary table 3) The

352 percentage of successful TB treatment did not differ significantly between the control and

353 intervention arm (70.1% vs. 67.8%), odds ratio (OR) for successful TB treatment 0.90 (95%CI:

354 (0.64,1.27)) comparing the intervention arm to the control arm; and was similar to adjusted ORs.

355 (Tables 3 and 4)

356

357 **Secondary outcomes**

358 Cure rates

359 Among the 403 participants who had at least one positive bacteriological result at baseline, 168

360 (41.7%) were recorded as cured; of these, 83/205 (39.9%) were in the control arm compared to

361 85/195 (43.6%) in the intervention arm. The OR of being cured was 1.16 (95% CI: 0.83,1.63) in the

362 intervention versus the control arm; and was similar to the adjusted OR. (Tables 3 and 4)

363

364 Continuous smoking abstinence

365 Among those who identified as cigarette smokers at baseline (345 (60.1%)), 27 had information (self-

366 report plus biochemical verification) to enable the identification of continuous abstinence at 6-

367 months of which 22 had continuously abstained from smoking. These were similarly distributed

368 across the two study arms: 10 (5.59%) participants in the intervention arm compared to 12 (7.23%)

369 in the control arm, OR 0.76 (95% CI: 0.35,1.63). (Tables 3 and 4) At the 3-month follow-up 20 (11.2%)

370 participants in the intervention arm compared to 27 (16.3%) in the control arm continuously

371 abstained from smoking, OR 0.65 (95% CI: 0.37,1.14). (Tables 3 and 5)

372

13

1
2
3
4
5
6
7
8
9
10
11
12
13
14
...

TABLE 3 Descriptive statistics for primary and secondary outcomes by study arm at baseline (where available), 3-months (where available) and 6-months									
	Baseline n (%)*			3-months follow-up n (%)*			6-months follow-up n (%)*		
	Control	Intervention	Total	Control	Intervention	Total	Control	Intervention	Total
TB treatment status[a]									
Successful**							204 (70.1)	192 (67.8)	396 (69.0)
Not Successful							87 (29.9)	91 (32.16)	178 (31.01)
Cured [a, *]**									
Yes							83 (39.9)	85 (43.6)	168 (41.7)
No							125 (60.1)	110 (56.4)	235 (58.3)
Continuous smoking abstinence[b]									
Yes				27 (16.3)	20 (11.2)	47 (13.6)	12 (7.2)	10 (5.6)	22 (6.4)
No				139 (83.7)	159 (88.8)	298 (86.4)	154 (92.8)	169 (94.4)	323 (93.6)
Harmful/hazardous drinkers[ı]: N =	188†	206†	394†	141†	130†	271†	112†	127†	239†
AUDIT score: mean (SD)	12.76 (3.42)	13.12 (3.47)	12.94 (3.45)	8.28 (6.18)	8.84 (5.38)	8.55 (5.81)	8.79 (6.66)	8.70 (5.83)	8.74 (6.22)
Difference from baseline: mean (SD)				-4.61 (6.26)	-4.07 (5.33)	-4.35 (5.83)	-4.25 (6.56)	-4.17 (6.61)	-4.21 (6.57)
HIV positive patients:	163† (56.2)	142† (50.2)	305† (53.2)	122†	83†	205†	100†	83†	183†
Taking ART medication if HIV positive‡	139 (85.3)	115 (81.0)	254 (83.3)	91 (74.6)	58 (69.9)	149 (72.7)	80 (80.0)	74 (89.2)	154 (84.2)

36
37
38
39
40
41
42
43
44
45
46

14

ART medication adherence[b]						
Optimal adherence	101 (99.0)	64 (98.5)	165 (98.8)	75 (97.4)	64 (97.0)	139 (97.2)
Suboptimal adherence	1 (1.0)	1 (1.54)	2 (1.2)	2 (2.6)	2 (3.0)	4 (2.8)
TB medication adherence						
Optimal adherence	181 (92.3)	138 (90.8)	319 (91.7)	61 (89.7)	59 (90.8)	120 (90.2)
Suboptimal adherence	15 (7.6)	14 (9.2)	29 (8.3)	7 (10.3)	6 (9.2)	13 (9.8)

a: only assessed at 6-months

b: assessed at 3 and 6-months; this table refers to *cigarette* smokers only (other forms of tobacco smoking are excluded)

* Frequencies and (percentages) are presented unless otherwise stated

**Primary Outcome: This is a binary variable defined as either successful treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss to follow-up or treatment interrupted for more than 2 months, or outcome not evaluated/unknown.

***Based on having a cured treatment outcome among those who were bacteriologically positive at baseline.

! hazardous/harmful drinkers who are not alcohol dependent= AUDIT score ≥ 8 for men or ≥ 7 for women but < 20; *! Important distinction at baseline for eligibility purposes.

†Denominator for the mean (SD) or denominator for %

‡ Information on HIV-positivity was obtained from information from TB records combined with patient self-report at baseline. True HIV-positivity rates may have been higher.

15

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

TABLE 4 Regression analysis results for the primary and secondary outcomes at 6-months				
	Crude Odds Ratio (95% CI)*	P Value*	Adjusted Odds Ratio (95% CI)*	P Value*
Primary outcome				
TB treatment status: Successful (Ref: Not successful)	0.90 (0.64,1.27)	0.548	0.86‡ (0.60,1.24)	0.421
Secondary outcomes				
Cured (Ref: Not Cured)	1.16 (0.83,1.63)	0.374	1.07‡ (0.76,1.51)	0.684
Continuous smoking abstinence (Ref: No)***	0.76 (0.35,1.63)	0.482		
TB medication adherence (Ref: Optimal)	0.89 (0.26,3.07)	0.849		
ART medication adherence (Ref: Optimal)	1.17 (0.14,9.94)	0.884		
Taking ART medication (Ref: No)	2.05! (0.80,5.27)	0.136		
AUDIT	-0.04** (-2,1.91)	0.966	0.02!! (-1.55,1.6)	0.976

* Analyses accounted for potential clustering by centre.

‡ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline. It is worth noting that of the variables in the adjusted model; the only statistically significant result is for the district variable.

! Adjusting for art status at baseline

**Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.

!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.

***Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.73 and 0.76 with similar confidence limits as for the crude estimate.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

16

Secondary outcome	Crude Odds Ratio (95% CI)*	P Value*	Adjusted Odds Ratio (95% CI)*	P Value*
TABLE 5 Regression analysis results for secondary outcomes measured at 3-months				
Continuous smoking abstinence (Ref: No)**	0.65 (0.37,1.14)	0.135		
TB medication adherence (Ref: Optimal)	1.22 (0.52,2.87)	0.641		
ART medication adherence (Ref: Optimal)	1.58 (0.10,26.12)	0.750		
Taking ART medication (Ref: No)	0.79[!] (0.38,1.65)	0.53	0.74‡ (0.35,1.58)	0.443
AUDIT	0.55† (-1.01,2.11)	0.474	0.74[!!] (-0.62,2.1)	0.273

*Analyses accounted for clustering.

[!] Adjusting for art status at baseline

‡ Adjusted for art status at baseline, district, sex, and smoking/drinking status and HIV status at baseline.

†Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.

[!!] Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.

** Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.63 and 0.66 with similar confidence limits as for the crude estimate.

17

373   Change in harmful/hazardous drinking

374   AUDIT scores were about 4 points lower at both follow-up times than at baseline, independent of

375   the intervention.(Table 3) In the intervention arm, participants had, on average, a reduction of 0.04

376   points (95% CI: -2,1.91) on the AUDIT score at 6-months, compared to those in the control arm

377   controlling for baseline scores; whereas an average increase of 0.55 (95% CI: -1.01,2.11) was

378   observed at 3-months. (Tables 4 and 5)

379

380   Medication adherence and ART uptake

381   At 6-months, the OR of taking ART medication was 2.05 (95% CI: 0.80,5.27) comparing the

382   intervention arm to the control arm and controlling for ART baseline medication status; whereas it

383   was 0.79 (95% CI: 0.38,1.65) at 3-months. The proportion of participants who had optimal TB

384   medication adherence was 90.2% (120/133) at 6-months and 91.7% (319/348) at 3-months.

385   Suboptimal TB medication adherence ORs were 0.89 (95%CI: 0.26,3.07) and 1.22 (95%CI: 0.52,2.87)

386   comparing intervention arm to the control arm at 6-months and 3-months, respectively. The

387   proportions of participants on ART who had optimal ART medication adherence were high at both 3-

388   months (165/167, 98.8%) and 6-months follow-up (139/143, 97.2%). Suboptimal ART medication

389   adherence ORs were 1.17 (95%CI: 0.14,9.94) and 1.58 (95%CI: 0.10,26.12) comparing the

390   intervention arm to the control arm at 6-months and 3-months, respectively. (Tables 3, 4 and 5)

391

392   **Intervention fidelity**

393   Motivational interviewing fidelity

394   The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In terms

395   of the global ratings, the LHWs' counselling sessions were above proficiency levels on all items,

396   namely, cultivating change talk, softening sustain talk, partnership, and empathy (as the mean scores

397   were all above 2). In terms of the summary measures, the LHWs' counselling sessions did not

398   achieve the basic proficiency threshold of 3.5 for the Relational component (Partnership + Empathy)

399   as their mean score was 3.1 (SD=1.19). However, their mean score on the Technical component

400   (Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For

401   behavioural counts, "Asking Questions" had the highest mean score (24.2; SD=10.42), followed by

402   "Affirm" with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the

403   following: Persuade with permission and emphasising autonomy. The mean Reflections to Questions

404   Ratio was 0.23 (SD=0.24). The LHWs made on average 9.3 (SD=4.74) MI adherent (Affirm, Emphasize

405   Autonomy and Seek Collaboration) and 1.2 (SD=2.28) MI non-adherent (Confront and Persuade)

406   statements per session. (Supplementary Ttable 4)

18

407

408   SMS-delivery

409   Of the total number of Information-Motivation-Behaviour messages triggered, 3583 (80.4%) were

410   delivered. All due SMS messages were delivered to 95 (41.9%) of the participants who completed

411   the first MI, See Supplementary Table 5 for more details.

412

413   **Costs and health related quality of life**

414   Unit costs used to estimate the mean costs are presented in the Supplementary Table 6. Incremental

415   cCost-utility ratios are not presented since the intervention was not clinically effective. The mean

416   cost of the ProLife intervention was ZAR 2601 (SD 6) ($180.02 (SD $0.42)) per participant in the

417   intervention arm (n=283). The mean cost of usual care was ZAR 681 (SD 357) ($47.13 (SD $24.71)) in

418   the intervention arm (n=122) versus ZAR 706 (SD 302) ($48.86 (SD $20.90)) in the control arm

419   (n=131). The total mean cost of care including the intervention was ZAR 3285 (SD R357) ($227.37 (SD

420   24.71)) in the intervention arm (n=122). EQ-5D-3L data were available at the 3 time points for 137

421   intervention and 159 control arm participants. The mean QALYs estimated over six months were

422   0.442 (SD 0.061) in the intervention arm versus 0.430 (SD 0.074) in the control arm (adjusted mean

423   difference 0.006 (95% CI -0.001 to 0.013)).

424

425   **DISCUSSION**

426

427   This RCT did not finprovided evidence for improved TB treatment success rates in those receiving the

428   ProLife intervention compared to those receiving usual care. We could also There was also not

429   demonstrate significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol

430   consumption, medication adherence and ART initiation. To our knowledge there are no other

431   published studies of similar complex interventions that aim to improve TB treatment outcomes in

432   patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other

433   studies were either complex interventions or complex SMS-based interventions aimed at improving

434   TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking

435   intervention component (43,44) or or focused on a single behaviour, namely smoking or

436   drinking.(45,46). Of the latter studies, a brief smoking cessation intervention was effective in

437   inducing smoking cessation in TB patients with TB but did not improve TB outcomes.(45) Conversely,

438   in another study in India, intensive counselling for alcohol disorders led to significantly better TB

439   treatment outcomes in the intervention group compared to the control group.(46) Smoking

440   cessation also led to better TB treatment outcomes in a secondary analysis of a large tobacco

19

441 cessation trial in ~~TB~~ patients with TB in Bangladesh and Pakistan.(47) Our non-significant result for

442 smoking-related outcomes is not consistent with findings from our previous TB study, which used a

443 single MI session and found that the chance of sustained smoking cessation was twice as high in the

444 MI intervention group compared to the control group,(14) albeit with a less stringent exhaled CO

445 cut-off point. Evidence on the effectiveness of MI for smoking abstinence in non-TB settings has

446 been equivocal.(48) Self-reported alcohol consumption decreased with about 4 points in both

447 intervention and control arms in our study at both follow-up times. Answering questions on drinking

448 in brief intervention trials may alter subsequent self-reported behaviour.~~(51)~~: ~~e~~Exposing non-

449 intervention control groups to an integral component of the intervention may therefore

450 underestimate the effect of the intervention.(49) There have been few previous studies looking at

451 MI and SMS interventions for the modification of hazardous/harmful drinking in the context of TB. A

452 previous trial of a brief counselling intervention to reduce alcohol consumption in patients with TB

453 did not find a significant effect on alcohol reduction.(50) Outside a TB setting, results have been

454 mixed. A meta-analysis showed a small but significant improvement in outcomes when MI was used

455 in conjunction with cognitive behavioural therapy for co-morbid alcohol use and depression.(51)

456 Self-reported TB and ART medication adherence was high overall in our~~this~~ study population, which

457 is consistent with other studies conducted in South Africa.(52,53) It is possible that we did not find a

458 difference in treatment adherence due to a ceiling effect.

459

460 There were several key strengths in this RCT. This was an individually RCT with a relatively large

461 sample size and a high follow up rate (87%) for the primary outcome. Primary outcome assessment

462 was blinded. This was a novel intervention, which built on previous successes with both MI and

463 mHealth interventions and was aligned with the WHO's call to increase the use of digital

464 technologies to improve TB care.(15) We utilized a validated alcohol consumption questionnaire

465 (AUDIT) (29) and a four-day timeline follow-back for medication adherence to reduce recall bias as

466 self-reports tend to underreport drinking while overestimating adherence behaviour compared

467 with.(54) (35) Smoking cessation was confirmed with exhaled CO using strict cut-off points. Overall,

468 the quality of the counselling was acceptable. The results of our MI analyses suggest that the LHWs

469 trained as counsellors were more proficient in MI than during the feasibility stage, as observed by

470 their global rating scores on cultivating change talk, softening sustain talk, partnership and empathy.

471 (Supplementary Table 4) These results were achieved by ongoing monitoring and training of LHWs

472 during the trial and adapting the training based on feedback from the feasibility stage. Extra

473 counsellors were also appointed to minimise travel distances to clinics. There were some limitations

474 associated with this RCT. Trial recruitment had to be terminated before the planned sample size

475 because of funding and time constraints. Nevertheless the calculation of sample size was based on

476 an anticipated 25% LTFU for the primary outcome, while in reality only 13.4 %, of the TB outcomes

477 were not available. As a result, we achieved a slightly higher power to detect the a 10% difference in

478 primary outcomes, than we had aimed for (83% vs. 80%). The smaller sample size did however

479 reduce the power to detect a difference for secondary outcomes for which the LTFU was much

480 higher than 25%. Also, the calculated sample size was not powered for subgroup analysis which was

481 the case for outcomes relating to smoking, drinking, ART and cure rates. In addition, due to COVID-

482 19 lockdown in March 2020, we had to switch to telephonic follow-up of participants using a

483 shortened questionnaire (22 participants) and could not access clinics to retrieve outstanding TB

484 treatment outcomes. The low intervention uptake meant that half of the participants received only

485 one or two MI sessions combined with SMS messages. SMS messages were only used for the first

486 half of the study period, and one quarter of participants did not receive their messages, a commonly

487 occurring problem in developing countries.(20,55) It could be argued that in the absence of ongoing

488 text messages, the MI and associated text messages were not enough to keep participants focussed

489 for the second three months of the trial. The 2-arm study design did not permit the untangling of the

490 individual effects of SMS and MI. Understanding their separate effects could have important cost

491 implications as SMS-communication would be cheaper and easier to organise than individual

492 counselling.

493

494

495

496 The lack of effectiveness of our intervention consisting of three sessions of MI combined with SMS

497 on the primary outcome (TB treatment success) can have a number of possible explanations.

498 Although intervention uptake was high (80.2%) for the first counselling session, many participants

499 did not return for the second (29.7%) and third (47%) sessions. As a result of this only about half of

500 the intervention arm participants received all three MI sessions. Furthermore, about one quarter of

501 all participants did not receive any SMS-messages. Low intervention uptake leads to a dilution of any

502 potential effects. There were a number of possible technical barriers to SMS delivery: invalid phone

503 numbers, phones that are off for a long duration of time, numbers that are deactivated, and phones

504 that are disconnected from the network leading.(41) The proportion of participants with TB

505 treatment outcomes recorded was high, but follow-up rates at 3- and 6-months were low. Due to

506 COVID-19 lockdown, we had to switch to telephonic follow-up of participants using a shortened

507 questionnaire (22 participants) and could not access clinics to retrieve outstanding TB treatment

508 outcomes.

21

509

510 The lack of effectiveness on TB treatment success couldmay perhaps also be explained by the

511 complexity of the ProLife intervention itself: counsellors had to address multiple behaviours, namely

512 medication adherence, tobacco smoking and hazardous/harmful drinking. This integrated approach

513 was nevertheless adopted to avoid the need for multiple vertical counselling services (in addition to

514 TB treatment and HIV treatment), to allow the different elements of the programme to reinforce

515 one another, and to improve the affordability, feasibility and acceptability for a future roll-out of the

516 programme. Despite having established the feasibility and acceptability of this approach ,(31) and

517 ongoing on site performance monitoring and feedback of counsellors, it is possible that MI for

518 multiple behaviour change in the ProLife study was counterproductive as counsellors may have

519 ended up not focusing on any of the behaviours at optimal levels. Similarly, patients might have

520 found it difficult to change multiple behaviours simultaneously, especially because smoking and

521 drinking are mutually reinforcing. This integrated approach was nevertheless adopted to avoid the

522 need for multiple vertical counselling services (in addition to TB treatment and HIV treatment), to

523 allow the different elements of the programme to reinforce one another, and to improve the

524 affordability, feasibility and acceptability for a future roll-out of the programme. It is also possible

525 There is some indirect evidence that sequential interventions may be better, at least for smoking

526 cessation.(56) More intensive counselling (more sessions) or a modified counselling method with or

527 without MI may have been more appropriate, even more so since a recent review of reviews of MI

528 casts doubt on its efficacy.(48,57,58) For example, m, more emphasis on increasing patient

529 knowledge in addition to increasing self-efficacy may have been more effective.(59) The cause of the

530 mobile health message delivery problems (such as poor network coverage, no electricity to charge

531 phones) (60) would need to be investigated in order to increase the effectiveness of future mHealth

532 interventions. Messages may also have to be intensified or modified to be more interactive and/or

533 tailored to specific circumstances of each individual. This would improve the personal value of the

534 intervention to the individual, which is likely to increase the chances of their participation in the

535 intervention.(61) Consistent with the normalisation process theory,(62) cognitive participation in the

536 intervention might have been higher had we been deliberate in the implementation to ensure the TB

537 nurse who would have routinely seen the participants, provided additional support and motivated

538 participants to attend MI sessions with the counsellor. In this way, the intervention would have

539 gained 'legitimacy' but this would have led to unblinding of the nurses to the intervention arm.

540

541 In conclusion, Thwe could not demonstrate that the ProLife intervention was is RCT provided

542 evidence that the ProLife intervention was not effective in modifying the primary o improving TB

22

543 treatment outcomes. This may be due to the lack of effect of the intervention, but ~~r~~ the study may

544 also have been underpowered for the intermediary secondary outcomes~~secondary outcomes~~.

545 Valuable lessons were learnt on challenges relating to training LHWs in MI counselling and delivery,

546 ~~the~~ SMS-delivery in a challenging socio-economic context and the reasons for loss to follow-up of TB

547 participants with multiple health problems. Further research is needed to provide answers on how

548 to increase intervention uptake in poor resource settings and whether our complex intervention

549 should have been more intensive ~~(with several sessions for each behavioural problem)~~. Other

550 important questions are whether another counselling method would have been more effective.

551 Lastly, in the light of the already existing evidence of SMS and the costs and implementation

552 challenges relating to MI, intervention studies limited to an mHealth intervention but using different

553 intensities, duration and type of interventions (oneway, twoway, interactive) are needed.

554

23

1
2
3   **Acknowledgements**
4
5   555
6
7
13
14   562
15
16   563   **Contributors**
17
18
32
33   578
34
35   579   **Funding**
36
37

24

589

Competing interests

591 OA Ayo-Yusuf, the principal investigator, received a research grant (MRC-RFA-02: TB -

592 05-2015) which was allocated to Sefako Makgatho Health Sciences University to pay

593 for the expenses related to the research project. As co-prinicipal investigator K Siddiqi

594 received part of the MRC-Newton research grant (MRC-RFA-02: TB -05-2015) which

595 was allocated to the University of York to support the research by the authors

596 affiliated to the University of York (K Siddiqi, ND Mdege, M Kanaan, S Parrot, J Lee).

597 Goedele Louwagie received a small monthly remuneration per month from 1 October

598 2018 until 30 June 2020 as academic research coordinator. André van Zyl was

599 employed as a research data manager on a part-time basis from 1 September 2017

600 and 30 June 2020. OA Ayo-Yusuf received support for attending meetings and for

601 travel by Tax Justice Network Africa. He is the Vice Chair of the Standing Committee on

602 Health, Academy of Science, SA (not remunerated). The remaining authors declare no

603 competing interests.

604

Ethical considerations

606 This study received ethics approval from the Research Ethics Committees of: Sefako

607 Makgatho Health Sciences University (SMU; Ref: SMUREC/D/234/2017: IR); the South

608 African Medical Research Council (with the SMU Ethics Committee serving as the

609 Research Ethics Committee Record); the University of Pretoria (Ref: 434/2017); the

610 University of Witwatersrand (M160455); and the University of York (no reference

611 number, approval date 15 January 2017 (29).

612

Patient Consent for publication

614 Not applicable

615

Data aAvailability statementof data and material

617 The study protocol was previously published (ImPROving TB outcomes by modifying

618 LIFE-style behaviours through a brief motivational intervention followed by short text

619 messages (ProLife): study protocol for a randomised controlled trial). The de-identified

620 participant and SMS data sets are stored in labelled Stata files and are accompanied by

621 a statistical analysis plan and metadata explaining each variable. Although data can be

622 viewed immediately, data will be embargoed for data analysis until 30 June 2023.
623 Thereafter, permission must be obtained from the principal investigators (OA and KS)
624 for any data analysis not yet performed by the primary research group. Data are
625 stored in the institutional data repository at Sefako Makgatho Health Sciences
626 University called Discover research (https://smu-za.figshare.com/) with a CC-BY 4.0
627 (Attribution) license (Creative Commons — Attribution 4.0 International — CC BY
628 4.0). The statistical analysis plan are available as supplementary material.

629 ~~Data are stored in the institutional data repository at Sefako Makgatho Health~~
630 ~~Sciences University called Discover research (https://smu-za.figshare.com/). Data~~
631 ~~access will be embargoed until 30 June 2023.~~

632

633 **Open access**

634 This is an open access article distributed in accordance with a Creative Commons
635 Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix,
636 transform and build upon this work for any purpose, provided the original work is
637 properly cited, a link to the licence is given and indication of whether changes were
638 made. See: https://creativecommons.org/licenses/by/4.0/.

639

640 **References**

641 1. World Health Organisation. Global tuberculosis report 2020. Available:
642 https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf
643 [Accessed 4 Aug 2021].
644 2. Fitchett JR, MacPherson P. Implementing the End TB Strategy and the intersection with the
645 Sustainable Development Goals. *Trans R Soc Trop Med Hyg* 2016;110:145–7.
646 3. Thomas BE, Thiruvengadam K, Rani S, et al. Smoking, alcohol use disorder and tuberculosis
647 treatment outcomes: A dual co-morbidity burdenthat cannot be ignored. *PLoS ONE*
648 14(7):e0220507.
649 4. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis:
650 meta-analyses and burden of disease. *Eur Respir J* 2017;50: 1700216.
651 5. Ogbo FA, Ogeleka P, Okoro A, et al. Tuberculosis disease burden and attributable risk factors
652 in Nigeria, 1990–2016. *Tropical Medicine and Health* 2018;46:34.
653 6. Azeez A, Mutambayi R, Odeyemi A, et al. Survival model analysis of tuberculosis treatment
654 among patients with human immunodeficiency virus coinfection. *Int J Mycobacteriol*
655 2019;8:244-51.

26

656   7.   Mollel EW, Chilongola JO. Predictors for Mortality among Multidrug-Resistant Tuberculosis

657   Patients in Tanzania. J Trop Med 2017;2017:9241238. doi: 10.1155/2017/9241238.

658   8.   Peltzer K. Conjoint alcohol and tobacco use among tuberculosis patients in public primary

659   healthcare in South Africa. *S Afr J Psychiatr* 2014;20(1):21–6.

660   9.   Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis

661   treatment outcomes: a systematic review and meta-analysis. *Int J Tuberc Lung Dis*

662   2020;24(1):73–82.

663   10.   Department of Health of South Africa. National Tuberculosis Management Guidelines.

664   Pretoria: 2014. Available from:

665   http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-

666   27.5.2014.pdf [Accessed 4 Aug 2021].

667   11.   Harder VS, Musau AM, Musyimi CW, et al. A randomized clinical trial of mobile phone

668   motivational interviewing for alcohol use problems in Kenya. *Addiction* 2020 ;115:1050-1060.

669   12.   Palacio A, Garay D, Langer B, et al. Motivational Interviewing Improves Medication

670   Adherence: a Systematic Review and Meta-analysis. *Gen Intern Med.* 31:929–40. DOI:

671   10.1007/s11606-016-3685-3.

672   13.   Madhombiro M, Kidd M, Dube B, et al. Effectiveness of a psychological intervention delivered

673   by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster

674   randomized controlled trial. *J Int AIDS Soc* 2020 Dec;23:e25641.

675   14.   Louwagie GMC, Okuyemi KS, Ayo-Yusuf OA. Efficacy of brief motivational interviewing on

676   smoking cessation at tuberculosis clinics in Tshwane, South Africa: a randomized controlled

677   trial. *Addiction* 2014;109:1942–52

678   15.   World Health Organization. Handbook for the use of digital technologies to support

679   tuberculosis medication adherence, 2017. Available:

680   https://apps.who.int/iris/handle/10665/259832 [Accessed 4 Aug 2021].

681   16.   Hirsch-Moverman Y, Daftary A, Yuengling KA, et al. Using mhealth for HIV/TB treatment

682   support in lesotho: Enhancing patient-provider communication in the start study. *J Acquir*

683   *Immune Defic Syndr* 2017;74:S37–43.

684   17.   Shah R, Watson J, Free C. A systematic review and meta-analysis in the effectiveness of

685   mobile phone interventions used to improve adherence to antiretroviral therapy in HIV

686   infection. *BMC Public Health* 2019;19:915.

687   18.   Gashu KD, Gelaye KA, Mekonnen ZA, et al. Does phone messaging improves tuberculosis

688   treatment success? A systematic review and meta-analysis. *BMC Infect Dis* 2020;20:42.

689   19.   Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on

27

690   tuberculosis treatment: a systematic review. Eur Respir J. 2018 11;51(1):1701596. doi:

691   10.1183/13993003.01596-2017

692   20.   Ggita JM, Ojok C, Meyer AJ, et al. Patterns of usage and preferences of users for tuberculosis-

693   related text messages and voice calls in Uganda. *Int J Tuberc Lung Dis* 2018;22:530-536.

694   21.   Oosterveen E, Tzelepis F, Ashton L, et al. A systematic review of eHealth behavioral

695   interventions targeting smoking, nutrition, alcohol, physical activity and/or obesity for young

696   adults. *Prev Med* 2017;99:197–206.

697   22.   Haug S, Paz Castro R, Kowatsch T, et al. Efficacy of a technology-based, integrated smoking

698   cessation and alcohol intervention for smoking cessation in adolescents: Results of a cluster-

699   randomised controlled trial. *J Subst Abuse Treat* 2017;82:55–66.

700   23.   Siddiqi K, Stubbs B, Lin Y, et al. TB multimorbidity: a global health challenge demanding

701   urgent attention. *Int J Tuberc Lung Dis* 2021;25:87–90.

702   24.   Moosa S, Derese A, Peersman W. Insights of health district managers on the implementation

703   of primary health care outreach teams in Johannesburg, South Africa: A descriptive study

704   with focus group discussions. *Hum Resour Health* 2017;15:1–9.

705   25.   Marcus TS, Hugo J, Jinabhai CC. Which primary care model? A qualitative analysis of ward-

706   based outreach teams in South Africa. *African J Prim Heal Care Fam Med* 2017;9:1–8.

707   26.   Seidman G, Atun R. Does task shifting yield cost savings and improve efficiency for health

708   systems? A systematic review of evidence from low-income and middle-income countries.

709   *Hum Resour Health* 2017;15:1–13.

710   27.   Heunis C, Wouters E, Kigozi G, et al. TB/HIV-related training, knowledge and attitudes of

711   community health workers in the Free State province, South Africa. *African J AIDS Res*

712   2013;12:113–9.

713   28.   World Health Organization & Centers for Disease Control (U.S.). Tobacco questions for surveys: a

714   subset of key questions from the Global Adult Tobacco Survey (GATS): global tobacco surveillance

715   system. *World Health Organization* 2011. Available from:

716   https://apps.who.int/iris/handle/10665/87331 [Accessed 16 Nov 2021]

717   29.   Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT):

718   validation of a screening instrument for use in medical settings. *J Stud Alcohol* 1995;56:423–

719   32.

720   30.   Moriarty AS, Louwagie GM, Mdege ND, et al. ImPROving TB outcomes by modifying LIFE-style

721   behaviours through a brief motivational intervention followed by short text messages

722   (ProLife): Study protocol for a randomised controlled trial. *Trials* 2019;20:1–12.

723   31.   Louwagie GM, Morojele N, Siddiqi K, et al. Addressing tobacco smoking and drinking to

724   improve TB treatment outcomes, in South Africa: A feasibility study of the ProLife program.

28

725   *Transl Behav Med* 2020; 10: 1491–1503.

726   32.   CommCare. Cambridge, MA: Dimagi; 2017. Available from:

727   https://play.google.com/store/apps/details?id=org.commcare.dalvik&hl=en_US&gl=US.

728   [Accessed 15 June 2021].

729   33.   Siddiqi K, Khan A, Ahmad M, et al. Action to stop smoking in suspected tuberculosis (ASSIST)

730   in Pakistan: a cluster randomized, controlled trial. *Ann Intern Med* 2013;158:667–75.

731   34.   West R, Hajek P, Stead L, et al. Outcome criteria in smoking cessation trials: proposal for a

732   common standard. *Addiction* 2005;100:299–303.

733   35.   van den Boogaard J, Lyimo RA, Boeree MJ, et al. Electronic monitoring of treatment

734   adherence and validation of alternative adherence measures in tuberculosis patients: A pilot

735   study. *Bull World Health Organ* 2011;89:632–9.

736   36.   OECD [Internet]. Available from: https://data.oecd.org/conversion/exchange-rates.htm

737   [Accessed 26 Oct 2021]

738   37.   Augustovski FA, Irazola VE, Velazquez AP, et al. Argentine valuation of the EQ-5D health

739   states. *Value Heal* 2009;12:587–96.

740   38.   StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 2017.

741   39.   Team RC. R: A language and environment for statistical computing. Vienna, Austria: R

742   Foundation for Statistical Computing; 2017. Available from: https://www.r-project.org/

743   [Accessed 04 Aug 2021]

744   40.   Moyers TB, Rowell LN, Manuel JK, et al. The Motivational Interviewing Treatment Integrity

745   Code (MITI 4): Rationale, Preliminary Reliability and Validity. *J Subst Abuse Treat* 2016;65:36-

746   42. doi:10.1016/j.jsat.2016.01.001

747   41.   International Monetary Fund. IMF DataMapper - GDP per capita, current prices (Purchasing

748   power parity; international dollars per capita), 2018. Available from:

749   https://www.imf.org/external/datamapper/datasets [Accessed 04 Aug 2021]

750   42.   Richardson GMA. Calculation of quality adjusted life years in the published literature: a

751   review of methodology and transparency. *Health Econ* 2004;13:1203–10.

752   43.   Khachadourian V, Truzyan N, Harutyunyan A, et al. People-centred care versus clinic-based

753   DOT for continuation phase TB treatment in Armenia: a cluster randomized trial. *BMC Pulm*

754   *Med* 2020;20:105.

755   44.   Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a strategy to improve adherence to

756   tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. *JAMA*

757   2007;297:380–6.

758   45.   Goel S, Kathiresan J, Singh P SR. Effect of a brief smoking cessation intervention on adult

29

759   tobacco smokers with pulmonary tuberculosis: A cluster randomized controlled trial from

760   North India. *Indian J Public Heal* 2017;61(Suppl 1):S47–53

46.   Manogaran C, Nagarajan K, Ovung S, et al. Alcohol intervention strategy among tuberculosis

762   patients: a pilot study from South India. *Int J Tuberc Lung Dis* 2017;21:947–52

763   47.   Siddiqi K, Keding A, Marshall AM, et al. Effect of quitting smoking on health outcomes during

764   treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial. *Thorax* 2021

765   Published Online First Jul 16:thoraxjnl-2020-215926. doi: 10.1136/thoraxjnl-2020-215926.

766   48.   Lindson N, Thompson TP, Ferrey A, et al. Motivational interviewing for smoking cessation.

767   *Cochrane Database Syst Rev*. 2019;2019(7).

768   49.   McCambridge J, Kypri K. Can simply answering research questions change behaviour?

769   Systematic review and meta analyses of brief alcohol intervention trials. *PLoS One*

770   2011;6(10):e23748.

771   50.   Peltzer K, Naidoo P, Louw J, et al. Screening and brief interventions for hazardous and

772   harmful alcohol use among patients with active tuberculosis attending primary public care

773   clinics in South Africa: results from a cluster randomized controlled trial. *BMC Public Health*

774   2013;13:699.

775   51.   Riper H, Andersson G, Hunter SB, et al. Treatment of comorbid alcohol use disorders and

776   depression with cognitive-behavioural therapy and motivational interviewing: a meta-

777   analysis. *Addiction* 2014;109:394–406.

778   52.   Moosa A, Gengiah TN, Lewis L, et al. Long-term adherence to antiretroviral therapy in a South

779   African adult patient cohort: a retrospective study. *BMC Infect Dis* 2019;19(1):775. doi:

780   10.1186/s12879-019-4410-8.

781   53.   Webb Mazinyo E, Kim L, Masuku S, et al. Adherence to Concurrent Tuberculosis Treatment

782   and Antiretroviral Treatment among Co-Infected Persons in South Africa, 2008–2010. *PLoS*

783   *One* 2016;11(7): e0159317. https://doi.org/10.1371/journal.pone.0159317.

784   54.   Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence

785   behavior: recommendations on optimal use. *Transl Behav Med* 2015;5:470–82.

786   55.   Wanyama JN, Nabaggala SM, Kiragga A, et al. High mobile phone ownership but low internet

787   access and use among young adults attending an urban HIV clinic in Uganda. *Vulnerable Child*

788   *Youth Stud* 2018;13:3,207-20.

789   56.   Meader N, King K, Wright K et al. Multiple risk behavior interventions: Meta-analyses of

790   RCTs. *Am J Prev Med* 2017;53:e19–e30.

791   57.   Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions.

792   *Health Psychol* 2008;27:379-87.

30

793   58.   Frost H, Campbell P, Maxwell M, et al. Effectiveness of Motivational Interviewing on adult

794   behaviour change in health and social care settings: A systematic review of reviews. *PLoS One*

795   2018;18:13(10):e0204890

796   59.   Kahwati L, Viswanathan M, Golin CE, et al. Identifying configurations of behavior change

797   techniques in effective medication adherence interventions: a qualitative comparative

798   analysis. *Syst Rev* 2016;5(83).

799   60.   Telerivet. Message Statuses . User Guide, 2021. Available from:

800   https://guide.telerivet.com/hc/en-us/articles/360038959611-Message-Statuses. [Accessed

801   21 June 2021]

802   61.   Lustria MLA, Noar SM, Cortese J, et al. A meta-analysis of web-delivered tailored health

803   behavior change interventions. *Journal of Health Communication* 2013;18:1039–69.

804   62.   Gallacher K, May CR, Montori V, et al. Understanding Patients' Experiences of Treatment

805   Burden in Chronic Heart Failure Using Normalization Process Theory. *Ann Fam Med*

806   2011;9:235-243.

31

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trials

STUDY PROTOCOL

Open Access

ImPROving TB outcomes by modifying LIFE-style behaviours through a brief motivational intervention followed by short text messages (ProLife): study protocol for a randomised controlled trial

Andrew Stephen Moriarty[1]* , Goedele Maria Louwagie[2], Noreen Dadirai Mdege[3], Neo Morojele[4], John Tumbo[5], Olufemi Babatunde Omole[6], Max Oscar Bachmann[7], Mona Kanaan[3], Astrid Turner[8], Steve Parrott[3], Kamran Siddiqi[1] and Olalekan Abdulwahab Ayo-Yusuf[9]

Abstract

Background: South Africa is among the seven highest tuberculosis (TB) burden countries. Harmful lifestyle behaviours, such as smoking and alcohol, and poor adherence to medication can affect clinical outcomes. Modification of these behaviours is likely to improve TB treatment outcomes and has proven possible using motivational interviewing (MI) techniques or use of short message service (SMS) text messaging. There have been no studies assessing the effect of combined MI and SMS interventions on multiple lifestyle factors and TB treatment outcomes.

Methods: This is a prospective, multicentre, two-arm individual randomised controlled trial looking at the effectiveness and cost-effectiveness of a complex behavioural intervention (the ProLife programme) on improving TB and lifestyle-related outcomes in three provinces of South Africa. The ProLife programme consists of an MI counselling strategy, delivered by lay health workers, augmented with subsequent SMS. We aim to recruit 696 adult participants (aged 18 years and over) with drug-sensitive pulmonary TB who are current smokers and/or report harmful or hazardous alcohol use. Patients will be consecutively enrolled at 27 clinics in three different health districts in South Africa. Participants randomised individually to the intervention arm will receive three MI counselling sessions one month apart. Each MI session will be followed by twice-weekly SMS messages targeting treatment adherence, alcohol use and tobacco smoking, as appropriate. We will assess the effect on TB treatment success, using standard World Health Organization (WHO) treatment outcome definitions (primary outcome), as well as on a range of secondary outcomes including smoking cessation, reduction in alcohol use, and TB medication and anti-retroviral therapy adherence. Secondary outcomes will be measured at the three-month and six-month follow-ups.

Discussion: This trial aligns with the WHO agenda of integrating TB care with the care for chronic diseases of lifestyle, such as provision of smoking cessation treatments, and with the use of digital technologies. If the ProLife programme is found to be effective and cost-effective, the programme could have significant implications for TB treatment globally and could be successfully implemented in a wide range of TB treatment settings.

Trial registration: ISRCTN Registry, ISRCTN62728852. Registered on 13 April 2018.

Keywords: Tuberculosis, Smoking, Alcohol, Motivational interviewing, Anti-retroviral therapy, Adherence

* Correspondence: andrewmoriarty1@doctors.org.uk
[1]Department of Health Sciences and the Hull York Medical School, University of York, York, UK
Full list of author information is available at the end of the article

Background

South Africa has the second highest incidence of tuberculosis (TB) and the sixth highest TB burden of the 30 high TB burden countries. It also has a high prevalence of human immunodeficiency virus (HIV) co-infection in patients with TB and a high mortality in these co-infected patients relative to most other high-burden countries [1]. In addition to HIV co-infection, a range of social, psychological and economic factors influence treatment success in TB. Of these, tobacco smoking and hazardous or harmful alcohol use are specifically mentioned in the South Africa National TB Management Guidelines [2]. Tobacco use and problem drinking are prevalent in TB patients, often co-occur [3–5] and are known to increase the risk of death and poor treatment adherence and outcomes [6–9].

As well as increasing the risk of TB infection and progression of disease [10], smoking is also known to increase the risk of treatment failure [11], relapse [12, 13] and death [14], and is associated with resistance to isoniazid, one of the main antimicrobials used to treat TB [15]. There is evidence that patients who stop smoking have better TB treatment outcomes and, if co-infected, better HIV treatment outcomes than current smokers [16–18]. In addition, alcohol misuse is associated with poorer TB outcomes through a range of mechanisms including decreased effectiveness of medications used to treat TB (including drug resistance), increased recurrence and treatment default rates and social marginalisation [3]. It has been estimated that 10% of the global burden of TB is attributable to alcohol use [19, 20].

Poor adherence to TB medication and anti-retroviral therapy (ART) significantly increases the risk of adverse effects and death in TB patients. Strategies are needed to improve medication adherence in TB-HIV co-infected patients, in whom integration of TB and HIV care has been shown to decrease mortality [21].

A number of studies have attempted to evaluate the effectiveness of tobacco cessation, alcohol reduction or TB treatment adherence interventions in TB patients [21, 22], but few have assessed the effect on TB treatment outcomes [23, 24]. We know that brief smoking cessation interventions, ranging from opportunistic advice and proactive telephone support through to in-person behavioural support over multiple sessions, are effective and affordable in low-income countries, in both TB patients and smokers in the general population [25, 26]. We also know that disease diagnosis could constitute a 'teachable moment', when people are more amenable to advice and motivated to modify harmful lifestyle behaviours [27]. For this reason, it is likely that patients receiving a TB diagnosis may be more successful in quitting smoking and moderating alcohol use if offered behavioural support, compared with smokers and problem drinkers in the general population.

Motivational interviewing (MI) is a counselling technique known to facilitate behaviour change [28], which has demonstrated effectiveness for the reduction of hazardous drinking, tobacco cessation, and TB treatment and/or ART adherence [19, 29, 30]. Our group has had previous success in achieving sustained smoking abstinence in TB patients through a brief MI intervention delivered by lay health workers (LHWs) [31]. There is also evidence to suggest that adherence to ART [32] and possibly TB medication [33], as well as tobacco cessation, can be enhanced with the use of short message service (SMS) text messages on mobile phone technology [34]. To our knowledge, no study has used MI in combination with SMS text messages to address multiple harmful behaviours that adversely impact TB outcomes.

The ProLife programme is a novel complex behavioural intervention targeting tobacco smoking, problem drinking, and TB and HIV medication adherence in patients with TB. This is the study protocol for the randomised controlled trial (RCT) aiming to assess the effectiveness and cost-effectiveness of the ProLife programme in improving TB treatment outcomes in primary healthcare clinics located in high TB-burden communities in three provinces in South Africa (Gauteng, Free State and North West). The protocol has been written in accordance with the Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) guideline.

Methods/Design

Objectives

The primary objective is to assess the effectiveness and cost-effectiveness of the ProLife programme compared to usual care in improving pulmonary TB (PTB) treatment outcomes. We also aim to assess the effectiveness and cost-effectiveness of the programme in achieving abstinence from smoking, reducing harmful and hazardous drinking, and improving TB and ART medication adherence.

Trial design and setting

This is a pragmatic, prospective, multicentre, two-arm, parallel, individual RCT taking place in 27 purposively selected primary care clinics with the highest TB caseload in three districts in South Africa: Welkom in the Free State; Bojanala in the North West province; and Sedibeng in Gauteng province. To be eligible for inclusion in the trial, TB clinics had to be under the control of the provincial or local government (i.e. not a mining TB clinic). The intervention will be delivered by LHWs and three district coordinators who will each cover 1–2 clinics.

Participants will be randomly allocated to one of two arms:

Arm 1: Intervention arm – participants in the interventions arm will receive the ProLife programme;
Arm 2: Control arm – participants will receive usual treatment and support provided to TB patients in TB treatment clinics in South Africa ('usual care').

Intervention

The ProLife programme is a complex behavioural intervention aimed at improving treatment outcomes in TB patients who smoke tobacco, drink alcohol at harmful or hazardous levels, or do both. The ProLife programme has been developed in line with the Medical Research Council (MRC) guidance on developing and evaluating complex interventions [35] and has undergone a period of development and feasibility testing in South Africa. The paper reporting the results of this evaluation has not yet been published. The conceptual framework used to develop the ProLife programme assumes that smoking cessation, reducing harmful alcohol use and improved adherence to TB and HIV treatment will result in improved TB treatment outcomes.

Participants randomised to the intervention arm will receive three brief MI counselling sessions, lasting 15–20 min, each one month apart, from a trained LHW at their TB clinic. In the initial MI session, occurring at the start of TB treatment, the counsellor will establish the participant's tobacco smoking habits and problem drinking; potential obstacles and facilitators for medication adherence or treatment initiation (both TB treatment and ART) will be determined. The participant will determine which factor should be prioritised (i.e. agenda setting), which could be a plan either to quit tobacco smoking, reduce or quit drinking or deal with barriers relating to ART or TB medication adherence. For participants who are HIV-infected and not yet on ART, beliefs and attitudes regarding HIV-testing or ART will be explored to facilitate ART initiation and adherence. The second session will build on the previous one and will focus on the previous agenda before moving on to the next behavioural problem (tobacco, alcohol or medication adherence) where applicable. The third session will deal with the last identified problem.

The individual counselling sessions will be re-enforced with SMS text messages regarding information, motivation and behaviours (IMB) supporting tobacco cessation, alcohol use and medication adherence. Text messages will be delivered twice a week over 12 weeks. All participants will first receive 10 TB-related messages. These messages will be followed by seven alcohol or smoking-related messages depending on whether the

participant smokes or drinks. Co-joint users will receive all sets of messages (i.e. 24 in total).

Comparator

Participants in the second group are the controls and will receive usual TB treatment and support offered to TB patients. Control participants are seen by a TB nurse and receive the same biochemical investigations and medical treatments as the intervention arm. However, they will not receive the MI and SMS package of care as described above. Usual care also includes HIV testing with pre- and post-test HIV test counselling by a lay counsellor or a nurse (this varies by district).

In addition, health education is given on:

- nature of TB, treatment adherence, treatment side-effects/complications, drug interactions, tobacco use, alcohol use and other substance abuse. This is mostly done by the TB nurses, is not intensive and is educational in nature rather than a form of counselling;
- healthy diet by a dietician where possible;
- social problems and family support for treatment by a social worker as needed and depending on the availability of social workers; and
- point of care blood glucose, haemoglobin and pregnancy tests are performed. If co-infected with HIV, a full blood count, liver function test and creatinine are also carried out.

Participants

The inclusion criteria for participants are:

- adult patients (aged ≥ 18 years) with drug-sensitive (bacteriologically or clinically confirmed) PTB;
- initiating TB treatment or on TB treatment for < 1 month (these include both 'new' and 'retreatment' patients);
- current smokers and/or hazardous/harmful drinkers who are not alcohol dependent (Alcohol Use Disorders Identification Test [AUDIT] score ≥ 8 for men or ≥ 7 for women but < 20);
- access to a functional mobile phone; and
- understands one of the four languages used for the trial (Sesotho, Setswana, Isizulu or English).

Exclusion criteria:

- alcohol-dependent participants (AUDIT score ≥ 20);
- Extrapulmonary TB without PTB; or
- Resistance to one or more TB drugs at baseline (because drug-resistant TB needs further investigations which take several months and is treated through

a long, specialised treatment programme if present).

Recruitment process

Participants will be recruited consecutively from the starting date of the trial until the required sample size for each clinic has been achieved. The sample size per clinic will vary depending on the workload for each clinic. TB patients who initiate treatment (or who have been on treatment for < 1 month) will be asked if they would like to participate. If they agree, they will then be screened for eligibility by trained fieldworkers immediately after the TB nurse at the clinic has initiated TB treatment and started the routinely used TB treatment record. Eligibility screening will involve being assessed in line with the inclusion criteria listed above and being asked about their:

- smoking status: using the Global Adult Tobacco Survey [36] questionnaire, patients will be asked whether they currently smoke daily, less than daily or not at all, and in the past daily, less than daily or not at all. As TB patients in South Africa often smoke little or may not have smoked for a few days because of ill-health and the word 'current' is open to interpretation (particularly when translated); 'current' has been defined as smoking daily and non-daily in the last four weeks for the purpose of this study. Smoking habits will be further quantified at baseline interview;
- current alcohol usage: AUDIT, a validated tool for identifying problem alcohol behaviours [37], will be used to quantify alcohol intake. Those with an AUDIT score ≥ 8 for men or ≥ 7 for women but < 20 will be eligible for the trial.

If eligible, patients will be invited to join the trial. For those who wish to be enrolled into the trial, written informed consent will be obtained (Additional file 1).

Randomisation and allocation

Patients will be randomised using a randomised sequence generator performed by the trial statistician (MK) who will remain blind to the arm allocation. We will use block randomisation with varying block sizes stratified by the clinic to achieve equal numbers in intervention and control groups within each clinic (see the 'Sample size' section). Allocation concealment will be done with consecutively numbered, sealed, opaque envelopes.

Ethics and consent

Potential participants will be approached and given an introduction to the study and basic eligibility criteria required for participation. Participants who meet the eligibility criteria for language, age, PTB, treatment duration and mobile phone access will be given a consent form (Additional file 1) to sign before screening for alcohol and tobacco use eligibility as the alcohol-related questions are sensitive and the fieldworkers must access the patient treatment record. If recruited to the trial, participants will be ask to consent to enter the trial, including consent for audio recording of the MI counselling sessions (Additional file 1). A witness signature will be required where the participant is unable to read or write.

The identity of participants will be protected by allocating each participant a unique trial number, which will be used on all research documents and will ensure anonymity for the data analysis. Participation will be voluntary; participants will be informed of their right to withdraw from the study at any time without giving a reason for their withdrawal. The project is unlikely to be directly harmful to TB patients with the exception of inconvenience in terms of time spent on the counselling sessions. Participants will receive ZAR 60 (US$4.19) travel and other expenses reimbursement for each MI counselling session and follow-up visit related to the study.

Timeline and procedures

Figure 1 Additional file 4 outlines the overall participant flow through the trial. Eligible and consenting patients will be enrolled in the trial and the baseline interviewer-administered questionnaire and record review completed. Participants will receive a baseline interview on the same day as the recruitment or on the nearest available date suitable to both the participant and the LHW. The initial part of the questionnaire covers socioeconomic and demographic factors. We will also assess for depression using the CES-D10 [38], a validated tool, as depression may be a potentially moderating or mediating factor affecting treatment outcome. See Additional file 2 for the full case report form (CRF).

The next part will cover medical history, particularly TB and HIV history and current medications. Participants identified as current smokers at eligibility screening will be asked more in-depth about their smoking habits and quit history. All participants will be asked about their use of smokeless tobacco and exposure to second-hand smoke. Participants will also be asked about time and money spent on TB-related healthcare visits in the past three months and health-related quality of life (see the 'Economic evaluation' section). After administering the baseline interviews, fieldworkers will draw the allocation envelopes and organise the follow-up sessions for the participants. Each of the interviews on health status, tobacco and alcohol use at

Fig. 1 CONSORT Flow diagram outlining randomisation and participant recruitment

baseline, three months and six months is not expected to last > 25 min.

Primary outcome

The primary outcome is TB treatment success at 6–9 months of follow-up, measured using the routinely collected programmatic TB treatment outcomes as defined by the World Health Organization (WHO) and adopted in South Africa. This is a binary variable defined as either successful treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss to follow-up or 'default', or not outcome evaluated. Table 1 defines the different treatment outcomes according to the South African Department of Health National Tuberculosis Management Guidelines [2].

Individual TB treatment records will be used as the primary source of information. The TB treatment record is the routinely used clinical document initiated by the TB nurse when the patient first presents at the TB clinic and includes demographic information as well as a comprehensive overview of the patient's treatment over time. The TB treatment outcomes will be obtained 6–9 months after the TB treatment start dates. This is to allow for short periods of treatment interruption and time needed to confirm the TB treatment outcomes status. For example, the TB nurse may have to wait for end of treatment TB sputum or culture results or time may be required to determine

whether a participant died. In some cases, TB patients may also undergo a longer TB treatment regimen.

Routinely reported outcomes will be verified for correctness by checking the actual individual diagnosis and treatment records. For example: if the outcome is classified as cured, then the criteria for diagnosis and outcome definitions should have been adhered to. Attempts will be made to verify the information of patients classified as 'defaulted' or who are lost to follow-up by contacting them telephonically or sending them a short text message. Sputum cultures and smears will be performed at baseline, two months, three months and six months per routine care.

Secondary outcomes

The following outcome measures will also be recorded at the six-month follow-up:

- sputum conversion at the end of treatment: this will be measured by negative culture or smears in the group of participants who had bacteriology confirmed PTB at baseline, i.e. cure rates in intervention group versus control group for participants who initially had sputum AFB-positive, culture-positive or GeneXpert-positive PTB;
- six-month continuous smoking abstinence: the Russell Standard defines continuous abstinence as a self-report of not smoking > 5 cigarettes from the

Table 1 Definitions for TB treatment outcomes according to the South African Department of Health National Tuberculosis Management Guidelines

Treatment outcome	Definition
Cure	Patient in whom baseline smear or culture was positive at beginning of treatment AND is smear/culture negative in the last month of treatment and on at least one previous occasion at least 30 days prior According to local protocol, a patient who is diagnosed using Gene Xpert and is sputum negative for TB at 11 and 23 weeks is considered 'Cured'.
Treatment completed	Patient whose baseline smear or culture was positive at the beginning and has completed treatment but does not have a negative smear/culture in the last month of treatment and on at least one previous occasion > 30 days prior. Patients diagnosed with PTB whose baseline smear (or culture) result was negative and who started treatment based on clinical and radiological findings who have shown clinical improvement and completed the prescribed course of treatment. *N.B. The smear examination may not have been done or the results may not be available at the end of treatment.*
Treatment failure	Patient whose baseline smear or culture was positive and remains or becomes positive again at 5 months or later during treatment. Patients who were negative at baseline but were later found to be positive. *N.B. This definition excludes those patients who are diagnosed with RR-TB or MDR-TB during treatment.*
Died	Patient who dies for any reason during the course of TB treatment.
Treatment default	Patient whose treatment was interrupted for two consecutive months or more during the treatment period.
Transfer out	Patient who was referred to a facility in another district to continue treatment and for whom the treatment outcome is not known.
Acquired resistance	Participants who are subsequently referred for MDR treatment.

start of the abstinence period (in this case, six months), supported by a negative biochemical test (exhaled carbon monoxide [CO] < 10 ppm) at final follow-up [39]. For the purpose of our study, we will, however, use a more stringent criterion of exhaled CO < 7 ppm, based on findings from our previous study that some participants who reported continued smoking had an exhaled CO < 10 ppm [26]. This analysis will be performed on the group of participants who were current tobacco smokers at baseline;

- reduction in harmful or hazardous drinking: alcohol use will be measured using the AUDIT questionnaire. The questionnaire will be administered at screening (which will take place on the same day or shortly after the baseline assessment) and again at three months and six months. Changes in the total AUDIT score will be used to compare change in drinking behaviour between control and intervention groups. This analysis will be performed on the group of participants who were harmful or hazardous drinkers at baseline.
- TB and ART medication adherence: adherence to both TB and ART medications will be measured using a modified version of the AIDS Clinical Trials Group (ACTG) Adherence Questionnaire. The questionnaire is a validated tool for measuring adherence specifically to ART and we will use an adapted version to also measure TB medication adherence [40]. Field workers will administer the baseline part of this questionnaire as part of the

baseline CRF and adherence will be measured at both three months and six months.

Adherence will be measured using an adherence index calculated by the formula (using the four-day recall table):

[Total number of doses taken/Total number of doses prescribed] x 100

ART patients with at least 95% of adherence will be considered as having optimal adherence and those with < 95% will be considered as having low (or suboptimal) adherence. For the TB medication regimen, patients with at least 95% of adherence will be considered as having optimal adherence and those with < 95% will be considered as having low (or suboptimal) adherence:

- increase in proportion of HIV-positive participants on ART: HIV status will be recorded in the TB Treatment Record. HIV-positive participants will be asked about ART status at baseline, three months and six months using standardised questions on the CRF.

The following outcomes will be measured at three months:

- biochemically verified three-month sustained tobacco cessation;
- reduction in harmful or hazardous drinking;
- TB drug and ART adherence;

- increase in proportion of HIV-positive participants on ART.

The schedule for enrolment, intervention and assessments is presented in Fig. 2. Table 2 summarises the methods of data collection and analysis for each of the primary and secondary outcomes.

Data collection and management

Data will be collected and recorded by field workers equipped with Android phones with a mobile data collection application installed. MI counselling and data collection will take place in a well-ventilated private area inside or outside the clinic (but within the grounds of the health facility); MI sessions will be audio-recorded where consent has been obtained. Fieldworkers and

	STUDY PERIOD					
	Enrolment	Allocation	Post-allocation			Close-out
TIMEPOINT	*-t*	**0**	*1m*	*2 m*	*3 m*	*6-9m*
ENROLMENT:						
Eligibility screen (including smoking status and baseline AUDIT)	X					
Informed consent	X					
Allocation		X				
Assigned trial ID and initial visit date		X				
INTERVENTIONS:						
The ProLife Programme		←——————→				
Usual care		←——————→				
ASSESSMENTS:						
Clinical review of TB treatment record	X	X				X
HIV Status ART status (if HIV-positive)		X			X	X
Smoking history	X	X				
Socio-demographic history		X				
Depression screen (CES-D10)		X			X	X
Record sputum culture, smear or Gene Xpert result		X		X	X	X
Smoking abstinence (self-report)					X	X
Smoking abstinence (Exhaled CO)					X	X
Repeat AUDIT					X	X
Modified ACTG					X	X
Economic evaluation		X			X	X

Fig. 2 SPIRIT Figure outlining data collection throughout trial

LHWs will be provided with high particulate respirator masks to minimise the risk of infection.

Fieldworkers will follow-up all participants in both arms at three and six months within a window period of two weeks before and two weeks after the ideal three-month and six-month visit. Participants will receive SMS reminders three days before each planned visit. Participants will also be in a position to send 'please call me' messages to the district coordinators, who will then call the participant to solve problems that may have arisen with the appointment.

The electronic data captured will be stored on secured and password-protected storage servers and mobile phones which ensure data privacy through only allowing authorised research staff access to the data. The electronic data collection system used for the study requires an SMS gateway to send and receive messages to the research participants. Consenting participants' phone numbers, participant IDs and associated SMS messages will be stored on the SMS gateway's secured and password-protected server.

Data quality will be ensured by providing fieldworkers with standard operating procedures (SOPs), training and ongoing support on the importance of data quality, data collection and data collection problem solving. Training will consist of a four-day session before the commencement of the pilot and a one-day training session focusing on problems identified during the pilot preceded the trial. The data manager will continuously monitor the captured data for missing variables and inconsistencies in order to resolve any data problems.

The data manager will export the data from the secured server, conceal the participants study arm allocation and de-identify the data before sharing the data in STATA and R compatible formats. The exported de-identified data will be stored in Dropbox, a secure cloud storage platform, for sharing with the lead trial statistician at the University of York for analysis.

All research data and documents referring to the ProLife trial will be stored and maintained in a secured storage space at SMU for a minimum of 15 years from the end of the ProLife trial. Study materials will be destroyed 15 years after the study.

Blinding and limitation of risk of bias

This is a complex behavioural intervention and the team dynamics mean that all team members work very closely with one another. As such, LHWs and participants cannot be blinded to the intervention. The determination of the primary outcome will be done by the TB nurses who are blinded to the intervention status of the participants based on routinely collected data. Blinding of the field researchers collecting other questionnaire data (Additional file 2)

Table 2 Summary of methods of data collection and analysis for primary and secondary outcomes

Variable	Method of data collection	Method of data analysis
Primary outcome: TB treatment outcome as defined by WHO and the South Africa TB Management Guidelines (see Table 1)	• CRF and TB treatment record • Treatment outcome as recorded by TB nurses in TB cards using the standard WHO definitions of cure, completions, failure, death, TB treatment interruption, drug resistance developed in course of treatment (confirmed for correctness by checking sputum culture/smear at baseline, at 5 and 6 months)	Binary outcome: successful (cured of completed) vs not successful (died, failure, treatment interruption, drug-resistant TB) All participants, excluding those transferred out
Secondary outcome: sputum conversion	• Sputum culture/smear at baseline, 5 and 6 months to determine cure rates for PTB patients who had a positive smear or culture at baseline • Sputum conversion at 2–3 months	Binary cured vs not cured for the subgroups of participants who had a positive smear/culture at baseline Binary conversion vs not for the subgroups of participants who had a positive smear/culture at baseline
Secondary outcome: change in smoking behaviour	• CRF – questions as per Russell's Standard – baseline smoking behaviours and then at 3 and 6 months • Exhaled carbon monoxide reading at 3 and 6 months	Binary outcome validated 3 and 6 months sustained smoking cessation for the subgroup of participants who were smoking at baseline
Secondary outcome: percentage reduction in harmful or hazardous drinking (change in AUDIT score)	• AUDIT score at baseline and at 3 and 6 months	Change in AUDIT score (continuous) for subgroups of participants who were hazardous or harmful drinkers at baseline
Secondary outcome: HIV and TB medication adherence	• CRF – questions modified from ACTG	Binary outcome (% adherent vs non-adherent)
Secondary outcome: proportion of HIV-positive participants on ART	• HIV status at baseline • ART status at baseline, 3 months and 6 months	Binary on ART vs not on ART for the subgroup of HIV-positive participants, taking into account baseline % on ART

will not be possible. The statistician will be blinded to the intervention or control arm allocation of participants during the analysis stage.

There is a potential of biased outcome reporting on self-reported tobacco smoking or alcohol consumption favouring the intervention arm. This will be minimised by training the fieldworkers in open communication and standardised data collection. Tobacco cessation will also be verified by exhaled CO monitoring. Given the use of the TB treatment record as a primary source of information pertaining to TB outcomes, there is a risk of non-differential misclassification. However, this risk is equal in both the treatment and control arms and therefore the decision has been taken that the TB treatment record can be used as a primary data source (i.e. bias would be towards the null).

Sample size
The sample size has been set at 696 participants (348 participants per arm). This sample size is sufficient to detect a 10% difference in TB treatment success rates (0.86 vs 0.76) in the ProLife group versus the control group with 80% power, a significance level of 0.05 and 25% attrition. The sample size per clinic was in the range of 14–74 participants per clinic with a median of 24. The assumed success rates in the control group are based on actual success rates in TB patients in the studied provinces.

Statistical analysis
We will summarise baseline data descriptively by trial arm; however, we will not undertake statistical comparisons. For continuous measures, we will report means and standard deviations (SD); for skewed data, we will also provide medians and interquartile ranges. For categorical data, we will report counts and percentages. For the primary outcome, we will conduct analysis on an intention-to-treat basis. We will use binary logistic regression to compare the main outcome between the intervention and the usual care arm.

We will carry out similar analyses for the secondary outcomes with appropriate regression techniques: logistic regression for categorical outcomes and linear regression for continuous outcomes. We will also adjust for baseline characteristics and other covariates (HIV status, sex, alcohol versus tobacco versus both, district) if these differ between trial arms at baseline.

In case of missing data, we will employ a number of methods including multiple imputations to assess the sensitivity of the results. We will conduct subgroup analyses to determine whether TB treatment outcomes differ between subgroups, as follows: HIV-positive versus HIV-negative participants; participants with an alcohol problem only versus smokers only versus participants who are conjoint smokers and drinkers; and participants who were GeneXpert positive versus participants who were GeneXpert negative at baseline.

We will follow the CONSORT statement guidelines in reporting. We will use the statistical packages STATA and R to carry out the analyses and a P value < 0.05 will be considered as statistically significant. The statistical analysis pertaining to cost-effectiveness will be described in the section detailing the planned economic evaluation.

Monitoring

Each centre will be responsible for its own data entry and local trial management. Monitoring and site training will be carried out at each site within specified intervals. The project manager will visit each district every third month with the counselling supervisor. The district co-ordinators will visit each clinic bi-weekly; the site leads and data manager will visit the sites when required.

The monitoring will adhere to the principles of Good Clinical Practice and will follow an agreed monitoring plan. During their bi-weekly visits, the district coordinators will be guided by a checklist to confirm adherence to protocol, review eligibility verification and consent procedures, and provide additional training as needed. Any adverse events will be formally recorded and reported where appropriate.

The mobile data collection tool was improved based on findings from the pilot phase and feedback from the field staff capturing the data. Validation was added to the mobile questionnaires to ensure that all questions should be answered, participants only answer question relevant to them and that no unusual values (range checks) are entered. Coordinators can use the mobile data collection tool on their phones to monitor incomplete data activities, outstanding and upcoming appointments with participants and basic project performance indicators per clinic.

The data captured during the interviews with the participants are only captured on the electronic mobile data collection tool and can therefore not be verified by the site coordinators. However, the district coordinators will require access to all (enrolled TB) patient medical records including, but not limited to, laboratory test results and prescriptions. They will do spot checks by comparing the captured data with the medical records and look for missed outcomes reporting: verify completeness; consistency; and accuracy of data being entered on CRFs. The site leads (or delegated personnel) should work with the district coordinators to ensure that any problems detected are resolved.

The data will also be checked by the data manager for missing or unusual values (range checks) and checked for consistency within participants over time. If any such problems are identified, the individual centres will be contacted and asked to verify or correct the entry.

Indicators related to enrolment, premature withdrawal, motivational interviewing completion, CRF completion and SMS delivery will be analysed and included in monthly reports.

As the ProLife programme is a low-risk intervention, the decision was taken not to appoint an external data monitoring committee.

Training and intervention fidelity monitoring

Eighteen LHWs, three district coordinators and one person who will be focusing on counselling supervision underwent MI training over five days, which covered: basic knowledge of TB; treatment adherence; tobacco and alcohol use; overview of the overall spirit of MI and communication style; core interviewing skills; evoking change talk, hope and confidence; developing a change plan; and strengthening commitment. The LHWs' knowledge in terms of TB, alcohol use, tobacco smoking, TB and ART treatment adherence, and motivational interviewing was assessed before and after the training

To ensure that all the essential steps, techniques and skills of an MI session are covered during each session, the LHWs will be provided with a checklist to use during each session (Additional file 3). At the end of each session, they will also complete a post-session semistructured form onto which they will indicate the extent to which they implemented each element of MI, as well as their general qualitative impressions of that particular session.

During the trial, the LHWs will receive regular supervisory support from the district and national study coordinators. In addition, an appointed supervisor with proficiency in MI will be providing monthly counselling supervision to the LHWs in each site, by travelling to each of the three sites and then providing support to the LHWs in a group, followed by individualised support to each LHW separately. All lay counsellors completed grade 12 and have at least one year of prior counselling experience in TB and/or HIV.

In order to assess the fidelity of the counsellors' delivery of motivational interviewing during the trial, the validated Motivational Interviewing Treatment Integrity Coding Manual 4.2.1 (MITI) tool will be used [41]. We will tape record each LHW's counselling sessions and then randomly select 5% of each counsellor's patients and then use the recordings of all three sessions with those patients for the MITI task. Those selected recordings will be transcribed and translated into English. Two independent raters who are Setswana/Sesotho speakers will listen to the recordings and code a randomly selected 20-min portion of the written transcript. In the case of shorter counselling sessions, the entire recording will be assessed. The coding will entail making 'Global Ratings' (on four dimensions: Cultivating change talk;

Softening sustain talk; Partnership; and Empathy) and 'Behaviour Counts' (with respect to the items: giving information; persuade; persuade with permission; question; simple reflection; complex reflection; affirm; seeking collaboration; emphasising autonomy; and confront). A score will be assigned to each of these items and the scores compared against the competency and proficiency thresholds that are specified in the MITI manual.

Economic evaluation

The economic evaluation will be a within-trial incremental cost-effectiveness analysis of the ProLife package over and above usual care conducted alongside the RCT. In each arm of the trial, we will estimate the costs of delivering the intervention to participants. Costs consist of the delivery of ProLife intervention (staff costs, overheads and consumables) in the intervention arm and the costs of behavioural support and support (staff time, overheads and consumables) in the control arm. Costs will be calculated based on the length of time of contacts and the unit cost of the healthcare worker delivering the intervention. These costs should demonstrate some within patient variability as cost will be partly dependent upon the length of the recorded appointments.

We will also record contacts with health services for TB by patients in each trial arm, using the questionnaires adapted from those used in a previous trial of TB [42]. Applying unit costs of healthcare to quantities recorded in the service use questionnaire will produce a healthcare cost profile for each patient at baseline, three-month and six-month follow-ups. Healthcare cost profiles based on TB contacts can then be used to investigate differences in total costs between the treatment and control groups. The base case analysis will use healthcare costs as the study perspective. This is justified by presenting the cost implications of delivering the ProLife intervention from a healthcare decision maker's perspective. However, we will also record participants' travel costs associated with making the journey to the intervention site. This will estimate the wider societal cost to patients associated with receiving treatment.

We will estimate the cost per additional successful TB outcome by computing an incremental cost-effectiveness ratio (ICER) combining treatment and wider healthcare costs with outcome data from the trial. The analysis will also use measures of health utility. We have registered on the EuroQol website to use the country specific version of EQ-5D-3 L for South Africa to measure health-related quality of life at baseline, three-month and six-month follow-ups. We will use EQ-5D-3 L to estimate changes in quality-adjusted life years (QALY) using the area under the curve by using the utility score at each time point to create a profile [41]. A cost utility analysis is then performed by combining incremental health outcomes using

QALYs with the incremental cost. The cost utility analysis will estimate the cost per QALY that estimates the value for money afforded by administering the ProLife intervention over and above usual care. We will plot incremental cost against incremental outcome using a cost-effectiveness plane. We will also conduct sensitivity analyses to assess the robustness of the ICER and use bootstrapping techniques to calculate cost-effectiveness acceptability curves. Supporting analysis will also present the costs to patients incurred by making visits to both trial arms to present the wider cost burden. However, these costs will not be included in the base case scenario as the objective is to present the value for money from the perspective of the purchaser or commissioner.

Discussion

Ending the TB epidemic is one of the Sustainable Development Goals (SDG) established by the United Nations. The WHO calls for a 90% reduction in TB incidence by 2030 compared to 2015 and has highlighted the need for intensified research and innovation. The WHO has recently published guidance advocating the use of digital technologies, specifically mobile text messaging campaigns, in the treatment of TB as a means of improving the provision of patient-centred care and supporting medication adherence [43]. This publication highlights advances in mobile technologies and network coverage as opportunities to more effectively support patients during what can be a long period of treatment. This study is well-aligned with this guidance and, to our knowledge, this is the first trial looking at a complex behavioural intervention aiming to use MI techniques, alongside SMS, to modify a range of harmful lifestyle factors with the aim of improving TB treatment outcomes.

Work already undertaken in the formative phase suggests that the ProLife intervention is feasible and acceptable to patients. However, we anticipate some potential procedural challenges throughout the trial as we recognise that patients with TB may feel unwell and have taken steps to ensure that the MI and data collection are as brief and comfortable for patients as possible. The district coordinators will call participants to follow-up with those who missed appointments.

Implementing complex interventions in the real world can pose logistical challenges and careful process evaluation will be required to fully understand the challenges that may be presented. However, there is evidence to suggest that using MI techniques can be cost-effective when implemented in healthcare settings and the ProLife programme could represent a scalable and feasible approach to improving the care of patients with TB globally. Its scalability is particularly relevant in South

Africa as the government plans to formally introduce community health workers as part of its health workforce.

Trial status

Protocol Version 1.2, 5 January 2018. Recruitment on-going; piloting started at 30 clinics: 7 May 2018 and was completed by 31 August. The actual trial enrolment started on 13 November 2018. We expect to enrol the target sample size by May 2019 and plan to continue with follow-up until December 2019. The trial was piloted internally from May 2018 until the end of August 2018; piloting results will be reported at a later stage, to-gether with the trial results.

Additional files

Additional file 1 Participant consent form for screening and for trial. (DOCX 94 kb)

Additional file 2 Case report form. (DOCX 58 kb)

Additional file 3 Counselling Activities Reporting Form. (DOC 103 kb)

Additional file 4 SPIRIT Checklist. (DOC 120 kb)

Abbreviations

ACTG: AIDS Clinical Trials Group; ART: Anti-retroviral therapy; AUDIT: Alcohol Use Disorders Identification Test; CO: Carbon monoxide; CRF: Case report form; EPTB: Extra-pulmonary TB; HIV: Human immunodeficiency virus; LHW: Lay health worker; MI: Motivational interviewing; PTB: Pulmonary TB; SADHS: South Africa Demographic and Health Survey; SMS: Short Message Service; TB: Tuberculosis

Authors' contributions

ASM contributed to study design and preparation of the manuscript. GML led on study design and contributed to intervention development and preparation of the manuscript. NDM contributed to study design and intervention development. NM contributed to study design, particularly with respect to development of the MI intervention. JT is site lead for the Bojanala sub-district. OBO is site lead for the Sedibeng sub-district. MOB con-tributed to study design. MK contributed to study design and led on the sample size determination and statistical analysis plan. AT contributed to the planned economic evaluation. SP contributed to study design and led on the planned economic evaluation. KS and OAA are co-principle investigators. All authors read and approved the final draft of the manuscript.

Availability of data and materials

The data sharing plans for the current study are unknown and will be made available at a later date. Research results will be published in international indexed journals and disseminated to managers of the provincial and national Departments of Health. Furthermore, the provincial and national Departments of Health will be involved in the design and final evaluation of the project so as to assure their ownership, sustainability and scaling the programme beyond the life of the trial.

Ethics approval and consent to participate

The trial has received approval from the Research Ethics Committees of Sefako Makgatho Health Sciences University (SMU; Ref. SMUREC/D/234/2017: IR), the South African Medical Research Council (with the SMU Ethics Committee serving as the Research Ethics Committee Record), the University of Pretoria (Ref. 434/2017), the University of the Free State (Ref. HSREC 71/2016), the University of Witwatersrand (M160455) and the University of York (no reference number, approval date 15 January 2018). The protocol has gone through full external peer review throughout this process. In the case of any protocol amendments, these will be submitted to the SMU Ethics Committee for approval. Managerial approval has been obtained from the provincial and/or district managers to conduct the study at clinics in Bojanala district (North West Province), Lejweleputswa district (Free State province) and Sedibeng district (Gauteng province). Informed consent will be obtained from all study participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

[1]Department of Health Sciences and the Hull York Medical School, University of York, York, UK. [2]School of Health Systems and Public Health, University of Pretoria and Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa. [3]Department of Health Sciences, University of York, York, UK. [4]Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa. [5]Department of Family Medicine, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa. [6]Department of Family Medicine, University of Witwatersrand, Johannesburg, South Africa. [7]Norwich Medical School, University of East Anglia, Norwich, UK. [8]School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa. [9]Africa Centre for Tobacco Industry Monitoring and Policy Research, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa.

References

1. World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization. https://www.who.int/tb/publications/global_report/en/. Accessed 2 Dec 2017
2. Department of Health, Republic of South Africa. National Tuberculosis Management Guidelines. 2014. http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-27.5.2014.pdf. Accessed 8 Jan 2018
3. Peltzer K, Naidoo P, Louw J, Matseke G, Zuma K, McHunu G, et al. Screening and brief interventions for hazardous and harmful alcohol use among patients with active tuberculosis attending primary public care clinics in South Africa: results from a cluster randomized controlled trial. BMC Public Health. 2013;13:699. http://doi.org/https://doi.org/10.1186/1471-2458-13-699.
4. Louwagie GM, Ayo-Yusuf OA. Tobacco use patterns in tuberculosis patients with high rates of human immunodeficiency virus co-infection in South Africa. BMC Public Health. 2013;13:1031. https://doi.org/10.1186/1471-2458-13-1031.
5. Peltzer K. Conjoint alcohol and tobacco use among tuberculosis patients in public primary healthcare in South Africa. S Afr J Psych. 2014;20(1):21–6 http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S2078-67862014000100005&lng=en.
6. Naidoo P, Peltzer K, Louw J, Matseke G, McHunu G, Tutshana B. Predictors of tuberculosis (TB) and antiretroviral (ARV) medication non-adherence in public primary care patients in South Africa: a cross sectional study. BMC Public Health. 2013;13:396. http://doi.org/https://doi.org/10.1186/1471-2458-13-396.

7. Sendagire I, Cobelens F, Kambugu A, Konde-Lule J, van der Loeff MS. Frequency and predictors for late start of antiretroviral therapy in primary care clinics, Kampala, Uganda. J Acquir Immune Defic Syndr. 2012;61(3):e33–9. https://doi.org/10.1097/QAI.0b013e318265aad7.

8. Finlay A, Lancaster J, Holtz TH, Weyer K, Miranda A, van der Walt M. Patient - and provider-level risk factors associated with default from tuberculosis treatment, South Africa, 2002: a case-control study. BMC Public Health. 2012; 12:56. https://doi.org/10.1186/1471-2458-12-56.

9. Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 2011;15(7): 871–85. https://doi.org/10.5588/ijtld.10.0352.

10. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med. 2007;4(1):e20 Review.

11. Tachfouti N, Nejjari C, Benjelloun MC, Berraho M, Elfakir S, El Rhazi K, et al. Association between smoking status, other factors and tuberculosis treatment failure in Morocco. Int J Tuberc Lung Dis. 2011;15(6):838–43. https://doi.org/10.5588/ijtld.10.0437.

12. Yen YF, Yen MY, Lin YS, Lin YP, Shih HC, Li LH, et al. Smoking increases risk of recurrence after successful anti-tuberculosis treatment: a population-based study. Int J Tuberc Lung Dis. 2014;18(4):492–8. https://doi.org/10.5588/ijtld.13.0694.

13. Leung CC, Yew WW, Chan CK, Chang KC, Law WS, Lee SN, et al. Smoking adversely affects treatment response, outcome and relapse in tuberculosis. Eur Respir J. 2015;45(3):738–45. https://doi.org/10.1183/09031936.00114214.

14. Sitas F, Urban M, Bradshaw D, Kielkowski D, Bah S, Peto R. Tobacco attributable deaths in South Africa. Tob Control. 2004;13:396–9.

15. Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N, Elisarova E, et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax. 2005; 60(2):130–5.

16. Gegia M, Magee MJ, Kempker RR, Kalandadze I, Chakhaia T, Golub JE, et al. Tobacco smoking and tuberculosis treatment outcomes: a prospective cohort study in Georgia. Bull World Health Organ. 2015;93(6):390–9. https://doi.org/10.2471/BLT.14.147439.

17. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206–16.

18. van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J. 2010;35(1):27–33. https://doi.org/10.1183/09031936.00072909.

19. Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lönnroth K, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009;9:450. https://doi.org/10.1186/1471-2458-9-450.

20. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–501.

21. Suwankeeree W, Picheansathian W. Strategies to promote adherence to treatment by pulmonary tuberculosis patients: a systematic review. Int J Evid Based Healthc. 2014;12(1):3–16. https://doi.org/10.1097/01.XEB.0000444614.17658.46.

22. Shin S, Livchits V, Connery HS, Shields A, Yanov S, Yanova G, et al. Tomsk Tuberculosis Alcohol Working Group. Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia. Addiction. 2013;108(8):1387–96. https://doi.org/10.1111/add.12148.

23. Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, Fielding KL, et al. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA. 2007;297(4):380–6.

24. Khachadourian V, Truzyan N, Harutyunyan A, Thompson ME, Harutyunyan T, Petrosyan V. People-centered tuberculosis care versus standard directly observed therapy: study protocol for a cluster randomized controlled trial. Trials. 2015;16:281 10.1186/s13063-015-0802-2.

25. West R, Raw M, McNeill A, Stead L, Aveyard P, Bitton J, et al. Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development. Addiction. 2015;110(9):1388–403. https://doi.org/10.1111/add.12998.

26. Siddiqi K, Khan A, Ahmad M, Dogar O, Kanaan M, Newell JN, et al. Action to stop smoking in suspected tuberculosis (ASSIST) in Pakistan: a cluster randomized, controlled trial. Ann Intern Med. 2013;158(9):667–75. https://doi.org/10.7326/0003-4819-158-9-201305070-00006.

27. McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: The case of smoking cessation. Health Educ Res. 2003;18:156–70.

28. Rubak S, Sandbæk A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55(513):305–12.

29. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2010;1:CD006936. https://doi.org/10.1002/14651858.CD006936.pub2.

30. Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr. 2006;42(1):42–51.

31. Louwagie GMC, Okuyemi KS, Ayo-Yusuf OA. Efficacy of brief motivational interviewing on smoking cessation at tuberculosis clinics in Tshwane, South Africa: a randomized controlled trial. Addiction. 2014;109:1942–52.

32. Hirsch-Moverman Y, Daftary A, Yuengling KA, Saito S, Ntoane M, Frederix K, et al. Using mHealth for HIV/TB treatment support in Lesotho: Enhancing patient–provider communication in the START study. J Acquir Immune Defic Syndr. 2017;74:S37–43.

33. Nglazi MD, Bekker LG, Wood R, Hussey GD, Wiysonge CS. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis. 2013;13:566. https://doi.org/10.1186/1471-2334-13-566.

34. Free C, Phillips G, Watson L, Galli L, Felix L, Edwards P, et al. The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis. PLoS Med. 2013;10(1):e1001363. https://doi.org/10.1371/journal.pmed.1001363.

35. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655.

36. Global Adult Tobacco Survey Collaborative Group. Tobacco Questions for Surveys: A Subset of key questions from the Global Adult Tobacco Survey (GATS). 2nd ed. Altanta: Centres for Disease Control and Prevention; 2011.

37. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56(4):423–32.

38. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for Depression in Well Older Adults: Evaluation of a short from of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10:77–84.

39. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005; 100(3):299–303.

40. van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89:632–9.

41. Moyers TB, Rowell LN, Manuel JK, Ernst D, Houck JM. The Motivational Interviewing Treatment Integrity Code (MITI 4): Rationale, Preliminary Reliability and Validity. J Subst Abuse Treat. 2016;65:36–42.

42. Dogar OF, Barua D, Boeckmann M, Elsey H, Fatima R, Gabe R, et al. The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients - protocol for a double-blind, placebo-controlled randomised trial. Addiction. 2018;20:1–24.

43. World Health Organization/European Respiratory Society. Digital health for the End TB strategy: an agenda for action. Geneva: World Health Organization; 2015. http://www.who.int/tb/publications/digitalhealth-TB-agenda/en/. Accessed 2 Dec 2017

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.